Systems-Level Analysis of the Toll-like Receptor Network of Dendritic Cells by Chevrier, Nicolas
 Systems-Level Analysis of the Toll-like Receptor Network of
Dendritic Cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 10:19:15 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9549940
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA

Systems-Level Analysis of the Toll-like Receptor Network of Dendritic Cells 
 
 
 
 
A dissertation presented 
by 
Nicolas Chevrier 
to 
The Division of Medical Sciences 
 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
Immunology 
 
 
 
 
Harvard University 
Cambridge, Massachusetts 
April 2012 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 – Nicolas Chevrier 
All rights reserved 
 iii 
Dissertation Advisor: Dr. Nir Hacohen          Nicolas Chevrier 
 
Systems-Level Analysis of the Toll-like Receptor Network of Dendritic Cells 
Abstract 
 
Cells detect and respond to environmental changes using intracellular networks, and 
defects in the wiring of these networks contribute to diseases. For example, Toll-like receptors 
(TLRs) sense microbial molecules and trigger pathways critical for host defense. Genetic 
defects in components of the TLR and other pathogen-sensing pathways have been linked to 
human diseases. Hence, rational targeting of these pathways should help to manipulate 
immune responses associated with infections, autoimmunity, or vaccines. A fundamental 
challenge is to dissect the intracellular networks mobilized by pathogen-sensing pathways. Here 
we present approaches to dissect the TLR network of innate immune dendritic cells (DCs), 
focusing on two regulatory layers: signaling and transcription. 
First, we present a strategy to systematically perturb candidate regulators and monitor 
cellular transcriptional responses. We apply this approach to derive regulatory networks that 
control the transcriptional response to TLR engagement by microbial molecules. Our approach 
revealed the regulatory functions of 125 transcription factors (TFs), chromatin modifiers, and 
RNA binding proteins, which enabled the construction of a network model consisting of 24 core 
regulators and 76 “fine-tuners” that help explain how TLR pathways achieve specificity. 
Second, we report the systematic discovery of signaling components in TLR responses. 
By combining transcriptional profiling, genetic and small molecule perturbations, and 
phosphoproteomics, we uncover 35 signaling regulators, including 16 known members of the 
TLR signaling pathways. In particular, we find that Polo-like kinases (Plk) 2 and 4 are essential 
components of antiviral pathways in vitro and in vivo and activate a signaling branch involving a 
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dozen proteins, among which is Tnfaip2, a gene associated with autoimmune diseases but 
whose role was unknown.  
Lastly, we expand these approaches to integrate functional and physical interactions 
linking the ‘signaling-to-transcription’ TLR network. By combining our perturbation-based 
approach with measurements of physical interactions, including phosphorylation, protein 
complexes, and TF binding to DNA, we uncover 30 signaling regulators mechanistically linked 
to 19 downstream TFs. The integration of these datasets into a model reveals the organization 
of the TLR response. 
Overall, these studies illustrate the power of combining systematic measurements and 
perturbations to elucidate complex intracellular circuits and discover potential therapeutic 
targets. 
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Chapter 1 – Systems-Level Analysis of Biological Processes 
 
1.1. Overview 
In this thesis work, we report three systems-level approaches to dissect pathogen-sensing 
pathways of innate immunity, focusing on two regulatory layers: signaling and transcription. 
Using these approaches in the context of dendritic cells (DCs), we discovered a host of Toll-like 
receptor (TLR) network components that participate in the control of both of these regulatory 
layers. Prior to detailing our findings, we provide in the following sections a brief overview of: (i) 
systems approaches to biological and immunological questions, (ii) the current knowledge of 
pathogen-sensing pathways, and (iii) the main goals and questions driving the work presented 
here. 
 
1.2. Studying Complex Biological Systems 
Cells detect and respond to environmental changes using intracellular networks. These 
networks arise from interactions among cellular components, including proteins, nucleic acids, 
and metabolites. Furthermore, the spatial and temporal arrangement of these components and 
the network that they comprise are key to appropriate cellular behavior. To reach a mechanistic 
understanding of these networks, a fundamental challenge is thus to identify and connect all 
cellular components, and to uncover the rules governing their design principles and functioning. 
 
Conceptual Framework. The past decade has witnessed a fundamental transition from the 
study of individual components to modules emanating from many interacting components 
(Hartwell et al., 1999). This shift can be attributed to conceptual and technological advances 
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leading to what are now commonly denominated systems approaches (Ideker et al., 2001; 
Kitano, 2002). These approaches may vary in their implementation but largely rely on a similar 
conceptual framework: (i) identify all components of biological system; (ii) systematically perturb 
these components by deleting or modifying their properties or concentrations, and monitor the 
effect on the system’s output; (iii) extract and connect the functional modules of the system to 
derive quantitative models (Ideker et al., 2001; Ross, 2008). 
 
The sequencing of the human genome (Lander et al., 2001; Venter et al., 2001) has perhaps 
been the single-most important study in terms of driving these conceptual and technological 
changes. Following the completion of this project, much of the past decade has led to an 
exponential increase in studies using systems approaches across a variety of prokaryotic and 
eukaryotic models. Furthermore, recent advances in measurement tools now allow the capture 
of entire sets of cellular components. 
 
The next challenge is now to dissect cellular circuitry (Lander, 2011). The technological 
advances enabling large-scale to complete listing of biological components (e.g., transcripts, 
phosphorylated proteins, chromatin marks), have outpaced data analysis and integration that 
translate large-scale measurements into biologically meaningful information. To start tackling 
this challenge and reach a mechanistic understanding of biological networks and their 
constitutive modules, it is crucial to move toward integrative analyses across types of 
components (e.g., RNA and proteins) and regulatory layers (e.g., signaling and metabolic 
networks), and incorporating temporal and spatial variables (e.g., short-term vs. evolutionary 
time scale). 
 
Technological Framework. Many technological advances have propelled biology to the next 
level of understanding and helped starting to accomplish the vision delineated above. Over the 
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last twenty years, many technological developments and inventions have enabled the capture of 
entire sets of cellular components including nucleic acids, proteins, lipids, or metabolites. For 
example, complete genomic DNA sequences of microbes, plants, insects, or humans can be 
readily generated, if not already available. Beyond these now typical DNA sequencing projects, 
metagenomic measurements of the DNA content within communities of organisms such as 
bacteria are more and more widely applied. Next-generation sequencing approaches are also 
steadily replacing hybridization-based, microarray methodologies to monitor gene expression 
and discover novel transcripts or alternative splice forms. Finally, great advances in mass 
spectrometry instrumentation have been at the origin of “next-generation” proteomics, as 
opposed to previous methods that would rely, for example, on 2D electrophoresis of proteins 
based on mass and charge followed by identification of proteins contained within individual 
spots on the gel. Current mass spectrometry instruments allow the measurements of entire 
proteomes in simpler model organisms such as yeast, and with unprecedented depth of 
coverage in mammalian cells. Furthermore, enrichment of subproteomes such as 
phosphorylated, ubiquitinylated, or acetylated proteins using antibodies or chromatographic 
methods, has led to the investigation of many aspects of protein function, regulation, and 
modification within a cell that had remained out of reach for a long time. 
 
In parallel to these advances in measurement technologies of cellular components, the toolbox 
for perturbing these components at nearly any level (e.g., DNA, RNA, protein) has greatly 
expanded as well. For example, we have moved from gene knockouts and random mutagenesis 
as being the only feasible approaches to perturb or delete a gene, to conditional mutants (e.g., 
in cell types of interest), to post-transcriptional silencing (e.g., RNAi), or more recently to 
genome editing (e.g., zinc-finger nucleases). For human biology, the pendant for these 
perturbations may be seen in natural genetic variations across the human population, given that 
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human genomes exhibit on average ~20 inactivated genes per individual due to loss-of-function 
variants (MacArthur et al., 2012). 
 
Overall, the implementation of this conceptual framework – in concert with the model and 
biological questions at hand – may help building the functional wiring of a cell. The complexity of 
mammalian systems together with remaining technical limitations still preclude us from 
connecting these functional wires, but recent advances in lower model organisms have 
demonstrated how this view may be attained to some extent. For example, a recent multi-lab 
effort focused on Mycoplasma pneumoniae – a bacterium with 689 proteins encoded in a ~800 
kilobase genome – to perform detailed measurements of multiple regulatory layers including: 
protein-coding and non-coding RNA expression, RNA splicing, protein-protein interactions, and 
metabolic pathways (Ochman and Raghavan, 2009). This landmark analysis suggested that the 
level of complexity of the regulatory pathways in place in this “simpler” organism was higher 
than previously thought. Furthermore, it provides a data framework for many studies including 
systems-level analyses of this bacterium’s physiology and evolution. Other examples come from 
studies using yeast, a unicellular eukaryotic organism. For example, genome-scale genetic 
interaction maps have proven useful in dissecting the functional redundancy underlying the 
functional wiring of cells and organisms (Costanzo et al., 2011). Systematic efforts for mapping 
these genetic interactions in Saccharomyces cerevisiae, using mutant libraries with double gene 
deletions, have led to enormous amounts of information regarding interactions between and 
within biological pathways, and thus, helped in starting to derive the functional map of a yeast 
cell (Costanzo et al., 2011). The few examples cited above demonstrate the power of systems-
level approaches in elucidating the wiring of biological processes, and help laying the path to 
move forward with more complex mammalian systems. However, they also clearly remind us 
that the level of complexity of biological models, as simple as they may seem, is still high 
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enough that many more technological and conceptual advances will be required to generate 
truly functional maps of a cell. 
 
1.3. Studying Complex Immunological Systems 
Systems approaches have also made a steady foray into the study of the immune system 
(Benoist et al., 2006; Germain et al., 2011), including innate immune pathways (Zak and 
Aderem, 2009). Numerous reports have focused on various regulatory layers of immune cells, 
and here, we will focus on systematic studies of signaling and transcriptional layers, which are 
directly connected to the primary goals of this thesis work. Of note, other regulatory layers are 
equally important to the understanding of immune processes. For example, studies of the 
epigenome and associated regulatory pathways that are important for immune functions have 
also emerged in recent past (Northrup and Zhao, 2011). Human CD4+ T cells are among the 
cell types that have been the most widely characterized at the epigenomic level (Northrup and 
Zhao, 2011). Indeed, several studies have collectively profiled the genome-wide distributions of 
many histone modifications and TF binding events, and are setting up the stage to many more 
similar studies. These studies have contributed to the basic understanding of chromatin biology 
and immune cell type division and differentiation. 
 
Transcriptional Regulatory Layer. Studies of transcriptional responses and networks have 
perhaps led to most contributions of systems approaches to deciphering immune functions. This 
is likely due to the early advent of enabling technologies in transcriptional profiling, such as 
microarrays (Schena et al., 1995), compared to the more recent advances in protein-based 
profiling using mass spectrometry. It led to many contributions in fields ranging from pathogen 
sensing (Gilchrist et al., 2006; Jenner and Young, 2005; Litvak et al., 2009; Suzuki et al., 2009), 
to hematopoiesis (Novershtern et al., 2011), to human diseases such as autoimmunity 
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(Guiducci et al., 2010; Pascual et al., 2010) or tuberculosis (Berry et al., 2010), to vaccinology 
(Nakaya et al., 2011; Pulendran et al., 2010; Querec et al., 2009), and even to the 
Immunological Genome Project (Heng and Painter, 2008). 
 
Host transcriptional responses to microorganisms and viruses have been extensively studied 
following the advent of microarrays (Jenner and Young, 2005). For example, some of the initial 
studies in this field led to the identification of IFN-induced genes (ISGs), which are regulated in 
host cells upon exposure to IFNs (Jenner and Young, 2005). These studies have thus 
highlighted common sets of components induced at the transcriptional level, either directly or 
indirectly, by pathogens. Depending on the host cell-type or pathogen considered, the sets of 
induced components may vary, but in all cases, it appeared clear that multiple transcriptional 
regulators were necessary to coordinate every aspect of these responses. Altogether, these 
studies paved the way to functional studies whereby host genes may be perturbed genetically 
(e.g., knockout) or post-transcriptionally (e.g., RNAi) and the result of such perturbation on 
pathogen-induced responses may be monitored by transcriptional profiling. 
 
In the field of TLR biology, initial studies using TLR4 signaling induced by lipopolysaccharide 
(LPS; Gram-negative bacterial wall component) have generated important insights for the 
understanding of the transcriptional regulation occurring in pathogen sensing (Gilchrist et al., 
2006; Litvak et al., 2009). For example, using microarray profiling to identify LPS-regulated 
genes in macrophages, these studies identified candidate transcriptional regulators by scanning 
for TF-binding sites in the promoter regions of LPS-regulated genes (Gilchrist et al., 2006; Litvak 
et al., 2009). The transcription factors ATF3 and C/EBPδ were identified as critical regulators 
downstream of the LPS sensor TLR4, and their roles were further investigated using functional 
(i.e., knockouts) and physical (i.e., chromatin immunoprecipitation) approaches. Overall, these 
studies highlighted the necessity for multiple TFs to work in concert as sub-circuits to finely 
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control LPS-regulated gene expression, raised the questions of how these TFs may be 
systematically identified and how their inter-relationships may be mapped. 
 
Studies in other model systems have made important contributions to start tackling these 
challenges using integrated computational and experimental approaches. For example, a group 
combined transcriptional profiling together with functional studies using siRNA in a myeloid cell 
line, THP-1, in the context of stimulation with phorbol myristate acetate (PMA) (Suzuki et al., 
2009). First, they scanned for TF binding motifs within close proximity of the promoter regions of 
PMA-regulated genes in their THP-1 cellular model system. Second, identified binding sites 
were used to infer the variation in activity of TFs over time upon PMA stimulation. Third, the 30 
core TFs identified by these analyses were assembled in a predicted transcriptional regulatory 
network. Finally, the authors of this study were able to validate some of the predictions 
emanating from their network modeling by knocking down selected TFs from their core network 
using siRNAs. Altogether, this study in THP-1 cells and the work highlighted above in TLR4-
mediated transcriptional regulation helped advancing our knowledge of transcriptional regulatory 
circuits. However, these studies remain limited by the use of TF binding sites which remains a 
poor predictor of TF-target gene relationships, and thus, limits de novo identification of TFs 
involved in a biological response to a stimulus since many TF’s binding sites remain poorly 
defined or unknown. 
 
As exemplified by the studies delineated above, transcriptional regulatory networks are critical in 
controlling acute cellular responses to a stimulus such as a pathogen or its molecular 
components. Transcriptional networks are also critical in driving differentiation processes such 
as hematopoiesis, and in maintaining differentiated cell types such as immune cell subsets. For 
example, the Immunological Genome Project has undertaken a multi-laboratory effort to 
generate genome-wide mRNA profiles of >200 immune cell types (Heng and Painter, 2008). 
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These datasets will undoubtedly be key to start dissecting the transcriptional networks operating 
the division of labor within cell types of the immune system. Another example of this view comes 
from a recent study that carried out genome-wide mRNA profiling of 38 human hematopoietic 
cell types (Novershtern et al., 2011). From these profiles, ~80 modules of co-expressed genes 
were identified across these 38 cell types. Furthermore, enriched cis-regulatory elements within 
each module highlighted TFs that are likely to contribute to the regulation of these modules. 
Using shRNA-mediated knockdowns, some of these TFs were validated as being functionally 
important in driving the differentiation of hematopoietic lineages in vitro. Altogether, this 
integrated computational and experimental study provided an initial draft for the complex 
transcriptional regulatory circuits driving the differentiation of human hematopoietic lineages. As 
stated above, because the binding sites for many TFs are still unknown, this study is likely to be 
underestimating the actual number of TFs necessary to finely control these differentiation 
programs. 
 
Studies of transcriptional responses in immune cells have also helped with deciphering the 
mechanism of action and predicting the efficacy of therapies against infectious and non-
infectious diseases. For example, recent studies have used transcriptional profiling in human 
blood immune cells to identify early gene regulatory events that correlate with effective vaccine 
regimens, as measured by antibody and T cell responses several weeks upon administration 
(Nakaya et al., 2011; Pulendran et al., 2010; Querec et al., 2009). Using a similar approach, 
others have highlighted a previously unrecognized role for type I interferons (IFNs) in the 
pathogenicity of tuberculosis, and furthermore, identified potential biomarkers for various stages 
of the disease (Berry et al., 2010). Another study, focused on systemic lupus erythematosus 
(SLE), suggested a mechanism that helps explain why many SLE patients show resistance to 
glucocorticoids, common treatment against autoimmune disorders such as SLE (Guiducci et al., 
2010).  
 9 
 
Collectively, the studies presented in this section exemplify how transcriptional regulation may 
be harnessed to generate advances in both basic understanding of immune processes, and in 
therapies aiming to manipulate these processes. 
 
Signaling Regulatory Layer. In this section, we focus on the emergence of systems 
approaches applied to the understanding of signal transduction. The regulation of signaling 
processes is tightly connected to downstream transcriptional programs. Generally speaking, the 
propagation of signaling events is linked to changes in the post-translational modifications 
(PTMs) of proteins (e.g., phosphorylation), in protein-protein interactions, and in protein 
concentrations (Choudhary and Mann, 2010). These various components of signaling regulatory 
layers can now be measured and studied in an unbiased fashion thanks to recent advances in 
mass spectrometry (MS)-based proteomics (Choudhary and Mann, 2010). These advances 
have spurred numerous findings in various immunological processes such as signaling 
regulation in dendritic cells (Luber et al., 2010), macrophages (Weintz et al., 2010), and T cells 
(Navarro et al., 2011), among other cell types (Fraser and Germain, 2009).  
 
Large-scale measurements of PTMs using MS-based proteomics have perhaps led to one of 
the biggest data explosion in the field of signaling regulation. For example, analyses of 
phosphorylation levels at steady state and upon stimulation have identified tens of thousands of 
phosphosites across the eukaryotic proteome. In the field of TLR biology, the study of the TLR4-
regulated phosphoproteome led to the identification of potentially new signaling modules as 
players of the TLR pathways (Weintz et al., 2010). Another example comes from a recent study 
of the T cell receptor-regulated phosphoproteome (Navarro et al., 2011). Navarro and 
colleagues identified a subset of transcriptional regulators as significantly enriched among the 
phosphoproteins measured in their T cell model system. Among these regulators, HDAC7 
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appeared as a key regulator of the expression of the IL-2 receptor by T cells (Navarro et al., 
2011). 
 
Besides the numerous studies of PTMs, measurements of total protein abundance across 
various cell types have led to important advances in our knowledge of the division of labor of 
immune cell subsets. For example, measurements of protein levels in classical and 
plasmacytoid DCs from the mouse spleen have uncovered differences in pathogen sensor 
expression among these cells (Luber et al., 2010). Altogether, the studies described above as 
examples clearly demonstrate the power of MS-based proteomics to map intracellular 
processes such as signal transduction. 
 
Integrative Analyses. Building upon these developments in dissecting various regulatory layers 
of cell biology, integrative studies that aim to tackle the challenge of dissecting immune cellular 
circuitries have emerged. Broadly speaking, they focus on explaining immunological functions 
by providing functional and physical information across various regulatory layers. For example, 
a landmark study on the TNF-α/NF-κB signal transduction pathway has paved the way to these 
integrative studies (Bouwmeester et al., 2004). In this study, the authors focused on 32 known 
signaling and transcriptional components of the tumor necrosis factor (TNF)-α pathway. Then, 
they placed each of these components within their functional context in the activated pathway 
by identifying their binding partners using MS-based proteomics. Furthermore, functional 
perturbations of selected binding partners using RNAi led to the identification of novel 
components of the TNF-α pathways such as the E3 ubiquitin ligase TRAF7. This study 
constitutes one of the first examples of an integrated approach to dissect a signal transduction 
pathway from both physical and functional standpoints. 
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More recent works relying on a similar conceptual framework have also participated in our 
systems-level understanding of processes important to DC biology such as antigen presentation 
by major histocompatibility complex (MHC) molecules (Neefjes et al., 2011; Paul et al., 2011), 
and pathogen-sensing pathways (Chiang et al., 2012; Li et al., 2011). To further our knowledge 
of MHC class II biology, one of the studies mentioned above (Paul et al., 2011) has taken 
advantage of RNAi perturbations to screen for new modulators of MHC II trafficking and surface 
expression in a cell line model. Using a genome-wide RNAi screen, a couple hundred of 
candidate regulators were shown to have an impact on MHC II expression at the cell surface 
and/or MHC II peptide loading (Paul et al., 2011). Several GTPases and motor proteins not 
previously linked to the MHC II pathway were identified as regulators of the transport of MHC II 
within antigen-presenting cells (APCs) (Paul et al., 2011). These types of studies will help in 
increasing the pace of discovery of regulators of MHC processes, and point towards clear 
mechanistic hypotheses that may be tested by standard biochemical and cell biological 
approaches. Ultimately, given the central role of MHC presentation in normal and pathological 
immunological events, such detailed understanding of antigen processing may lead to improved 
therapeutics in the future (Neefjes et al., 2011). 
 
In the field of pathogen sensing, recent studies (Chiang et al., 2012; Li et al., 2011) have 
followed approaches conceptually similar to the works mentioned above. In the study reported 
by Li and colleagues, 58 components of the signaling pathways leading to type I IFN production 
were subjected to immunoprecipitation followed by MS to identify binding partners (Li et al., 
2011). Among the numerous interacting proteins found for these 58 known components, MIB1 
and MIB2 were found to play a redundant role in regulating type I IFN production via the TBK1-
IRF3 signaling axis. MIBs were shown to directly ubiquitinylate TBK1, which was important for 
TBK1 activity and downstream antiviral gene expression in the context of viral infection or 
stimulation with viral ligands (Li et al., 2011). On the other hand, Chiang and colleagues 
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performed a genome-wide RNAi screen to identify regulators of TLR7- and TLR9-mediated 
activation of NF-κB (Chiang et al., 2012). Using a variety of independent evidence of 
functionality together with re-screening with multiple siRNAs, they were able to identify nearly 
200 regulators of these pathways with putative roles at various levels of regulation such as 
transcription, signaling, or TLR intracellular trafficking (Chiang et al., 2012). For example, HRS, 
a component of the endosomal sorting complex required for transport (ESCRT) machinery, was 
shown to play a role in the delivery of TLR7 and 9 to endolysosomes from where these 
receptors have been shown to initiate signal transduction (Chiang et al., 2012). 
 
Overall, the selected studies described in this section clearly exemplify the growing role of 
systems approaches in helping to understand immunological processes, and to generate 
hypotheses and models regarding these processes. Many challenges remain, including the use 
of immune cell types that are more relevant to the pathways and processes under study. For 
example, genome-wide RNAi screen and targeted interaction proteomic studies were performed 
in cancer cell lines that may not express all of the components relevant to the pathways under 
study. Furthermore, there is a need for systematic approaches that start addressing mechanistic 
questions – a challenge which is not limited to immunology. For example, how can we better 
define the function of candidate emanating from large-scale RNAi screens? 
 
1.4. Pathogen-Sensing Pathways of Innate Immunity  
Toll-Like Receptors: Overview and Significance. The past decade has witnessed 
fundamental progress in our understanding of the innate immune system – the first line of host 
defense against pathogens. The identification of host sensors and their cognate ligands has 
shed light on the initiation of innate immunity. These advances stem from a body of theoretical 
and experimental work that led to the identification of sensors for microbial molecules in 
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Drosophila (Toll protein), and subsequently in mammals (Toll-like receptor; TLR) (Beutler and 
Rietschel, 2003; Kawai et al., 1999; Lemaitre et al., 1996; Medzhitov, 2009; Medzhitov et al., 
1997; Poltorak et al., 1998). Remarkably, these sensors are evolutionary conserved in 
vertebrates and insects, and share structural and mechanistic features with immune sensors of 
infection in plants (Ronald and Beutler, 2010).  
 
To date, several families of innate immune sensors have been revealed across most 
intracellular compartments: transmembrane TLRs and C-type lectin receptors (CLRs), and 
cytosolic nucleotide‐binding oligomerization domain (NOD)-like receptors (NLRs) and retinoic 
acid-inducible gene (RIG)-I-like receptors (RLRs) (Takeuchi and Akira, 2010). Even though 
many questions remain regarding the biology of TLRs, they are currently considered to be the 
best-characterized sensors of microorganism- and virus-derived molecules in mammals 
(Medzhitov et al., 2011). Ten human and twelve mouse TLRs have been uncovered, and 
exogenous and/or endogenous ligands have been identified for most of them. For example, 
TLR2 forms heterodimers with TLR1 and TLR6 to bind bacterial lipoproteins; TLR4 recognizes 
lipopolysaccharide together with MD-2 and CD14; and TLR3, 7, 8 and 9 detects nucleic acids 
(Takeuchi and Akira, 2010). 
 
TLRs have been implicated in a variety of infectious and non-infectious diseases, ranging from 
cancer to autoimmunity. Strong genetic evidence for these implications has emerged in recent 
years. For example, mouse and human genetic studies have associated TLRs and downstream 
pathway components with infectious disease susceptibility and progression (Beutler et al., 2006; 
Casanova et al., 2011; Chapman and Hill, 2012; Takeuchi and Akira, 2010). Genome-wide 
association studies (GWAS) have participated in connecting the TLR pathways to increased 
susceptibility to a variety of autoimmune disorders, such as systemic lupus erythematosus 
(SLE) or rheumatoid arthritis (Xavier and Rioux, 2008).  
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This broad range of biological functions and dysfunctions makes TLRs attractive targets for the 
development of immunotherapies in many clinical contexts (Hennessy et al., 2010; Kanzler et 
al., 2007). For example, in infectious diseases, the use of TLR agonists as vaccine adjuvants is 
an area of intense investigation. The effects of existing adjuvants have also been shown to rely 
on signals from TLRs and other innate immune sensors (Hennessy et al., 2010; Ishii and Akira, 
2007). Furthermore, TLRs and other innate immune sensing pathways play important roles in 
tumorigenesis (Grivennikov et al., 2010), and in other chronic inflammatory disorders such as 
autoimmunity (Mills, 2011). Altogether, these findings have spurred many clinical programs to 
translate the knowledge of TLR biology into therapeutics (Hennessy et al., 2010; Kanzler et al., 
2007), which illustrate the important need for a precise dissection of the TLR system across 
regulatory layers and cell types. 
 
Control of Dendritic Cell Processes by TLRs. TLRs act as sensors that allow the host to 
perceive the presence of microorganisms, an ongoing infection, or tissue damage. The signals 
emanating from TLRs are not only key in the initiation of innate immune responses, but also in 
the mounting of adaptive immune responses (Iwasaki and Medzhitov, 2010; Paul, 2011). DCs 
are perhaps the most important cellular nexus that integrate signals coming from TLRs and 
other innate immune receptors, and relay them to downstream adaptive immune cells such as T 
lymphocytes (Steinman and Banchereau, 2007).  
 
DCs consist of multiple subtypes that are collectively present in nearly every organ of the body 
(Idoyaga and Steinman, 2011). Upon detection of microbial constituents and/or other 
environmental signals, DCs ingest and process antigens for presentation at their cell surface on 
major histocompatibility complex (MHC) molecules, and migrate from the tissue into the draining 
lymph node where priming of antigen-specific lymphocytes occurs. Recent years have led to 
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major advances in understanding DC biology in terms, for example, of their developmental 
pathways (Liu and Nussenzweig, 2010) or their roles in humans (Collin et al., 2011). Because 
the primary focus of this thesis work is to decipher intracellular circuits, we will focus on 
introducing the initial changes induced in DCs by TLR signals (Watts et al., 2010), together with 
some of the associated regulatory mechanisms of TLR function. 
 
TLR Signaling. Upon TLR engagement, DCs activate multiple pathways leading to an increase 
in: (1) antigen uptake; (2) MHC molecule synthesis, trafficking, and turnover; (3) motility and 
migration; and (4) transcriptional and translational activity, including production of soluble 
mediators such as pro-inflammatory and antiviral cytokines (Watts et al., 2010). All of these 
changes are controlled, at least in part, by the cascades of signals acting directly downstream of 
TLRs. TLRs are type I transmembrane proteins composed of an ectodomain containing leucine-
rich repeats (LRRs), a single transmembrane domain, and a cytoplasmic Toll/IL-1 receptor (TIR) 
domain (Takeuchi and Akira, 2010). Upon ligand binding, TLRs form homo- or hetero-dimers, 
which leads to the recruitment of cytosolic adaptor molecules and initiates signaling. LRRs of 
the TLR ectodomains bind to cognate ligand, which is thought to trigger conformational changes 
responsible for the intracellular recruitment of TIR-domain containing adaptors. The association 
between these TIR-domain adaptors and the intracellular TIR domain of TLRs constitute the first 
step in the signaling cascade. The selective recruitment of subsets of TIR adaptors helps 
explaining, at least in part, the specificity in TLR signaling.  
 
Five TIR domain-containing adaptors have been reported to be functional in the TLR pathways:  
myeloid differentiation primary‐response protein 88 (MYD88), TIR‐domain‐containing adaptor 
inducing IFNβ (TRIF), TRIF-related adaptor molecule (TRAM), TIRAP that is also known as Mal, 
and Sterile-alpha and Armadillo motif-containing protein (SARM) (Takeuchi and Akira, 2010). 
Classically, the TLR signaling cascades have been subdivided into two pathways depending on 
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the use of the TIR domain-containing adaptors MYD88 and TRIF. These two pathways are 
referred to as the MYD88-dependent and the TRIF-dependent pathways, respectively. All TLRs 
but TLR3 have been shown to recruit the MYD88 to their cytoplasmic TIR domain. Some TLRs, 
such as TLR7 and 9, rely completely on MYD88 for signal transduction, whereas TLR3 depends 
on the recruitment of TRIF for signaling. TLR4 is the only TLR that signal through both MYD88 
and TRIF. 
 
The MYD88-dependent pathway initiates with the association of death domains (DD) between 
MYD88 and IL-1R-associated kinases (IRAKs), a family of serine-threonine protein kinases. 
MYD88 has been shown to first bind IRAK4, which in turn activates IRAK1 and 2 (Takeuchi and 
Akira, 2010). IRAKs activate the E3 ubiquitin ligase TNFR-associated factor 6 (TRAF6), which in 
turn, in combination with the E2 ubiquitin-conjugating enzymes Ubc13 and Uev1A, activates a 
complex comprised of TGF-β-activated kinase 1 (TAK1), TAK1-binding protein 1 (TAB1), TAB2, 
and TAB3. The formation of the TAK1 complex leads to the activation of both mitogen-activated 
protein kinases (MAPKs) and NF-κB pathways. The first members of the MAPK pathway to be 
activated by the TAK1 complex are MAPK kinase (MAPKK) 3 and 6, leading to the subsequent 
activation of the three canonical MAPK pathways: Jun kinase (JNK), p38, and ERK. Ultimately, 
MAPKs activate downstream transcriptional regulators that include CREB and AP-1. In addition, 
the TAK1 complex phosphorylates IκB kinase (IKK)-β, which is part of the IKK complex 
comprising IKK-α, IKK-β, and NF-κB essential modulator (NEMO). Upon activation, the IKK 
complex phosphorylates the NF-κB inhibitory protein IκBα, leading to its degradation via the 
ubiquitin pathway to the proteasome. Upon degradation of IκBα, NF-κB is relieved from 
cytoplasmic sequestration and translocates to the nucleus, where it will participate in the 
regulation of pro-inflammatory gene production, such as tumor necrosis factor (TNF), interleukin 
(IL)-6, IL-12, or IL-1. Interestingly, the MYD88-dependent pathway varies depending on the cell-
type considered. Whereas the canonical pathways described above are known to occur in 
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classical DCs (cDCs), in plasmacytoid DCs (pDCs) stimulated with TLR7 or 9 agonists, MYD88 
forms a complex containing TRAF6 and 3, IRAK family members, IKK-α and IRF7, among 
others, which leads to the phosphorylation of IRF7 followed by its translocation into the nucleus. 
Nuclear IRF7 controls the expression of type I interferons (IFNs). In addition, this MYD88-
dependent multiprotein complex downstream of TLR7 and 9 also controls the activation of the 
NF-κB and MAPK pathways. 
  
The TRIF-dependent pathway occurs downstream of only TLR4 and 3 (Takeuchi and Akira, 
2010). While TLR3 recruits TRIF directly to its intracellular TIR domain, TLR4 relies on an 
intermediate TIR domain-containing adaptor, namely TRAM, for TRIF recruitment and 
activation. TRIF harbors TRAF-binding motifs allowing the formation of a complex between 
TRIF and TRAF3 and 6. In addition, TRIF associates with receptor-interacting proteins 1 (RIP1) 
and 3 (RIP3) through a RIP homotypic interaction motif (RHIM). This TRIF complex has been 
described to activate two pathways leading to the transcriptional activation of both pro-
inflammatory genes and type I IFNs. For pro-inflammatory gene activation, the TRIF complex 
activates the NF-κB and MAPK pathways via TRAF6, RIP1, TNFR-associated death domain 
protein (TRADD), and TAK1. TRADD, upon association with FAS-associated death domain-
containing protein (FADD), ubiquitinates RIP1, which in turn leads to the activation of NF-κB and 
MAPKs to induce pro-inflammatory gene expression. For type I IFN induction, the TRIF complex 
activates via the ubiquitin ligase TRAF3 two IKK-related kinases: TANK-binding kinase 1 (TBK1) 
and IKK-i (also known as IKK-ε). TBK1 and IKK-i phosphorylate IRF3 and 7, which, upon 
hetero- and homo-dimerization, migrate into the nucleus to induce the expression of type I IFNs 
and IFN-inducible genes. Furthermore, TBK1 and IKK-i are modulated by a variety of factors 
such as TRAF family member-associated NF-κB activator (TANK), NAK-associated protein 1 
(NAP1), and the TBK1 adaptor (SINTBAD) (Takeuchi and Akira, 2010). The modulation of TBK1 
and IKK-i by these factors is motif-dependent. Indeed, these factors contain a TBK1-binding 
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motif and exhibit similarities in their coiled coil domains. Importantly, the relationships between 
these various factors still remain to be elucidated. 
 
Overall, the canonical pathways downstream of MYD88 include MAPKs and NF-κB, which 
drives the induction of pro-inflammatory cytokines, whereas the TRIF-dependent pathway 
culminates with the activation of NF-κB via TRAF6 and TAK1, and of IRF3 via TBK1 and IKKi, 
thus leading to the induction of both pro-inflammatory cytokines and type I interferons (IFNs) 
(Kawai and Akira, 2010). The balance between these pathways is critical in the control of 
infections, and their dysregulation has been associated with human disorders, including cancer 
and autoimmunity. 
 
Multilayer Regulation of the TLR System. TLR functions are regulated by control 
mechanisms operating at various cellular and molecular levels, which largely contribute to 
shaping TLR signaling and transcriptional networks. For example, TLRs may rely on different 
downstream components depending on the DC subset in which they are expressed (Blasius 
and Beutler, 2010). Indeed, while TLR7 or TLR9 activation on pDCs induces both inflammatory 
cytokines and type I IFNs, it only leads to inflammatory cytokine production in cDCs. TLR 
function is also tightly regulated by a variety of accessory molecules such as mediators of ligand 
delivery and/or recognition (e.g., HMGB proteins), chaperones, molecules facilitating 
intracellular trafficking or recycling of TLRs (e.g., Unc93b1), and TLR-processing enzymes (Lee 
et al., 2012). Some of these cofactors ensure that TLRs are delivered to specific subcellular 
compartments (e.g., endocytic pathway, plasma membrane), thus controlling the types of 
ligands to which given TLRs are exposed to, and the access to assigned signaling components 
and platforms (Barton and Kagan, 2009). 
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Additional control checkpoints operate at the transcriptional and post-transcriptional levels, 
which also participate in inducing and shutting off TLR-induced signals and downstream 
effectors. For example, the transcription factors (TFs) acting downstream of TLR4, which 
recognizes LPS, have been classified into three classes: (i) constitutively expressed but latent 
(e.g., NF-κB, IRF3), (ii) synthesized de novo upon TLR induction (e.g., Cebpd), and (iii) induced 
during cell differentiation (e.g., Cebpb, Runx1) (Medzhitov and Horng, 2009). Altogether, these 
various classes of TFs contribute to various phases of the TLR transcriptional response. While 
the rapid induction of these transcriptional changes is vital to the host, shutting them off and 
reducing the levels of inflammatory cytokines is equally as important. For example, specific 
RNA-binding proteins are important in regulating the stability or degradation of inflammatory 
cytokine mRNAs (Anderson, 2010). 
 
1.5. Main Goals and Questions 
Altogether, the regulatory processes highlighted above provide a brief description of some of the 
strategies contributing to the control of TLR function. The main goal of this thesis work is to start 
tackling the challenge of dissecting the modules and organizational rules driving the ‘signaling-
to-transcription’ TLR network. To do so, we designed experimental and analytic pipelines – 
easily transposable to other systems – and applied them to the study of TLRs in DCs. In brief, 
we build upon an initial approach focused on deciphering the transcriptional regulatory layer of 
TLRs (Chapter 2), by expanding it to signaling regulatory layers (Chapter 3), and by moving 
towards an integrative analysis of functional and physical interactions within and between these 
layers (Chapter 4). 
 
Some of the biological and immunological questions that have driven this work include: (i) how 
are pathogen-specific responses shaped by the regulatory circuitries of the TLR system; (ii) 
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what are the missing components and modules that account for the responses and help explain 
their overall functioning; (iii) how to address these questions in a large-scale and unbiased 
manner; and (iv) how to construct a model network, formulate hypotheses from it, and 
manipulate it? 
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Chapter 2 – Unbiased Reconstruction of the Mammalian 
Transcriptional Network Mediating TLR Responses 
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2.2. Introduction 
Regulatory networks controlling gene expression serve as decision-making circuits within cells. 
For example, when immune dendritic cells are exposed to viruses, bacteria or fungi, they 
respond with transcriptional programs that are specific to each pathogen (Huang et al., 2001) 
and are essential for establishing appropriate immunological outcomes (Kawai and Akira, 2009). 
These responses are initiated through specific receptors, such as Toll-like receptors (TLRs), 
that distinguish broad pathogen classes, and are propagated through well-characterized 
signaling cascades (Kawai and Akira, 2009). However, little is known about how the 
transcriptional network is wired to produce specific outputs. 
 
Two major observational strategies have associated regulators with their putative targets on a 
genome scale (Kim et al., 2009): cis-regulatory models rely on the presence of predicted 
transcription factor binding sites in the promoters of target genes (Kim et al., 2009; Ramsey et 
al., 2008; Suzuki et al., 2009), whereas trans-regulatory models are based on correlations 
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between regulator and target expression (Kim et al., 2009; Ramsey et al., 2008; Suzuki et al., 
2009; Segal et al., 2003). Because promoter binding sites and correlated expression are weak 
predictors of functional regulator-target linkages, such approaches are limited in their ability to 
produce reliable models of transcriptional networks (Kim et al., 2009). A complementary 
strategy is to systematically perturb every regulatory input and measure its effect on expression 
of gene targets. This strategy has been successfully employed in yeast (Capaldi et al., 2008; Hu 
et al., 2007; Workman et al., 2006) and sea urchin (Erwin and Davidson, 2009), but not in 
mammals. 
 
2.3. A Perturbation-Based Strategy for Network Reconstruction 
We developed a perturbation strategy for reconstructing transcriptional networks in mammalian 
cells, and applied it to determine a network controlling the responses of DCs to pathogens 
(Figure 2.1). 
 
 
Figure 2.1. A Systematic Strategy for Network Reconstruction 
The strategy consists of four steps (left to right): state measurement using arrays; selection of regulators 
and response signatures; network perturbation with shRNAs against each regulator, followed by 
measurement of signature genes; and network reconstruction from the perturbational data. 
 
First, we profiled gene expression at nine time points following stimulation with five pathogen-
derived components and identified specific and shared genes that respond to each stimulus. We 
used these profiles to identify 144 candidate regulators whose expression changed in response 
to at least one stimulus. We also identified a signature of 118 marker genes that captures the 
complexity of the response. We generated a validated lentiviral shRNA library for 125 of the 144 
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candidate regulators, used it to systematically perturb each of the regulators in DCs, stimulated 
the cells with a pathogen component, and profiled the expression of the 118 gene signature 
(Geiss et al., 2008). Finally, we used the measurements from the perturbed cells to derive a 
validated model of the regulatory network. 
 
2.4. Gene Expression Programs in Response to TLR Agonists 
We measured genome-wide expression profiles in DCs exposed to Pam3CSK4 (PAM), a 
synthetic mimic of bacterial lipopeptides; polyinosinic:polycytidylic acid (poly(I:C)), a viral-like 
double-stranded RNA; lipopolysaccharide (LPS), a purified component from Gram negative 
Escherichia coli; gardiquimod, a small molecule agonist; and CpG, a synthetic single-stranded 
DNA. These compounds are known agonists of TLR2, TLR3, TLR4, TLR7 and TLR9, 
respectively. poly(I:C) also activates MDA-5, and LPS can also act through co-receptors such 
as CD14. We therefore refer to the ligands rather than their receptors for clarity. Based on pilot 
experiments (Amit et al., 2009), we measured mRNA expression at 0.5, 1, 2, 4, 6, 8, 12, 16, and 
24 hours following stimulation with these pathogen components (Figure 2.2A). 
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Figure 2.2. Gene Expression Response to Pathogen Components 
(A) mRNA profiles of the 1800 genes whose expression was induced by a factor of at least 1.7 from 
baseline level in both duplicates of at least one time point in CD11c+ DCs stimulated with the indicated 
pathogen component across a time course of 0, 0.5, 1, 2, 4, 6, 8, 12, 16, or 24 hours (tick marks; pIC, 
poly(I:C); GRD, gardiquimod). Replicates were collapsed and genes hierarchically clustered (rows, 
genes; columns, experiments; red, induced from baseline; blue, repressed from baseline; white, 
unchanged from baseline).  
(B) Model illustrating the differential gene regulatory networks controlling the antiviral (“poly(I:C)-like”) and 
inflammatory (“PAM-like”) programs. 
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The observed transcriptional responses were classified into a “PAM-like”’ program and a 
“poly(I:C)-like” program, as well as a shared response (24.5% shared by PAM/poly(I:C)/LPS). 
The LPS response was largely the union of the “PAM-like” and “poly(I:C)-like” programs. This is 
partly explained by the known signaling pathways activated by these agonists. PAM binds TLR2 
and signals through the MYD88 pathway; poly(I:C) binds TLR3 and MDA-5 and signals mostly 
through the TRIF and IPS-1 pathways, respectively; and LPS binds TLR4 and co-receptors and 
uses the MYD88 and TRIF pathways (Kagan et al., 2008). It is also consistent with the known 
induction of an anti-viral response by poly(I:C) and LPS (Doyle et al., 2002). The “PAM-like” 
program is enriched for the transcription factor NF-κB and for inflammatory responsive genes (P 
< 6.1 x 10-8), whereas the “poly(I:C)-like” program is enriched for interferon regulatory factors 
(IRFs) and for viral- and interferon-responsive genes (ISGs, P < 8.3 x 10-24). For simplicity, we 
thus refer to them as the “inflammatory” and “antiviral” programs (Figure 2.2B). A small number 
of genes are specific to a single stimulus. For example, ~250 genes are poly(I:C)-specific (1250 
are shared with LPS), including several Type I interferons (e.g., Ifna2, Ifna4, Figure 2.2A). 
Surprisingly, 82% of the gardiquimod (TLR7) and CpG (TLR9) response was shared with the 
LPS response, but with a weaker anti-viral component (Figure 2.2). This observation is 
unexpected given their different signaling mechanisms (Kawai et al., 2004), but is highly 
reproducible and robust (Amit et al., 2009). 
 
2.5. Identification of Candidate Regulators and a Response Signature 
To select potential regulators that mediate the observed transcriptional response, we focused 
on regulator genes whose expression changes during pathogen sensing, which is a reasonable 
assumption for many mammalian responses (Amit et al., 2007; Pe'er et al., 2002), including 
pathogen-sensing (Huang et al., 2001; Ramsey et al., 2008). First, we reconstructed an 
observational trans-model of gene regulation that associated 80 modules of co-regulated genes 
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with 608 predictive regulators (Lee et al., 2009; Ramsey et al., 2008; Zou and Hastie, 2005), 
automatically chosen out of a curated list of 3287 candidate regulators. This draft observational 
model was generated from the transcriptional profiles using a modification of the Module 
Networks algorithm (Zou and Hastie, 2005). Briefly, we used a probabilistic graphical model that 
takes an expression dataset and a set of candidate regulators (e.g., all known and putative 
transcription factors in the genome), and reconstructs modules of co-regulated genes, and a 
regulation program that attempts to explain the expression of each module as a function of the 
expression of specific regulators. Here, we used a curated list of 3287 candidate proximal 
regulators of mRNA levels, including 1885 transcription factors, 1069 RNA binding proteins and 
333 chromatin factors. Filtering identified 117 regulators above a minimal expression signal in at 
least one experiment. These included known regulators from the NF-κB, STAT, and IRF 
families, as well as unexpected candidates such as the circadian regulator Timeless and the 
DNA methyltransferase Dnmt3a. Second, we added five constitutively expressed regulators 
(Irf3, Rela, Nfe2l2, Ets1, Creb3) whose cis-regulatory elements are enriched in the responsive 
genes. Third, to capture delayed responses or nonlinear relations, we incorporated 22 
regulators whose expression changed by at least a factor of 2. This resulted in 144 candidate 
regulators, with a distribution of expression patterns similar to the general response (Amit et al., 
2009). The regulators’ expression under LPS was conserved between DCs and functionally 
similar macrophages (Pearson correlation r = ~0.9 at 1 h) as well as between human 
macrophages and mouse DCs (r = ~ 0.6 at 2 h), supporting the functional relevance of the 
regulators’ transcription (Amit et al., 2009). 
 
To identify highly informative reporter genes for monitoring the effects of perturbing regulators, 
we devised an algorithm referred to as GeneSelector (Amit et al., 2009). This algorithm 
incrementally chooses genes (from our full expression dataset) whose expression profile 
improves our discrimination of stimuli given the previously chosen genes. Using this approach, 
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we identified the optimal time point (six hours post activation), and a set of 81 genes that 
distinguishes the stimuli. We added 37 candidate regulators with detectable expression at the 6-
hour time point, creating a signature set of 118 genes. Finally we added 10 control genes whose 
expression levels were unchanged under all stimuli, but whose basal, constant levels varied 
from very low to high.  
 
2.6. Perturbations, Profiling and Modeling 
We generated validated lentiviral shRNAs that knocked down expression of 125 of our 144 
candidate regulators by at least 75% and 32 shRNAs with no known gene targets as controls in 
bone marrow DCs (Amit et al., 2009). To carry out our perturbational study, we selected a single 
treatment, LPS, that activates the majority of both the inflammatory and antiviral programs. After 
stimulation of shRNA-perturbed DCs with LPS for 6 hours, we used a multiplex mRNA counting 
methodology to quantify the transcript levels of the 118 reporter and 10 control genes (Geiss et 
al., 2008). 
 
The changes in signature gene expression resulting from infection with each shRNA were used 
to construct a model that associated regulators to their targets. We expected increases in the 
transcript levels of reporter genes whose repressors are targeted by knockdown, and decreases 
in reporters whose activators are targeted. Our false discovery rate (FDR) model estimates the 
statistical significance of a change in transcripts in DCs infected with a given shRNA 
(Experimental Procedures). We controlled for gene-specific noise by comparing to changes in 
the expression of each gene after perturbation with the control shRNAs (Figure 2.3A), and for 
shRNA-specific noise by comparing to changes in the expression of the control genes after a 
given shRNA perturbation (Figure 2.3B). We estimated the sensitivity of our calls from the 37 
regulators, which are also included as target reporters (Amit et al., 2009). 
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Figure 2.3. Gene Regulatory Programs Controlling the Response to Pathogen Components 
(A-B) A strategy to minimize the false discovery rate (FDR) calls of significant changes in an output target 
gene resulting from knockdown of a regulator gene. (A) The first FDR procedure (top) compares the  
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Figure 2.3 (Continued) 
expression of the gene after a perturbation with a regulator shRNA (right) to its expression upon 
perturbation with 32 nontargeting shRNAs (left). The dashed lines identify the gene-specific FDR-based 
thresholds for induction (blue line) and repression (red line). A discrete vector of significant calls (bottom) 
is derived from the raw data (blue, regulator represses the target gene; red, regulator induces the target 
gene). (B) A second FDR procedure (top) compares the expression of the target gene to that of eight 
control (target) genes upon perturbation with the same shRNA. In the example shown, the gene’s 
induction (left) was significant relative to the variation in expression among the control target genes, 
resulting in a high score (bottom, dark blue), but its repression did not significantly differ from the controls, 
resulting in a lower score (bottom, weaker red). 
(C) All significant (95% confidence) relations between regulators (columns) and targets (rows), colored as 
in (B). The gray bar (right) represents the NMF-based calls for each target gene; black, antiviral program; 
dark gray, inflammatory program; light gray, control genes. The bottom bar shows the degree of effect by 
the regulator on each program as determined by the NMF projection of the regulator’s perturbation profile 
(yellow, high; green, low). 
 
On the basis of these results, we identified a densely overlapping network with 2322 significant 
regulatory connections, including 1728 activations and 594 repressions (Figure 2.3C, red and 
blue, respectively, at 95% confidence; Amit et al., 2009). Of the 125 tested regulators, we 
confidently identified 100 with at least four targets. Among those were 24 hub regulators that 
were predicted to regulate more than 25% of the 118 genes measured, as well as 76 specific 
regulators, each affecting the expression of 4 to 25 genes. On average, ~14 (± 8 SD) regulators 
activated a target gene, and 5 (± 5.8 SD) regulators repressed it. Indirect effects may account 
for the large number of regulators we observed for each target. 
 
Our perturbational model captured known regulatory features of the response and identified 
novel regulators. The reporter genes partition into two main clusters based on their response to 
perturbations (Figure 2.3C), consistent with the expression data: the antiviral (“poly(I:C)-like”) 
program reporters (e.g., Cxcl10, Isg15, Ifit1), and the inflammatory (“PAM-like”) program 
reporters (e.g., Il1b, Cxcl2, Il6, Il12b). We also found many known regulatory relations – for 
example, the NF-κB family of transcription factors (Rel, Rela, Relb, Nfkb1, and Nfkb2) regulating 
their known inflammatory gene targets. Our network provided evidence for the involvement of at 
least 68 additional regulators in the response to pathogens, of which 11 were hubs not 
previously associated with this system. Interestingly, 12 regulators identified (e.g., Hhex, Fus, 
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Bat5, Pa2g4) are in linkage disequilibrium with single nucleotide polymorphisms (SNPs) 
associated with autoimmune and related diseases in genome-wide association studies (Amit et 
al., 2009). 
 
2.7. The Core Inflammatory and Antiviral Programs 
We next addressed how each regulator contributes to the generation of specific cell states. We 
first automatically defined the two major states induced by the five pathogen components with 
the use of non-negative matrix factorization (NMF) (Brunet et al., 2004) and the original array 
data (Amit et al., 2009). This procedure identified two major expression components (termed 
“metagenes”): one predominantly determined by genes from the inflammatory program and the 
other by genes from the antiviral programs (Figure 2.2A). Next, we quantified the effects of 
each regulator’s knockdown on these two states (Figure 2.3C, Amit et al., 2009) by classifying 
the target mRNA expression measurements following a regulator’s perturbation (Brunet et al., 
2004; Daily et al., 2007). 
 
Finally, we used a regulator ranking score (Amit et al., 2009) to assign 33 (including 8 known) 
genes as regulators of the inflammatory state and 33 (including 15 known) genes as regulators 
of the antiviral state. This accurately classified the known activators of the inflammatory 
response (e.g., NF-κB and related factors Rela, Nfkbiz, Nfkb1, Figure 2.3C, yellow in the 
inflammatory metagene), and of the antiviral response (e.g., Stat1, Stat2, Stat4, Irf8, Irf9; Figure 
2.3C, yellow in the viral metagene). Although all perturbation experiments were conducted only 
under LPS stimulation (a bacterial component), we correctly classified factors known to mediate 
the response to other stimuli. Because 34 additional regulators were associated with both 
responses, it is possible that a single regulator can control genes in either state, depending on 
the differential timing of regulator activation, its level, or combinatorial regulation. Notably, for 12 
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of the transcription factors examined, we found an enriched cis-regulatory element in the 
appropriate metagene (Amit et al., 2009). 
 
On the basis of the NMF scores, we identified an inflammatory subnetwork (Amit et al., 2009), 
an antiviral subnetwork (Figure 2.4A), and several fine-tuning subnetworks that affect smaller 
numbers of genes from both responses (Amit et al., 2009). The inflammatory subnetwork 
consisted of three regulatory modes: dominant activators (Cebpb, Bcl3, Cited2) which induce 
more inflammatory targets than anti-viral ones; cross-inhibitors (Nfkbiz, Nfkb1, Atf4, Pnrc2) 
which induce inflammatory genes while repressing anti-viral ones, and specific activators 
(Runx1, Plagl2), that only target inflammatory genes (Amit et al., 2009). We observed that 
dominant activators mostly regulate effectors, whereas regulators are primarily controlled by 
cross-inhibitors. 
 
 38 
 
Figure 2.4. The Core Regulatory Circuits Controlling the Inflammatory and Antiviral Responses 
(A) The antiviral subnetwork shows regulatory relations between the core antiviral regulators (blue nodes, 
top), their targets (boxes, bottom), each other, and inflammatory regulators (green node, top right). The 
two top regulators, Stat1 and Stat2, activate all antiviral targets (dashed blue arrows). The second-tier 
regulators activate subsets of targets (dashed purple arrows).  
(B) Examples of feedforward loop classes identified in the network, with fraction of each class.  
(C) A core regulatory network of the inflammatory and antiviral programs, consisting of the most distinct 
regulators, and their relation to ligands and receptors (top). Pointed arrows, induction; blunt arrows, 
repression; green ovals, inflammatory regulators; blue ovals, antiviral regulators. Example target genes 
are noted.  
(D) mRNA expression profiles for the TLR target genes (rows) upon perturbation with shRNAs against a 
subset of viral regulators (columns) and followed by stimulation with LPS (left) or poly(I:C) (right). All 
values are normalized by expression in cells infected with a control shRNA and under the same stimulus 
(shCtl). 
 
Focusing on the network architecture, we found multiple feedforward circuits in this response, 
where an upstream regulator controls a target gene both directly and indirectly through a 
secondary regulator (Figure 2.4B) (Amit et al., 2009; Mangan and Alon, 2003). The majority 
(~75%, 4892 of 6444) of these feedforward circuits were found to be coherent (Mangan and 
Alon, 2003), having the same direct and indirect effect on the regulated gene. The vast majority 
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(80%) are type I loops (Alon, 2007) with all-positive regulation (e.g., Nfkbiz activates E2f5 and 
both activate IL6). Such feedforward circuits respond to persistent rather than transient 
stimulation, protecting the system from responding to spurious signals, as was shown for one 
circuit in LPS-stimulated macrophages (Litvak et al., 2009). Our finding suggests that coherent 
feedforward loops, especially class I (Mangan and Alon, 2003), are a general design principle in 
this system and may physiologically impact this response.  
 
In the antiviral sub-network, we identified a two-tiered regulatory circuit combining feed-forward 
and feedback loops (Figure 2.4A) (Amit et al., 2009). This circuit has at the top the antiviral 
regulators Stat1 and Stat2, which regulate a full complement of anti-viral reporters. The second-
tier regulators, Timeless, Rbl1 and Hhex are controlled by Stat1 and Stat2 and most likely form 
coherent feedforward loops that target specific subsets of genes. Timeless, Rbl1 and Hhex also 
feed back and promote the expression of the Stat regulators. This circuit is repressed through 
the cell cycle regulator and RNA binding protein Fus (Wang et al., 2008), acting as a single 
dominant inhibitor of 43 viral genes. 
 
Finally, we derived a core network incorporating the regulators with the most substantial impact 
on each response, on the basis of the number, magnitude, and logic of targets that each 
regulator affects (Experimental Procedures). The core network (Figure 2.4C) has 24 
regulators, 13 of which have previously been identified as key factors regulating the 
inflammatory or antiviral responses; the other 11 have not been previously implicated in either 
response. Of these, 19 are transcription factors, three are chromatin modifiers, and two are 
RNA binding proteins. The regulators apparently distinguish the two programs through cross-
inhibition (Figure 2.4C, gray lines) or dominant activation (Figure 2.4C). The core network also 
explains how differential expression of secreted factors is specified, leading to the activation and 
migration of appropriate cell types for different pathogens (Amit et al., 2009; Luster, 2002).  
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Embedded within the many known regulators of the antiviral response (Figure 2.4C), we found 
a large set of regulators not previously associated with this response. These included several 
known regulators of the cell cycle and the circadian rhythm, including Rbl1, Jun, Rb, E2f5, E2f8, 
Nmi, Fus, and Timeless, several of which were placed in our core network. This suggests that a 
cell cycle regulatory circuit was co-opted to function in the antiviral response in DCs (with no 
observable effect on cell cycle progression; Amit et al., 2009). Since we identified these antiviral 
regulatory relations in perturbation experiments using DCs stimulated with the bacterial 
component LPS, we silenced four regulators (Timeless, Rbl1, Jun and Nmi) after exposure to 
the viral component poly(I:C). Each of the four regulators had a strong impact on the antiviral 
program, more than was observed under LPS stimulation (Figure 2.4D), and on affected genes 
(e.g., Type I IFNs) whose expression is poly(I:C)-specific. Nmi affected a smaller set of genes, 
consistent with the model’s prediction. These results demonstrate our ability to correctly predict 
function in unobserved conditions. 
 
Although most antiviral genes are induced following stimulation with the bacterial component 
LPS, a few critical ones are expressed specifically in poly(I:C) stimulation, or follow distinct 
patterns in each stimulus. In response to viral infection cells induce the production of interferon 
β (Ifnb1), a crucial mediator of the antiviral response. Because high levels of interferon β may 
be deleterious to the host if infected by specific bacteria (Decker et al., 2005), we predicted that 
specific mechanisms insulate Ifnb1 mRNA regulation from the response to LPS. Indeed, 
although Ifnb1 expression was induced in the first two hours of stimulation with LPS, this 
expression declined at subsequent time points, in contrast to its sustained induction following 
poly(I:C) treatment (Figure 2.5A). Our model suggested that three regulators known to affect 
chromatin remodeling are Ifnb1 repressors in LPS (Figure 2.5B): the Polycomb complex 
subunit Cbx4 (Bernstein et al., 2006), Fus (Wang et al., 2008), and the DNA methyltransferase 
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Dnmt3a (Li et al., 2007). Cbx4 appeared to confer antiviral specificity to Ifnb1 mRNA induction 
as it is induced within the first two hours of PAM and LPS treatments but not by poly(I:C) 
(Figure 2.5C). Cbx4 knockdown caused induction of Ifnb1 mRNA and protein during LPS 
treatment (Figure 2.5D), but had no effect on the induction of the chemokine Cxcl10, a 
poly(I:C)- and LPS-induced gene (Amit et al., 2009). Cbx4 knockdown did not affect Ifnb1 during 
PAM activation (Figure 2.5E), when the antiviral response is not induced. Combined with 
evidence for chromatin changes around the Ifnb1 locus and its closest neighbor gene, Ptplad2, 
which has a similar dependence on Cbx4, these data are consistent with an effect by Cbx4 on 
local chromatin organization (Amit et al., 2009). Cbx4 knockdown affected few genes (~120 up-
regulated and ~120 down-regulated genome-wide) (Amit et al., 2009). Because most up-
regulated genes show a precise temporal pattern in unperturbed cells akin to that of Cbx4 – 
they are induced quickly and return to basal level by 2-4 hours (Amit et al., 2009) – we conclude 
that a chromatin modifier can act like a transcription factor controlling the precise expression of 
specific genes in the regulatory program. 
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Figure 2.5. The Polycomb Component Cbx4 Selectively Restricts Ifnb1 Production upon 
Stimulation with Bacterial Components 
(A and C) LPS (red), poly(I:C) (blue), and PAM (green)–induced expression of Ifnb1 (A) and Cbx4 (C) 
derived from data in Fig. 2A.  
(B) Ifnb1 expression (by nCounter) in response to LPS in DCs perturbed by control shRNAs or shRNAs 
targeting each of 125 regulators (format as in Figure 2.3B). 
(D) Ifnb1 mRNA levels (by quantitative reverse transcription polymerase chain reaction) after LPS 
treatment in unsorted mouse bone marrow DCs perturbed with an shRNA against Cbx4 (black) or a 
control shRNA (gray); signals are relative to t = 0. 
(E) Ifnb1 mRNA levels (by nCounter) at 6 hours after exposure to LPS or PAM in bone marrow DCs 
perturbed with an shRNA against Cbx4 or one of three control shRNAs.  
(F) Model for bacterial-specific repression of Ifnb1 by Cbx4. Both poly(I:C) and LPS induce Ifnb1 
expression early (left), but only LPS induces Cbx4, which then represses the Ifnb1 locus at a later time 
(right, top). 
 
Taken together, our results suggest a model of a transcriptional negative feedback loop, 
controlling Ifnb1 expression in LPS stimulation, wherein the induced pro-inflammatory regulator 
and chromatin modifier Cbx4 represses transcription by modifying the chromatin in the Ifnb1 
locus, generating the specificity needed to drive inflammatory versus the antiviral response 
(Figure 2.5F). The Type III coherent feedforward loop formed by Cbx4 and Dnmt3a (Figure 
2.4B) is consistent with a delayed repression of Ifnb1. Because neither regulator carries a 
sequence-specific DNA binding domain, the factors responsible for their guidance to the Ifnb1 
locus remain unknown.  
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2.8. Discussion 
A central goal of our study was to address the mechanistic basis for pathogen-specific 
responses. Consistent with previous studies (Doyle et al., 2002), we distinguished two key 
programs, a “PAM-like” inflammatory response and a “poly(I:C)-like” antiviral response, which 
are together induced by LPS, a Gram-negative bacterial component recognized by TLR4. These 
programs reflect both qualitative and quantitative differences between the required functional 
responses, and are consistent with the cross-protection between certain bacteria and virus 
infections (Doyle et al., 2002). The broad effect of LPS allowed us to focus on a single stimulus 
and time point, but screens with other stimuli may identify additional unique regulators. 
 
We found these two responses to be controlled by two corresponding regulatory arms, 
uncovering a mechanistic basis for the observed transcriptional responses. These two arms are 
integrated into a core network of two dozens regulators which balances specific and shared 
responses through dominant activation and cross-inhibition. In the inflammatory response, we 
found several feedforward loops, which may ensure response to only persistent, but not 
sporadic, signals. In the antiviral response, we discovered a two-tiered circuit involving feedback 
and feedforward loops, implicating a module of cell cycle regulators (Jun, Rbl1, Timeless, and 
Nmi), which we directly validated. Over 75 additional genes work to further fine-tune the 
regulation of gene targets. This perturbational model identifies many regulatory relations that 
would have been missed by non-systematic approaches. 
 
Our work establishes an unbiased, straightforward, and general framework for network 
reconstruction in mammalian cells (Amit et al., 2009). This approach can be executed at 
substantial scale and reasonable cost, and is compatible with the challenge of deciphering the 
multiple regulatory systems that operate in mammals. It can be expanded to derive increasingly 
detailed models, and distinguish direct from indirect targets. It will also facilitate the 
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development of new computational approaches to infer regulatory models. Although many 
computational approaches have attempted to derive observational models, their quality has 
been difficult to evaluate (Kim et al., 2009). The data generated here includes both expression 
profiles for training a model, as well as a perturbational unbiased screen for testing its quality 
(ftp://ftp.broadinstitute.org/pub/papers/dc_network/). When we compared the perturbational 
model to our observational model, we found that many candidate regulators were correctly 
identified in both; however, there were also numerous false positive relations in the 
observational model, attributable to the fact that both the correct regulator and many others 
have indistinguishable expression (Amit et al., 2009). 
 
The high-resolution map we constructed might have biomedical implications. By identifying 
regulators that mediate the differential control of specific gene pairs (e.g., IL-23 vs. IL-12) and 
entire regulatory arms (e.g., viral vs. inflammatory), it opens the way for therapeutic targeting of 
specific pathways to control disease or enhance vaccine efficacy. Furthermore, 12 of our 
regulators reside in genetic loci that were in linkage disequilibrium with SNPs associated with 
autoimmune and related diseases. The identified genes and their impact on DCs provide 
hypotheses to help explain how alleles of genes in a cascade may alter susceptibility to specific 
infections or immune disorders in humans. 
 
2.9. Experimental Procedures 
Preparation of dendritic cells 
Bone marrow-derived dendritic cells (BMDCs) were generated from 6-8 week old female 
C57BL/6J mice (Jackson Laboratories). Bone marrow cells were collected from femora and 
tibiae and plated at 106 cells/mL on non-tissue culture treated petri dishes in RPMI-1640 
medium (Gibco), supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, MEM non-
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essential amino acids, HEPES, sodium pyruvate, β-mercaptoethanol, and murine GM-CSF (15 
ng/mL; Peprotech) or human Flt3L (100 ng/mL; Peprotech). GM-CSF-derived BMDCs were 
used directly for all RNAi experiments unsing lentiviral shRNAs. For all other experiments, 
floating cells from GM-CSF cultures were sorted at day 5 by MACS using the CD11c (N418) 
MicroBeads kit (Miltenyi Biotec). Sorted CD11c+ cells were used as GM-CSF-derived BMDCs, 
and plated at 106 cells/mL and stimulated at 16 h post sorting. 
TLR agonists 
TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coli K12 LPS, CpG) and Enzo Life 
Sciences (poly(I:C)), and were used at the following concentrations: Pam3CSK4 (250 ng/mL), 
poly(I:C) (10 µg/mL), LPS (100 ng/mL), gardiquimod (250 ng/mL), CpG (1 µg/mL). 
 
mRNA isolation 
Total RNA was extracted with QIAzol reagent following the miRNeasy kit’s procedure (Qiagen), 
and sample quality was tested on a 2100 Bioanalyzer (Agilent). RNA was reverse transcribed 
with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). For experiments 
with more than 12 samples, we harvested polyA+ RNA in 96- or 384-well plates with the 
Turbocapture mRNA kit (Qiagen) and reverse transcribed with the Sensiscript RT kit (Qiagen). 
 
qPCR measurements 
Real time quantitative PCR reactions were performed on the LightCycler 480 system (Roche) 
with FastStart Universal SYBR Green Master Mix (Roche). Every reaction was run in triplicate 
and GAPDH levels were used as an endogenous control for normalization. 
 
Microarray hybridization and processing 
For oligonucleotide microarray hybridization, 1.5 µg RNA were labeled, fragmented and 
hybridized to an Affymetrix Mouse Genome 430A 2.0 Array. After scanning, the expression 
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value for each gene was calculated with RMA (Robust Multi-Array) normalization (Irizarry et al., 
2003). The average intensity difference values were normalized across the sample set. Probe 
sets that were absent in all samples according to Affymetrix flags were removed. All values 
lower than 50 were floored to 50. Only probe sets that changed in at least one pair of biological 
duplicates by 1.7 fold or more were analyzed further in this study. We defined induced 
probesets for each condition (TLR agonist) as probesets that display at least 1.7 fold up-
regulation in both duplicates of at least one time point, as compared to the control. Control 
values were defined as the mean expression of the control sample, calculated over control non 
stimulated samples times 0, 1, 2 and 4 hours. 
 
Regulatory network reconstruction 
We reconstruct a draft model with a modification of the Module Networks algorithm. We first 
applied Module Networks as original developed (Segal et al., 2003). Briefly, we use an iterative 
learning procedure using the Expectation Maximization (EM) algorithm. Each iteration consists 
of two steps: an E-step and an M-step. In the M-step, the procedure is given a partition of the 
genes into modules and learns the best regulation program (as a regression tree) for each 
module (for efficiency, some M-steps only optimize the parameters of the normal distributions at 
the leaves of the regulation tree). In the E-step, given the inferred regulation programs, we re-
assign each gene to the module that best predicts the gene’s behavior (we do not assign a 
regulator gene to a module in which it is also a regulatory input, directly or indirectly). The 
regulation program is learned from a pre-defined set of candidate regulators (3287 TFs, CFs 
and RNA-BPs). We applied Module Networks systematically when initialized to 10-250 modules 
(in increments of 10), and chose the model whose likelihood score was 70% of the best score. 
The chosen model consisted of 80 modules. 
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The regression tree in the original model suffers from two potential limitations: it allows only a 
single regulator in each split in the tree (even when several equally good ones exist), and it 
does not allow for time lags. To address these limitations, we next refined the regulatory 
programs of the 80 modules using the Elastic Net (Zou and Hastie, 2005), an L2-regularized 
linear regression procedure. For each module, we used the LARS-EN algorithm (Zou and 
Hastie, 2005) to regress the mean profile of the module’s genes with a selected combination of 
candidate regulators (to avoid cyclicity, we eliminated the regulator genes from the modules in 
this step). In addition, we allowed up to a fourth time point “lag” between the expression of the 
regulators and that of the target module. Finally, we used a bootstrap procedure, holding off 
20% of each module’s genes at a time and repeating the learning (Amit et al., 2009). 
 
Custom Nanostring CodeSet construction using the GeneSelector algorithm 
To choose a set of genes that will capture as much as possible of the information on the 
expression of all genes, we used an information-theoretic approach. We modeled the 
expression levels X given the experimental condition C with a naïve Bayes model where the 
expression of gene i under condition c follows a normal distribution ),Ν(~| 2iici cCX σµ= . In 
this model, the expression levels of all genes depend on the experimental condition C, and we 
selected genes that are highly informative about C.  Formally, for a set of genes Y we used the 
conditional entropy )|(log)|()()|( yYcCpcCyYpcCpCH
yc
=====−= ∑∑Y  as a 
measure of the remaining uncertainty in C once the expression levels Y are known. We then 
used this measure and a greedy procedure to select multiple disjoint gene sets, Y1, … ,Yk such 
that for each set Yi, η<)|( iYCH  (we set η = 0.5). In the greedy procedure, we select genes 
one at a time, and with each selected gene re-compute the entropy given the genes already 
selected in the current set. Once a set is complete (the remaining conditional entropy is below 
the threshold η), we add all the genes to the selected set, and repeat the procedure (excluding 
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all the selected genes from consideration). We stop when the number of selected genes has 
reached a user-defined threshold, set by the number of genes feasible for the experimental 
assay. 
 
To select a time point, we used the same approach. Here, we measured entropy under all time 
points for multiple randomly selected gene sets of several sizes and plotted the average entropy 
for each timepoint (Amit et al., 2009). We chose the time point with the minimal entropy (i.e., 6 h 
after LPS stimulation). 
 
Analysis of cis-regulatory elements 
Cis-regulatory elements were represented by a Position Weight Matrix (PWM). We compiled a 
set of 1651 PWMs from the TRANSFAC matrix database v8.3 (Matys et al., 2006), JASPAR 
Version 2008 (Sandelin et al., 2004) and experimentally determined PWMs (Badis et al., 2009; 
Berger et al., 2008). Given a PWM, for each nucleotide position in the promoter of each mouse 
gene, we calculated an affinity score defined as the log-likelihood ratio (LOD score) for 
observing the sequence given the PWM versus a given random genomic background. We then 
found the best conserved motif instance over the entire promoter region. We automatically 
computed a PWM-specific cutoff, by using the information content of each motif, computed as 
the 2-IC quantile of the PWM LODs distribution. We considered a “hit” in the promoter if the 
maximal LOD score was above this cutoff. Finally, we computed the enrichment of the motif in 
each of six clusters determined by the microarray experiments, using a two-sided Wilcoxon 
rank-sum test between the set and the background (Amit et al., 2009). To ensure that 
enrichment was not due to nucleotide bias within the promoter, we also shuffled the PWM and 
computed enrichment for the true PWM compared to the shuffled PWMs. A motif was 
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considered enriched in a gene set if it passed p-value < 0.01. We included a PWM in our final 
set of regulators if it was associated with at least one gene set. 
 
shRNA experiments 
High titer lentiviruses encoding shRNA-targeting genes of interest were obtained from The RNAi 
Consortium (TRC; Broad Institute, Cambridge, MA, USA) (Moffat et al., 2006). 105 bone marrow 
cells were plated in 100 µL complete RPMI on non-tissue culture treated flat bottom 96-well 
plates (Nunc). At day 2, cells were spin-infected (45 min, 37°C, 2200 rpm) with 20 µL of shRNA-
encoding lentiviruses in the presence of polybrene (8 µg/mL), and subsequently fed with 100 µL 
complete RPMI with GM-CSF. At day 4, infected cells were selected by adding puromycin (5 
µg/mL) to the culture in 25 µL complete RPMI with GM-CSF. Infected cells were used for 
analysis 3 days after initiating puromycin selection. For each regulator, we tested five shRNAs 
for knock down efficiency using qRT-PCR of the target gene. Lentivirus-infected cells were 
composed of ~90% DCs (Amit et al., 2009), which was highly similar to sorted CD11c+ DCs. 
 
mRNA measurements with nCounter 
Details on the nCounter system are presented in full in (Geiss et al., 2008). CodeSets were 
constructed to detect genes selected by the GeneSelector algorithm and additional controls as 
described. ~5 × 104 bone marrow cells were lysed in RLT buffer (Qiagen) supplemented with 
1% β-mercaptoethanol. 10% of the lysate was hybridized for 16 hours with the codeset and 
loaded into the nCounter prep station followed by quantification using the nCounter Digital 
Analyzer. 
 
Normalization of nCounter data 
We normalized the nCounter data in three steps. In the first step, we controlled for small 
variations in the efficiency of the automated sample processing. To this end, we followed the 
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manufacturer’s instructions, and normalized measurements from all samples analyzed on a 
given run to the levels of a chosen sample (in all cases we used the first sample in the set). This 
was done using the positive spiked-in controls provided by the nCounter instrument. In the next 
step, we relied on ten control genes (Ik, Ndufa7, Tomm7, Tbca, Ndufs5, Ywhaz, Mea1, Rbm6, 
Shfm1, and Gapdh), which were included as reporters and were identified from the microarray 
experiment as unchanged upon stimulation by any of the pathogen components. We found that 
two of these genes (Gapdh and Rbm6) showed too much variation and removed them from all 
subsequent analysis. We used the remaining eight genes for a second round of normalization. 
For every sample, we computed the weighted average mi of the mRNA counts of the seven 
transcripts and normalized the sample’s values by multiplying by the constant m1/mi. Finally, we 
obtained a normalized expression quantity that takes into account the intrinsic noise in our 
system. We used the 32 samples treated with control shRNAs (that do not target any gene in 
the mouse genome) to define a z-statistic z for each observation oij of transcript i in each shRNA 
experiment j: 
j
jij
ij s
mo
z
−
=  where mj and sj are, respectively, the mean and variance of the 
expression of transcript j in the control shRNA experiments. 
 
Confidence estimates for differential expression in perturbation experiments 
We used two permutation-based approaches to estimate our confidence in an observed z-score 
value for a transcript in an shRNA experiment. In the first approach, we defined a per-gene 
confidence score for each measurement, by using the variation in that gene’s expression in the 
control shRNA experiments. We computed the confidence scores for each measurement (one 
gene in one experiment) at a time, by swapping the measured value of that gene with each of its 
measurements in the control experiments in turn, and re-calculating a new z-score. We then 
assessed the significance of the real z-score, given the distribution of the permuted scores as a 
null distribution. More formally, for each of the observed counts oij of the reporter gene i in 
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sample j we generated r permuted values (where r is the number of control shRNA experiments) 
as follows. Let ci1, … , cir be the r transcript counts for gene i in each of the r control 
experiments. The k permuted z-score is obtained by swapping oij with cik and computing a z-
score as k
ij
k
ijikij
k s
mc
z
−
= , where 
r
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m irikijikikij
++++++
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. We take the 
permuted scores ijkz as a null distribution and the FDR for a given z-score zij for gene i in 
experiment j is given as 
 
FDR(z) =
Ek (# zk
ij | zk
ij > z; j = 1,…,n{ })
# zij > z; j = 1,…,n{ } , where n is the number of 
shRNA experiments. The confidence for z is )(1)( zFDRzconf −= . 
 
In the second approach, we devised a per-experiment confidence score for each measurement. 
We use a similar procedure to control the FDR on the z-statistic, based on variation in the 
expression of control genes in each experiment. Formally, let zij, … ,znj be the z-scores for the jth 
experiment (shRNA), and assume the first l transcripts are control transcripts whose expression 
does not change in response to any pathogen component (l = 8, see above). We defined 
j
jij
ij s
mz
z ~
~
~ −= where now jm~  and js~ are, respectively, the mean and variance of the z-scores of 
the control transcripts 1, … , l in the jth shRNA experiment. We perform l permutations as 
described above, by swapping each observed z-scores with a control transcript score and 
computing z~ , then computing an FDR as above. 
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NMF and scoring of regulator profiles 
We performed NMF as previously described (Brunet et al., 2004). Briefly, we represented the 
microarray expression dataset as an n × N matrix, M, whose rows contain the expression levels 
of the n genes in the N samples. We first used NMF to we find k=2 metagenes, as we focused 
on two key responses. Each metagene is a positive linear combination of the N genes. To do 
this we find an approximate factoring, M ≈ W × H, where both factors have only positive entries. 
W is an n × k matrix that defines the metagene decomposition model. Its columns specify how 
much each of the n genes contributes to each of the k metagenes. We assign a target gene to 
be inflammatory or anti-viral based on the larger of its two scores in W. H is a k × N matrix 
whose entries represent the expression levels of the k metagenes for each of the N samples. 
From the factoring of M, we next constructed a mapping that allows us to project the 
perturbation profiles into the space of the metagenes. To do this we used the Moore–Penrose 
generalized pseudoinverse (Brunet et al., 2004) of W, such that, Ĥ = (W)−1 × M, where Ĥ ≈ H. 
We then applied the resulting pseudoinverse to each of the perturbation experiments to obtain a 
score for the experiment (and hence the perturbed regulators) on each of the two metagenes 
(Amit et al., 2009). 
 
Regulator ranking score 
Interactions between regulators and target genes that passed the two FDR thresholds (above) 
were selected. For each regulator, we counted the number of target genes, and separated the 
interactions on the basis of their sign (activation or repression) and their NMF metagene 
classification [F1 (inflammatory) or F2 (viral)]. We subtracted the number of repressed genes 
from the number of activated genes for each metagene, and scaled the numbers on the basis of 
the metagene ‘size’ (since the number of genes assigned to F1 and F2 is different). Regulators 
were ranked by the difference between the resulting two numbers (metagene F2 and metagene 
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F1) for each regulator. The cutoff threshold was a score greater then 2 or -2 (and >5 
interactions). 
 
Analysis of loci from genome wide association studies (GWAS) 
We downloaded a list of disease-associated SNPs (P < 0.05) from the National Human Genome 
Research Institute catalog of published genome wide association studies (Hindorff et al., 2009). 
We then extracted regions which are in linkage disequilibrium (LD) with each of the SNPs by 
first finding the left-most and right-most SNPs that are in LD (R2 > 0.5) with the aforementioned 
SNP and then finding the closet recombination hotspots as described in Raychaudhuri et al., 
2009. We mapped the list of 125 regulators from the mouse genome (mm8; Mouse genome 
assembly 8, Feb 2006) to their orthologs in the human genome (hg17, Human genome 
assembly 17, May 2004) and identified those that resided within the aforementioned regions. 
 
ChIP-sequencing 
Dendritic cells were fixed with 1% formaldehyde, washed with ice-cold PBS, harvested by 
scraping, pelleted, and resuspended in SDS lysis buffer. Samples were sonicated with a 
Branson 250 Sonifier for 8 × 25 s cycles at 70% duty, output 3.5, centrifuged at 13,000 × g for 
10 min, and diluted 10-fold in ChIP dilution buffer. After removing a control aliquot (whole-cell 
extract), the sample was incubated at 4°C overnight with antibodies against H3K4me3 (Abcam 
8580) or H3K36me3 (Abcam 9050). Complexes were precipitated with protein A-Sepharose. 
Beads were washed sequentially with low-salt immune complex wash, high-salt immune 
complex wash, LiCl immune complex wash, and TE. Immunoprecipitated chromatin was eluted 
in elution buffer, incubated at 65°C for 8 h, and treated with proteinase K. DNA was purified by 
extracting twice with phenol and once with chloroform and precipitating in ethanol. The DNA 
was treated with RNase and purified with a MinElute Kit (Qiagen). Sequencing libraries were 
generated from 1–10ng of ChIP DNA by adaptor ligation, gel purification and 16 cycles of PCR. 
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Sequence reads from Illumina libraries were identified with standard Illumina basecalling 
software and then analyzed with a custom computational pipeline. Reads were aligned to the 
reference genome, and the fragment count at any given position (25-bp resolution) was 
estimated as the number of uniquely aligned reads oriented towards it and within 300bp. 
 
ELISA 
Cell culture supernatants were assayed using a sandwich ELISA kit for mouse IFN-β (PBL 
Biomedical Laboratories). 
 
Fluorescence Activated Cell Sorting 
Non-adherent cells were stained with A647 conjugated anti-CD11c (N418, Biolegend) and FITC 
labeled anti-I-A[b] MHC class II alloantigen (AF6-120.1, BD Pharmingen). Fc receptors were 
blocked with Mouse BD Fc Block (BD Pharmingen). Flow cytometry was done with a BD LSRII, 
and the data were analyzed with FlowJo software (Treestar). 
Accession numbers and supplementary tables 
Complete microarray data sets are available in the NCBI Gene Expression Omnibus under the 
accession number GSE17721. All 16 supplementary tables containing the datasets presented in 
this Chapter are available with the online version of this published work (Amit et al., 2009). 
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Chapter 3 – Systematic Discovery of TLR Signaling Components 
Delineates Viral-Sensing Circuits 
 
3.1. Author Contributions 
Reference (reproduced with permission from Cell): 
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I., Tonti, E., DeGrace, M.M., Clauser, K.R., Garber, M., Eisenhaure, T.M., Yosef, N., Robinson, 
J., Sutton, A., Andersen, M.S., Root, D.E., von Andrian, U., Jones, R.B., Park, H., Carr, S.A., 
Regev, A.*, Amit, I.*, Hacohen, N.* (2011). Systematic discovery of TLR signaling components 
delineates viral-sensing circuits. Cell 147, 853-867. (* equal contributions) 
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3.2. Introduction 
Signaling networks function to detect environmental changes and to trigger appropriate 
responses. Defects in the wiring of these networks can contribute to diseases. For example, 
Toll-like receptors (TLRs) in innate immune dendritic cells (DCs) sense microbial components 
and trigger signaling pathways critical for host defense (Takeuchi and Akira, 2010). Genetic 
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defects in components of the TLR network (e.g., Tnfaip3, Irf5, Tlr4) have been linked to human 
inflammatory diseases (Hennessy et al., 2010). 
 
Deciphering signaling networks is a challenging task. First, despite extensive studies, many 
components of key networks remain unknown, limiting our ability to understand the role of 
genes genetically associated with disease (Xavier and Rioux, 2008). Second, there are few 
systematic approaches to determine the function of a new component and place it accurately 
within pathways. Third, it is hard to compare and connect signaling nodes that have been 
studied in disparate systems and with different readouts. Filling in such gaps is critical for 
understanding signal processing in cells and for manipulating clinically relevant pathways. 
 
In a recent study (Amit et al., 2009), we developed a perturbational strategy to decipher 
transcriptional circuits and applied it to the TLR system of immune DCs (see Chapter 2). In this 
approach, we identified transcriptional regulators based on changes in their mRNA levels 
following TLR stimulation, perturbed each regulator with an shRNA, and measured the effect 
using a 118-gene signature. This allowed us to identify functional transcriptional regulators, and 
to associate them with specific targets and with the global responses they control. For example, 
we discovered that a host of cell proliferation-associated factors, such as Rbl1, Rb, Myc, Jun, 
and E2fs have been co-opted to control the antiviral transcriptional program in non-dividing 
terminal DCs.  
 
Here, we adapted and expanded this approach to develop a strategy for the discovery and 
validation of signaling components (Figure 3.1). We relied on the fact that in many responses, 
including pathogen sensing, there often are transcriptional feedbacks, whereby a signaling 
circuit also regulates the transcript levels of genes encoding some, but not all, of its components 
(Amit et al., 2007; Fraser and Germain, 2009; Segal et al., 2003). We therefore initially followed 
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the same strategy as that used for transcriptional regulators to identify candidate signaling 
molecules (from mRNA profiles), perturb them (using shRNAs), and measure the effect on a 
representative gene signature. Furthermore, to expand the pathway’s scope to additional 
components whose mRNA levels may be unchanged, we also used phosphoproteomics 
following perturbation of the initially discovered signaling molecules. 
 
We applied this iterative approach to study the TLR response, discovering 19 new functional 
components of TLR signaling pathways, including a new major arm in antiviral signaling. This 
arm is centered on Plk2 and 4, two Polo-like kinases that play a prominent and previously 
unknown role in all well-described host antiviral pathways, both in vitro and in vivo. Using 
phosphoproteomics, followed by RNAi, we identified eleven additional members of a Plk-
dependent, antiviral signaling module. These include Tnfaip2, which was recently genetically 
associated with two autoimmune disorders but whose role was unknown. Our work thus 
establishes an effective strategy to systematically assign functions to newly identified signaling 
components of a network, and to point towards potential therapeutic targets. 
 
Figure 3.1. A Systematic Approach to Dissect Signaling Pathways 
Shown is a schematic depicting the strategy consisting of 4 steps (from left to right): (1) extract both 
candidate signaling regulators and signature genes; (2) perturb each candidate with shRNAs and 
measure the effect on the expression of signature genes; (3) compare perturbation profiles of signaling 
and transcriptional regulators to start assembling pathways; (4) use small molecule targeting of signaling 
nodes of interest to a) evaluate the physiological relevance of new signaling node, and b) identify 
underlying pathways by discovering downstream effector molecules. 
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3.3. Transcripts for Signaling Components Are Regulated upon TLR Stimulation 
To analyze pathogen-sensing pathways, we studied DCs stimulated with agonists for TLR2, 3, 
or 4. These TLRs activate transcriptional programs referred to, here, as “inflammatory” (TLR2), 
“antiviral” (TLR3), or both (TLR4) (Figure 3.2A) (Amit et al., 2009; Doyle et al., 2002). The 
signaling pathways mediating these responses rely on both shared and unique components. For 
example, both antiviral and inflammatory pathways activate the MAPK and NF-κB signaling 
cascades, whereas only antiviral pathways activate the TBK1/IKK-ε/IRFs axis that leads to type 
I interferon (IFNs) production (Figure 3.2A) (Takeuchi and Akira, 2010). 
 
We chose candidate components in the TLR pathways by identifying genes encoding putative 
signaling proteins whose expression levels change following TLR stimulation (Figure 3.2B). We 
used genome-wide mRNA expression profiles, previously measured (Amit et al., 2009) at 10 
time points along 24 hours following stimulation of bone marrow-derived DCs (BMDCs) with 
lipopolysaccharide (LPS; TLR4 agonist), polyinosinic:polycytidylic acid (poly(I:C); recognized by 
TLR3 and the cytosolic viral sensor MDA-5), or Pam3CSK4 (PAM; TLR2 agonist) (Figure 3.2B). 
280 genes annotated as known or putative signaling components in the genome were 
differentially expressed following stimulation, including 115 kinases, 69 phosphatases, and 96 
adaptors, scaffolds and other signaling regulators (Figure 3.2B, and Experimental 
Procedures). These 280 genes were enriched for canonical pathways of the TLR network such 
as MAP kinase (P < 1.22×10-15, overlap 25/87, hypergeometric test), TLR (e.g., Myd88, Traf6, 
Irak4, Tbk1; P < 8.43×10-12, 21/86), and PI3K (P < 2.58×10-8, 11/33) pathways, as well as the 
PYK2 pathway (P < 3.12×10-10, overlap 12/29), which was recently associated with the TLR 
system (Wang et al., 2010). Overall, 94 of the 280 genes (33%) were previously associated with 
the TLR network in the literature, supporting the validity of our strategy. The remaining 186 
(67%) genes represent novel candidate components of the TLR system. Of these 186, we 
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selected 23 novel candidates for further experiments based on their strong differential 
expression and to proportionally represent the five main induced expression clusters (Figure 
3.2B and 3.2C). Six canonical TLR components (Myd88, Mapk9, Tbk1, Ikbke, Tank, and 
Map3k7) were selected as positive controls to benchmark our approach (Figure 3.2A and 
3.2D). 
 
Figure 3.2. mRNAs of Signaling Components Are Differentially Regulated upon TLR Stimulation 
(A) Schematic depicting simplified pathways triggered by TLR2, 3, and 4 (Reviewed in Takeuchi and 
Akira, 2010). 
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Figure 3.2 (Continued) 
(B) mRNA expression profiles of differentially expressed signaling genes. Shown are expression profiles 
for 280 differentially expressed signaling genes (rows) across different time points (columns): a control 
time course (no stimulation, Ctrl) and following stimulations with Pam3CSK4 (TLR2 agonist, PAM), 
lipopolysaccharide (TLR4 agonist, LPS), and poly(I:C) (TLR3 agonist). Tick marks: time point post-
stimulation (0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours). Shown genes had at least a 1.7 fold increase or decrease 
in expression compared to pre-stimulation levels in both duplicates of at least one time point. The three 
leftmost columns indicate kinase (KIN), phosphatase (PSP), and signaling (SIG) regulator functions 
(black bars). Values from duplicate arrays were collapsed and gene expression profiles were 
hierarchically clustered: the rightmost color-coded column indicates the 5 major expression clusters. 
(C and D) mRNA expression profiles of candidate (C) and canonical (D) TLR signaling regulators that 
were selected for subsequent experiments. The color-coding of the gene names highlight the 
corresponding expression cluster from the complete matrix of 280 signaling genes from (B). 
 
3.4. A Perturbation Strategy Places Uncharacterized Signaling Components 
within the Antiviral and Inflammatory Pathways 
We perturbed each of the 6 positive controls and 17 of the 23 novel candidates in DCs with 
lentivirus-delivered shRNAs (Experimental Procedures), stimulated the cells with LPS, and 
measured the effect on the mRNA levels of 118 signature genes, plus 10 control genes, at 6 
hours post-stimulation (Figure 3.3A). (Six of the 23 initial candidates were not studied further 
due to poor knockdown efficiency.) 
 
We have previously shown that there is no significant alteration in function in DCs infected with 
shRNA-encoding lentiviruses and selected with puromycin for 4 days during GM-CSF-induced 
differentiation (Amit et al., 2009). The stimulus, time point, and gene signature were defined in 
our previous study as representatives of both the inflammatory and the antiviral programs 
(Experimental Procedures) (Amit et al., 2009).  
 
We used a multiplex mRNA counting methodology to quantify the transcript levels of these 
signature genes, and determined statistically significant changes in signature transcripts by 
relying on both control genes and control shRNAs (Experimental Procedures) (Geiss et al., 
2008). Finally, we associated signaling molecules and downstream transcriptional regulators 
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that may act in the same pathway by comparing the perturbational profiles of the 23 signaling 
molecules (6 canonical and 17 candidates) to each other and to those of the 123 transcription 
regulators previously tested (Figure 3.3 and Figure 3.4) (Amit et al., 2009). 
 
Figure 3.3. A Perturbation Strategy Assigns Function to Signaling Components within the TLR 
Pathways 
(A) Perturbation profiles of six canonical (purple) and 17 candidate (light blue) signaling components, and 
20 core TLR transcriptional regulators belonging to the inflammatory (orange) and the antiviral (green) 
programs. Shown are the perturbed regulators (columns) and their statistically significant effects (False 
discovery rate, FDR < 0.02) on each of the 118 TLR signature genes (rows). Red: significant activating 
relation (target gene expression decreased following perturbation); blue: significant repressing relation 
(target gene expression increased following perturbation); white: no significant effect. The column on the 
right indicates whether signature genes belong to the antiviral (light grey) or the inflammatory (dark grey) 
programs. 
(B) Functional characterization based on similarity of perturbation profiles. Shown is a correlation 
(Pearson) matrix of the perturbation profiles from A. Yellow: positive correlation; purple: negative 
correlation; black: no correlation. 
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Figure 3.4. Perturbations of Signaling and Transcriptional Regulators Have Similar Effects on the 
TLR Signature Genes 
(A) Perturbation profiles of 6 canonical (purple) and 17 candidate (light blue) signaling regulators, and 123 
transcriptional regulators (TF) partitioned into regulators of the inflammatory (orange) and antiviral (green) 
programs, and fine tuners (grey), as previously defined in Amit et al., 2009. Shown are the perturbed 
regulators (columns) and their statistically significant effects (False discovery rate, FDR < 2%) on each of 
the 118 TLR signature genes (rows). Red: significant activating relation (target gene expression 
decreased following perturbation); blue: significant repressing relation (target gene expression increased  
123 transcriptional regulators
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Figure 3.4 (Continued) 
following perturbation); white: no significant effect. The column on the right indicates whether signature 
genes belong to the antiviral (light grey) or the inflammatory (dark grey) programs. 
(B-D) Shown are the numbers of signature gene hits (Y axis) significantly affected by knockdown of each 
regulator (X axis) for the regulator categories shown in A: 123 transcriptional (B) and 6 previously known 
(C) and 17 candidate (D) signaling regulators. 
(E) Candidate signaling regulators affect a similar number of ‘signature’ genes compared to 
transcriptional regulators. Shown is the cumulative distribution of the number of hits for the regulators 
shown in B-D. 
 
Perturbing five of the six positive control signaling molecules strongly affected the expression of 
TLR signature genes in a manner consistent with their known roles (Figure 3.3A), thus 
validating our approach. For example, perturbing the known inflammatory adaptor Myd88 
specifically abrogated the transcription of inflammatory genes (e.g., Cxcl1, Il1a, Il1b, Ptgs2, Tnf; 
Figure 3.3A), an effect similar to that of perturbations of downstream inflammatory transcription 
factors (e.g., Nfkb1, Nfkbiz; Figure 3.3B). In addition, Tank acted as a negative regulator of a 
subset of antiviral genes (Figure 3.3A), consistent with previous observations (Kawagoe et al., 
2009), and Tbk1 knockdown affected both antiviral and inflammatory outputs (Figure 3.3A), 
consistent with recent findings that Tbk1 regulates NF-κB complexes (Barbie et al., 2009; Chien 
et al., 2006). Notably, Ikbke (IKK-ε) knockdown did not affect our gene signature, consistently 
with previous observations that IKK-ε-/- DCs respond normally to LPS and viral challenges 
(Matsui et al., 2006). Thus, IKK-ε may either not be functional or be redundant in our system. 
 
All of the 17 candidate signaling molecules tested, except Plk2 (discussed below), affected at 
least 6 targets in the 118-gene signature (on average, 16.6 targets ± 10.4 SD), and 12 affected 
more than 10% of the targets (Figure 3.4A and 3.4D). Notably, perturbations of these 17 
candidates did not affect BMDC differentiation (88.3% ± 6.8 SD of CD11c+ cells). These effects 
on TLR signature gene expression are comparable to those observed for known signaling 
molecules and transcriptional regulators in this system (Figure 3.4B-E). For example, the 
receptor tyrosine kinase Met, not previously associated with TLR signaling, affected a number of 
signature genes similar to Tbk1 (Figure 3.4C and 3.4D), in both the inflammatory and antiviral 
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programs (Figure 3.3A). Conversely, both the phosphatase Ptpre and the adaptor Socs6 acted 
as positive regulators of the inflammatory program, while negatively regulating a subset of 
antiviral genes (Figure 3.3A). Of the 17 candidates tested when we originally conducted this 
targeted screen, 10 have subsequently been reported by other groups to be functional in the 
TLR system, providing an independent confirmation of our results. For example, in our 
experiments, Map3k8 knockdown affected both inflammatory and antiviral target genes (Figure 
3.3A), consistent with its reported role in the TLR pathways based on phenotypic analysis of 
Sluggish mice (Xiao et al., 2009). 
 
Our approach identified both primary (e.g., Myd88) and secondary (e.g., Stat1) mediators of 
TLR responses. While secondary mediators are not part of the initial intracellular signaling 
cascade, they are important physiological components of the TLR response and their 
perturbation leads to the same phenotypic outcome as primary components. For example, we 
re-discovered a member of the TAM family of receptor tyrosine kinases, Mertk, which acts 
secondarily as a positive regulator of part of the inflammatory program, and as a negative 
regulator of several antiviral genes, including Ifnb1 (Figure 3.3A). This is consistent with the 
reported inhibitory roles of TAM family members in the IFN pathway (Rothlin et al., 2007). 
 
3.5. Crkl Modulates JNK-mediated Antiviral Signaling in the TLR Network 
Among the 17 candidate signaling proteins, perturbation of the tyrosine kinase adaptor Crkl 
decreased expression of a relatively large fraction (13%) of the signature genes (Figure 3.3A 
and Figure 3.4D), especially antiviral ones. Crkl is a known component of several signaling 
pathways, including early lymphocyte activation (Birge et al., 2009), but has not been previously 
associated with the TLR network. Crkl’s perturbation profile closely resembled those of known 
antiviral regulators, most notably JNK2 (Mapk9; (Chu et al., 1999) (Figure 3.3A and 3.5A). 
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Indeed, when Crkl-/- DCs were stimulated with LPS, the expression of antiviral cytokines 
(Cxcl10, Ifnb1) was strongly and specifically reduced (Figure 3.5B, left and middle), whereas 
that of an inflammatory cytokine (Cxcl1) remained unaffected (Figure 3.5B, right). 
 
 
Figure 3.5. Crkl Adaptor Functions in the Antiviral Arm of TLR4 Signaling 
(A) Comparison of Crkl and Mapk9 knockdown profiles. Shown are the effects of Crkl and Mapk9 
perturbation (columns) on the 118 signature genes (rows). Data was extracted and is presented as in 
Figure 3.3A.  
(B) Inhibition of transcription of mRNAs of antiviral cytokines in Crkl-/- BMDCs. Shown are mRNA levels 
(qPCR; relative to t = 0) for Ifnb1 (left), Cxcl10 (middle) and Cxcl1 (right) in three replicates per time point. 
Error bars represent the standard error of the mean (n = 3 mice).  
(C) Crkl phosphorylation is induced following LPS stimulation. Top: Schematic depiction of experimental 
workflow. From left: Protein lysates from unstimulated (Control) and LPS-treated BMDCs grown in “light” 
and “heavy” SILAC medium were mixed (1:1) and digested into peptides with trypsin before phospho-
tyrosine (pY) peptide enrichment by immunoprecipitation, and LC-MS/MS analysis. Bottom: Shown are 
the differential phosphorylation levels (log 2 ratios, Y axis) of all 62 phosphopeptides identified and 
quantified by LC-MS/MS (X axis). Black: peptides with more than 2 fold differential expression (left: 
induced; right: repressed). 
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To test whether Crkl is a primary component of the TLR pathway, we determined whether Crkl 
phosphorylation is rapidly modified after TLR signaling initiation. We used SILAC-based 
quantitative phosphoproteomics that led to the identification and quantification of 62 phospho-
tyrosine (pTyr)-containing peptides from BMDCs stimulated with LPS for 30 minutes (Figure 
3.5C and Experimental Procedures) (Ong et al., 2002). Of these 62 phosphopeptides that 
were identified and quantified, 7 and 9 were significantly up- or down-regulated, respectively 
(Figure 3.5C). A pTyr-containing peptide derived from Crkl (Y132) – one of the top-six induced 
phosphopeptides – was induced 2.1 fold (Figure 3.5C). This observation corroborates the 
hypothesis that Crkl is active immediately downstream of TLR4 signaling. 
 
Several lines of evidence suggest that Crkl acts through Jnk2 (Mapk9) signaling. First, following 
LPS stimulation, the MAP kinase Jnk2 (Mapk9) is co-regulated at the phosphorylation level with 
Crkl (Figure 3.5C). Second, the Crk adaptor family – including CrkI, CrkII, and Crkl – has been 
previously reported to modulate Jnk activity in growth factor and IFN signaling (Birge et al., 
2009; Hrincius et al., 2010). Third, the perturbation profiles of Mapk9 and Crkl are strikingly 
similar (Figure 3.5A). Taken together, these observations suggest that Crkl modulates Jnk-
mediated antiviral signaling in the TLR4 pathway. 
 
3.6. Polo-like Kinases Are Critical Activators of the Antiviral Program 
To discover potential drug targets among our 17 candidates, we next focused on Polo-like 
kinase (Plk) 2, a well-known cell cycle regulator and drug target (Strebhardt, 2010), which was 
strongly induced by a viral-like stimulus. The roles of Plks in non-dividing, differentiated cells are 
poorly defined (Archambault and Glover, 2009; Strebhardt, 2010). We have previously shown 
that transcriptional regulators of cell cycle processes (e.g., Rbl1, Rb, Myc, Jun, E2fs) are co-
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opted to function in the antiviral responses in DCs (Amit et al., 2009). We therefore 
hypothesized that Plk2 might be an upstream signaling regulator of the antiviral program. 
 
Contrary to our hypothesis, neither knockdown (Figure 3.3A) nor knockout (Inglis et al., 2009) 
of Plk2 in BMDCs had any effect on the TLR response. We speculated that this could be the 
result of redundancy with another Plk, since Plk4 mRNA is induced in DCs with a similar pattern 
to Plk2 (Figure 3.6A), albeit at a lower amplitude (and thus was not included in the 17 initial 
candidates). Interestingly, functional redundancy between Plk2 and 4 has been suggested to 
account for the viability of Plk2-deficient mice (Strebhardt, 2010), and Plk2 and 4 have been 
reported to function together in centriole duplication (Chang et al., 2010; Cizmecioglu et al., 
2008). 
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Figure 3.6. Plk2 and 4 Regulate the Antiviral Program 
(A) Similarity of Plk2 and 4 mRNA expression profiles. Shown are mRNA levels (from Figure 3.2B) of 
Plk2 (left) and 4 (right) following stimulation with LPS (black) or poly(I:C) (grey). 
(B) Double knockdown of Plk2 and 4 represses the antiviral signature. Shown are significant changes in 
expression of TLR signature genes (rows) following double knockdown of Plk2 and 4. Red and blue mark 
significant hits as in Figure 3.3, only for genes where the effect was consistent between the two 
independent combinations of shRNAs. 
(C) Double knockdown of Plk2 and 4 represses antiviral cytokine mRNAs. Shown are expression levels 
(qPCR) relative to control shRNAs (Control) for two antiviral cytokines (Ifnb1 and Cxcl10) and for an  
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Figure 3.6 (Continued) 
inflammatory cytokine (Cxcl1), following LPS stimulation in BMDCs using two independent combinations 
of shRNAs (Plk2/4-1, Plk2/4-2). Three replicates for each experiment; error bars are the standard error of 
the mean. 
(D and E) BI 2536 specifically abrogates transcription of antiviral genes without affecting inflammatory 
genes following stimulation with LPS, poly(I:C), or Pam3CSK4. Shown are mRNA levels (qPCR; relative 
to t = 0) for 12 indicated antiviral (D) and 12 inflammatory (E) genes in BMDCs treated with BI 2536 (1 
µM; dark color bars) or DMSO vehicle (light color bars) and stimulated for 0, 2 or 4 h with LPS (dark and 
light blue), poly(I:C) (dark and light red), or Pam3CSK4 (dark and light green). Three replicates in each 
experiment; error bars are the standard error of the mean. 
 
Consistent with this revised hypothesis, double knockdown of Plk2 and 4 – by infecting cells 
with two different shRNA-carrying viruses, one shRNA targeting each gene (Figure 3.7B) – led 
to a significant and specific decrease in expression of 21 antiviral response genes (Figure 
3.6B). For example, the antiviral cytokines Ifnb1 and Cxcl10 mRNAs were decreased, whereas 
the expression of the inflammatory gene Cxcl1 and almost all inflammatory signature genes 
remained unaffected (Figure 3.6C). This specific response was observed using two 
independent mixes of shRNAs, in each case targeting Plks with a different pair of shPlk2/shPlk4 
(Figure 3.7B and Experimental Procedures). Two recent reports suggested a role for Plk1 
alone as a negative regulator of MAVS (Vitour et al., 2009) and NF-κB (Zhang et al., 2010) in 
cell lines. In BMDCs, however, both Plk1 and Plk3 are expressed at very low levels (100-fold 
lower than Plk2), and their knockdown did not affect the TLR transcriptional response (Figure 
3.7C). Notably, we did not observe a reduction in DC viability when cells were transduced with 
lentiviral shRNAs targeting Plk1, 2, 3 or 4 individually, or Plk2 and 4 together (based on mRNA 
levels of control genes). We thus conclude that in differentiated BMDCs, Plk2 and 4, but likely 
not Plk1 or 3, are critical to the regulation of antiviral but not cell cycle pathways. 
 75 
 
Figure 3.7. Individual Perturbation of Plk Family Members Does Not Affect TLR Output Gene 
Expression in DCs 
(A) Plk2-deficient BMDCs respond to LPS similarly to wild-type cells. Shown are mRNA levels (qPCR; 
relative to t = 0) for Ifnb1 (left), Cxcl10 (middle) and Cxcl1 (right) in three replicates per time point. Error 
bars represent the standard error of the mean. 
(B) Combinatorial knockdown levels of Plk2 and 4 in BMDCs. Shown are mRNA levels (qPCR), relative to 
non-targeting shRNAs (Control), of Plk2 and 4 in BMDCs using two independent combinations of shRNAs 
(Plk2/4-1 and -2). Three replicates in each experiment; error bars represent the standard error of the 
mean. 
(C) Perturbations of individual Plk family members do not affect TLR signature genes. Shown are the 
perturbed Plks (columns) and their statistically significant effects (FDR < 2%) on each 118 TLR signature 
genes (rows). Red: significant activating relation (target gene expression decreased following 
perturbation); blue: significant repressing relation (target gene expression increased following 
perturbation); white: no significant effect. The column on the right indicates whether signature genes 
belong to the antiviral (light grey) or the inflammatory (dark grey) programs. 
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3.7. A Small Molecule Inhibitor of Plks Represses Antiviral Gene Expression and 
IRF3 Translocation in DCs 
We next manipulated the antiviral responses in DCs using BI 2536, a commercial pan-specific 
Plk small molecule inhibitor (Steegmaier et al., 2007). First, we compared genome-wide mRNA 
profiles measured in LPS- or poly(I:C)-stimulated DCs that were pre-treated with either BI 2536 
or DMSO vehicle (Experimental Procedures). Most genes repressed by BI 2536 treatment but 
induced by either stimulus in the presence of vehicle, belonged to the antiviral program (99/193 
genes in response to poly(I:C), P < 1×10-71, hypergeometric test; 67/194 in response to LPS). 
The 311 unique LPS- and/or poly(I:C)-induced genes that are repressed by BI 2536, are 
significantly enriched for genes in canonical pathways related to cytokine signaling (e.g., IL-10, 
type I IFNs, IL-1), TLR signaling, and DC signaling, and for GO processes related to defense 
and immune responses (Figure 3.8A). This suggests a specific action of BI 2536 on the TLR 
system of DCs.  
 
To further investigate the Plks’ specificity of action, we measured the expression of 12 well-
studied antiviral and 12 well-studied inflammatory response genes in DCs stimulated with LPS, 
poly(I:C), or Pam3CSK4 in the presence and absence of BI 2536 (Figure 3.6D). All antiviral 
genes induced by LPS or poly(I:C) were strongly inhibited upon BI 2536 treatment, whereas 
inflammatory gene expression remained largely unaffected upon LPS or Pam3CSK4 
stimulation, in agreement with the microarray data (Figure 3.6D). 
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Figure 3.8. BI 2536-Mediated Plk Inhibition Abrogates Antiviral Cytokine Production at the Protein 
and mRNA Levels, without Affecting the Viability and Cell Cycle Status of DCs 
(A) Gene enrichment analysis of BI 2536-dependent genes from microarray measurements. Overlaps 
between the 311 unique genes downregulated 3-fold by BI 2536 treatment upon LPS or poly(I:C) 
stimulation, and Gene Ontology (GO) processes and canonical pathways (including the KEGG, 
REACTOME, and BIOCARTE databases present in the Molecular Signatures Database (MSigDB; see 
Experimental Procedures). Shown are P values (X axis) derived from the overlaps (n/N; top of each bar) 
between the number of queried genes (n) and genes present in indicated genesets (N). 
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Figure 3.8 (Continued) 
(B) BI 2536 strongly inhibits IFN-β secretion by BMDCs. Shown is IFN-β protein concentration (Y axis; 
measured by ELISA) in the supernatant of BMDCs treated with DMSO vehicle (-) or BI 2536 (1 µM; +), 
and stimulated with LPS (+) or left unstimulated (-) for 6 h. Three replicates in each experiment; error bars 
are the standard error of the mean.  
(C) BI 2536 inhibits antiviral cytokine mRNA production in a dose-dependent manner. Shown are mRNA 
levels (Y axis, qPCR; relative to vehicle control treatment) for two antiviral cytokines (Ifnb1, Cxcl10) and 
one inflammatory cytokine (Cxcl1) following LPS stimulation in BMDCs pre-treated with increasing 
amounts of BI 2536 (X axis). Three replicates in each experiment; error bars are the standard error of the 
mean. 
(D) BMDC viability is unaffected by Plk inhibition with BI 2536. Shown are viable cell numbers (Y axis, 
measured by Alamar blue; relative to a standard curve generated using a range of cell densities) after 
treatment with BI 2536 (white bars) or DMSO vehicle (black bars) at different time points following 
addition of BI 2536 (X axis). Three replicates in each experiment; error bars are the standard error of the 
mean.  
(E) The cell cycle state of BMDCs remains unchanged upon Plk inhibition with BI 2536. Shown are DNA 
contents (flow cytometry) of BMDCs stained with propidium iodide (PI) after treatment with BI 2536 or 
DMSO vehicle control for 0, 6, and 12 h. 
(F) Plk inhibitors structurally unrelated to BI 2536 also abrogate transcription of mRNAs for antiviral 
cytokines following stimulation with LPS. Shown are mRNA levels (qPCR; relative to t = 0) for Ifnb1, 
Cxcl10 and Cxcl1 in BMDCs stimulated with LPS and treated with GW843682X (GW84; top) or Poloxipan 
(Plxp; bottom) (black line), or with DMSO vehicle (grey line) for 1 hour prior to stimulation. Three 
replicates for each experiment; error bars are the standard error of the mean. 
(G) Plks are directly downstream of TLR engagement. Shown are Ifnb1 mRNA levels (Y axis, qPCR; 
relative to t = 0) following LPS stimulation for indicated times (X axis) in wild-type (top) and Ifnar1-/- 
(bottom) BMDCs treated with BI 2536 (1 µM; black) or vehicle control (DMSO; grey). 
 
Treatment with BI 2536 reduced the mRNA levels of Cxcl10 and Ifnb1 (by qPCR) and of 
secreted IFN-β in a dose-dependent manner (Figure 3.8B and 3.8C). Conversely, there was no 
significant change in the mRNA level of the inflammatory cytokine Cxcl1 (Figure 3.8C). 
Importantly, BI 2536 treatment prior to stimulation neither impacted the viability nor the cell cycle 
state of BMDCs (Figure 3.8D and 3.8E), suggesting that Plk inhibition does not act through cell 
cycle effects. In addition, two other pan-Plk inhibitors, structurally unrelated to BI 2536, caused 
a similar strong decrease in the mRNAs of the antiviral cytokines Ifnb1 and Cxcl10, without 
affecting Cxcl1 (Figure 3.8F and Experimental Procedures). These results, consistent with 
our knockdowns, strongly suggest that the effects induced by these three small molecules are 
due to the inhibition of Plks, and not off-target effects. 
 
To validate that Plks are primary components directly downstream of TLR activation, we 
measured the effect of BI 2536 on Ifnb1 induction upon LPS challenge in Ifnar1-/- DCs that lack 
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type I IFN receptor (Figure 3.8G). We found a strong inhibitory effect in these cells, consistent 
with Plks acting directly downstream of TLR signals, and not in an autocrine/paracrine feedback 
loop mediated by IFN receptor signaling. These observations are also supported by a recent 
phosphoproteomic study, showing that phosphorylated Plk substrates are enriched after 15 min 
of LPS stimulation in bone-marrow-derived macrophages (Weintz et al., 2010). 
 
Furthermore, BI 2536 inhibited the nuclear translocation of interferon regulatory factor 3 (IRF3), 
a key antiviral transcription factor (Figure 3.9). We monitored the subcellular localization of 
IRF3 at the single cell level using confocal microscopy (Experimental Procedures). To 
effectively deliver the drug, we plated DCs on vertical silicon nanowires (Shalek et al., 2010) 
pre-coated with BI 2536 prior to stimulation. Nanowires coated with the vehicle control did not 
affect the response of BMDCs to TLR activation (Figure 3.9A and Figure 3.10A). DCs treated 
with BI 2536 showed a dose-dependent decrease in IRF3 nuclear translocation following 
poly(I:C) or LPS stimulation, whereas the control JNK inhibitor SP 600125 had no effect on IRF3 
translocation (Figure 3.9B and 3.9C, and Figure 3.10B). On the other hand, BI 2536 did not 
affect NF-κB p65 localization (Figure 3.9D and 3.9E). Notably, IRF3 translocation was also 
decreased when delivering BI 2536 in solution, but to a lesser extent compared to nanowire-
mediated delivery (Figure 3.10C). This highlights the utility of highly efficient drug delivery 
methodologies to induce homogeneous effects in single-cell assays using microscopy. Taken 
together, these observations place Plk2 and 4 as critical components upstream of a major 
antiviral transcription factor. 
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Figure 3.9. BI 2536-Mediated Plk Inhibition Blocks IRF3 Nuclear Translocation in DCs  
(A) DCs on nanowires (NW) undergo normal morphological changes upon LPS stimulation. Shown are 
electron micrographs of BMDCs plated on bare vertical silicon NW that were left unstimulated (left; 
Control) or stimulated with LPS (right). Scale bars, 5 µm.  
(B-E) BI 2536 inhibits IRF3, but not NF-κB p65, nuclear translocation following TLR stimulation. (B and D) 
Shown are confocal micrographs of BMDCs plated on vertical silicon NW pre-coated with vehicle control 
(DMSO; B and D), Plk inhibitor (BI 2536; B and D), or control Jnk inhibitor (SP 600125; B), and stimulated 
with poly(I:C) for 2 h (B) or LPS for 30 min (D) (reflecting peak time of nuclear translocation for IRF3 and 
NF-κB p65, respectively), or left unstimulated (B and D). Cells were analyzed for DAPI (B and D), IRF3 
(B) and NF-κB p65 subunit (D) staining. Scale bars, 5 µM. (C and E) Nuclear translocation (from confocal 
micrographs) of IRF3 (C) and NF-κB p65 (E) was quantified using DAPI staining as a nuclear mask 
(purple circles; overlay in B and D) to determine the ratio of total versus nuclear fluorescence (Y axis) in 
BMDCs cultured on NW coated with different amounts of BI 2536 or SP 600125, or with vehicle control 
(DMSO; X axis). Three replicates in each experiment; error bars are the standard error of the mean. 
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Figure 3.10. BI 2536-Mediated Plk Inhibition Blocks IRF3 Nuclear Translocation in LPS-Stimulated 
DCs  
(A) DCs plated on vertical silicon nanowires (NW) respond normally to TLR stimulation. Shown are 
cytokine mRNA levels (qPCR; relative to Gapdh mRNA) in BMDCs plated on NW or a flat silicon surface, 
and stimulated (LPS) or left untreated (control). Left to right: Cxcl1, Cxcl10, Ifnb1. Three replicates in 
each experiment; error bars are the standard error of the mean. 
(B) BI 2536 inhibits IRF3 nuclear translocation following LPS stimulation. Shown are confocal 
micrographs (left panel) of BMDCs plated on vertical silicon NW pre-coated with vehicle control (DMSO), 
Plk inhibitor (BI 2536), or control Jnk inhibitor (SP 600125), and stimulated with LPS for 45 min (reflecting 
peak time of nuclear translocation for IRF3 in the context of LPS stimulation), or left unstimulated. Cells 
were analyzed for DAPI and IRF3 staining. Scale bars, 5 µM. Nuclear translocation (from confocal 
micrographs) of IRF3 was quantified (right panel) using DAPI staining as a nuclear mask (purple circles  
Flat silicon (control) 
Nanowires (control)
Flat silicon (LPS)
Nanowires (LPS)
R
el
at
iv
e 
m
R
N
A 
le
ve
l (l
og
 10
)
0
0.8
1.6
DMSO SP 600125
(0.1 µM)
BI 2536
(0.1 µM)
R
el
at
iv
e 
nu
cl
ea
r l
oc
al
iz
at
io
n
0 
0.6 
1.2 
1 0.001 0.01 0.1 1 0.001 0.01 0.1 1
DMSO BI 2536 (µM) DMSO BI 2536 (µM) 
Nanowire In solution
0.0001 
0.001 
0.01 
0.1 
1 
10 
Cxcl1 Cxcl10 Ifnb1
Unstimulated LPS
DMSO DMSO BI 2536 (0.1 µM) SP 600125 (0.1 µM)
IR
F3
D
A
PI
O
ve
rla
y
A
B
C
R
el
at
iv
e 
nu
cl
ea
r l
oc
al
iz
at
io
n
0 
0.6 
1.2 
R
el
at
iv
e 
nu
cl
ea
r l
oc
al
iz
at
io
n
 82 
Figure 3.10 (Continued) 
on micrographs) to determine the ratio of total versus nuclear fluorescence (Y axis) in BMDCs cultured on 
NW coated with BI 2536, SP 600125, or vehicle control (DMSO; X axis). Three replicates in each 
experiment; error bars are the standard error of the mean. 
(C) Decrease in IRF3 nuclear translocation may be more efficient with NW-mediated delivery of BI 2536 
than with delivery in solution. Shown are quantifications of confocal micrographs from BMDCs plated on 
vertical NW pre-coated with different amounts of BI 2536 (Nanowire; left panel) or left blank to allow in-
solution delivery of BI 2536 (In solution; right panel). Cells were stimulated with poly(I:C) for 2 h prior to 
staining for DAPI and IRF3 as in B. 
 
3.8. Plks Are Essential for Activation of All Well-Established IFN-Inducing 
Pathways in Conventional and Plasmacytoid DCs 
DCs can be broadly categorized into two major subtypes – conventional and plasmacytoid DCs 
– each relying on distinct mechanisms to induce type I IFNs and antiviral gene expression 
(Blasius and Beutler, 2010; Luber et al., 2010). In conventional DCs (cDCs), antiviral responses 
are activated through TLR4/3 signaling (via TRIF), or through the cytosolic sensors RIG-I or 
MDA-5 (via MAVS) (Figure 3.11A). In plasmacytoid DCs (pDCs; specialized IFN-producing 
cells), the antiviral response depends solely on endosomal TLR7 and 9 that signal via MYD88 
(Figure 3.11A) (Blasius and Beutler, 2010; Kato et al., 2005; Kato et al., 2006; Takeuchi and 
Akira, 2010). 
 
BI 2536 treatment showed that Plks are essential for the viral-sensing pathways in both cDCs 
and pDCs. In cDCs, BI 2536 inhibited the transcription of antiviral genes (Ifnb1 and Cxcl10) 
upon infection with each of four different viruses: vesicular stomatitis virus (VSV) (Figure 3.11B, 
top), Sendai virus (SeV; Figure 3.12A top), or Newcastle disease virus (NDV; Figure 3.12A 
bottom), all three sensed through RIG-I, and encephalomyocarditis virus (EMCV), sensed 
through MDA-5 (Figure 3.11B, bottom). 
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Figure 3.11. Plks Are Critical in the Induction of Type I Interferons In Vitro and In Vivo 
(A) IFN-inducing pathways in conventional DCs (cDCs) and plasmacytoid DCs (pDCs) (Blasius and 
Beutler, 2010).  
(B, C) BI 2536 inhibits mRNA levels for antiviral cytokines in response to diverse stimuli in cDCs and 
pDCs. Shown are Ifnb1, Cxcl10 and Cxcl1 mRNA levels (qPCR; relative to t = 0) in cells treated with BI 
2536 (1 µM; white bars) or DMSO vehicle (black bars) in cDCs (B) infected with VSV (MOI 1; B top) or 
with EMCV (MOI 10; B bottom), and in pDCs (C) stimulated with CpG type A or B, or infected with EMCV 
(MOI 10). Three replicates in each experiment; error bars are the standard error of the mean.  
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Figure 3.11 (Continued) 
(D) BI 2536 inhibits the CpG-A response, but has little effect on the CpG-B response. Shown are mRNA 
levels (nCounter) for the 118 TLR signature genes (rows) in pDCs treated with DMSO vehicle or BI 2536 
(1 µM) and left untreated (Ctrl) or stimulated with CpG-A or -B for 6 h (columns). Three clusters of genes 
are shown: CpG-A-specific (top), CpG-B-specific (bottom), and shared by CpG-A and -B (middle). 
(E-G) BI 2536 inhibits IFN-β production in primary mouse lung fibroblasts (MLFs), leading to an increase 
in viral replication. MLFs treated with BI 2536 (1 µM; white bars) or vehicle control (DMSO; black bars) 
were infected with influenza ∆NS1 or PR8 strains at indicated MOIs. Shown are Ifnb1 mRNA levels 
measured by qPCR (relative to t = 0; E), viral replication as measured by luciferase (Luc) activity in 
reporter cells (F), and cell viability measured by CellTiter-Glo assay (G). 
 (H and I) BI 2536 inhibits antiviral cytokine mRNA production, while increasing viral replication during in 
vivo VSV infection. Shown are Ifnb1, Cxcl10 and Cxcl1 mRNA (H), and VSV viral RNA (I) levels (qPCR; 
relative to uninfected animals) from popliteal lymph nodes of mice injected with BI 2536 (white circles) or 
DMSO vehicle (black circles) prior to and during the course of infection with VSV (intra-footpad). Nodes 
were harvested six hours post-infection. Each circle represents one animal (n = 3). Data is representative 
of three independent experiments for each condition. 
 
Notably, BI 2536 neither affected the mRNA level of Cxcl1 (an inflammatory cytokine) in 
response to any of these four viruses, nor affected the response to heat-killed Listeria 
monocytogenes, a natural TLR2 agonist (Figure 3.11B and Figure 3.12A and 3.12B). In pDCs, 
BI 2536 treatment nearly abrogated the transcription of mRNAs for the antiviral cytokines Ifnb1, 
Ifna2, and Cxcl10 after stimulation with type A CpG oligonucleotides (CpG-A), or infection with 
EMCV, sensed by TLR9 and 7, respectively (Figure 3.11C, Figure 3.12C). Conversely, in pDCs 
stimulated with CpG-B – a ligand known to activate inflammatory pathways but not IFN-inducing 
pathways – BI 2536 treatment decreased Cxcl10 mRNA while moderately increasing Cxcl1 
mRNA (Figure 3.11C). Finally, we measured the impact of BI 2536 treatment on the 118-gene 
signature in pDCs. BI 2536 strongly inhibited genes that are typically induced by CpG-A alone 
or by both CpG-A and -B, while having a minor effect, if any at all, on CpG-B-specific genes in 
pDCs (Figure 3.11D). Our findings thus contribute to revealing the molecular determinants of 
IFN production in pDCs, which are still poorly characterized (Reizis et al., 2011). More 
importantly, these results demonstrate a critical role for Plks across all well-known IFN-inducing 
pathways. 
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Figure 3.12. Plks Are Critical in Antiviral Responses In Vitro and In Vivo  
(A) Plks are critical in RIG-I-mediated antiviral responses in vitro in DCs. Shown are mRNA levels (qPCR; 
relative to control, “medium”) in conventional DCs (GM-CSF-induced BMDCs) treated with BI 2536 (white 
bars) or DMSO vehicle (black bars), and infected at a multiplicity of infection (MOI) 1 with Sendai virus 
(SeV; top) or Newcastle disease virus (NDV; bottom). Three replicates in each experiments; error bars 
are the standard error of the mean. 
(B) Plk inhibition does not affect DC response to Listeria monocytogenes, a natural TLR2 agonist. Shown 
are mRNA levels (qPCR; relative to t = 0) for Ifnb1, Cxcl10 and Cxcl1 in BMDCs stimulated with heat-
killed Listeria monocytogenes (HKLM; MOI 5) and treated with BI 2536 (white bars), or with DMSO 
vehicle (black bars) for 1 hour prior to stimulation. Three replicates for each experiment; error bars are the 
standard error of the mean. 
(C) Plks are critical in type I interferon α2 (Ifna2) gene production by plasmacytoid DCs (pDCs). Shown is 
the mRNA level (qPCR; relative to control, “medium”) of Ifna2 in pDCs (Flt3L-induced BMDCs) treated 
with BI 2536 (1 µM; white bars) or DMSO control (black bars), and stimulated with CpG-A or -B, or 
infected with EMCV (MOI 10). Three replicates in each experiment; error bars are the standard error of 
the mean. 
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Figure 3.12 (Continued) 
(D) Plk inhibition in vivo inhibits type I IFN α2 production in the lymph node. Shown is Ifna2 mRNA level 
(qPCR; relative to uninfected animals) from popliteal lymph nodes of  mice injected with BI 2536 (white 
circles) or DMSO vehicle (black circles) prior to and during the course of infection with VSV intra-footpad. 
Nodes were harvested six hours post-infection. Each circle represents one animal (n = 3). Data is 
representative of two or three independent experiments for each condition. 
 
3.9. Plks Are Essential in the Control of Host Antiviral Responses 
To evaluate the impact of Plk inhibition on the outcome of viral infection, we infected primary 
mouse lung fibroblasts (MLFs) with influenza virus (Experimental Procedures). In the 
presence of BI 2536 treatment, primary MLFs infected with influenza failed to produce interferon 
(Figure 3.11E), and showed elevated replication of both a wild type and a typically poorly 
replicating mutant virus (Figure 3.11F). The reduced interferon response was not due to drug-
induced toxicity (Figure 3.11G).  
 
Next, we tested the effects of Plk inhibition during viral infection in mice in vivo. BI 2536 exhibits 
good tolerability in mice (Steegmaier et al., 2007) and humans (Mross et al., 2008), and is 
currently in Phase II clinical trials as an anti-tumor agent in pancreatic cancer, hormone-
refractory prostate cancer, and non-small cell lung cancer (Strebhardt, 2010). Given this efficacy 
and safety of BI 2536 in vivo, we tested whether Plk inhibition would also affect the response to 
viral infection in animals. In mice infected with VSV (Experimental Procedures), injections of 
BI 2536 strongly suppressed mRNA production in popliteal lymph nodes for type I IFNs (Ifnb1, 
Ifna2) and Cxcl10, whereas Cxcl1 mRNA induction remained unchanged (all compared to 
vehicle control; Figure 3.11H and Figure 3.12D). Concomitantly, VSV replication in the lymph 
node rapidly increased as reflected by elevated VSV RNA levels (Figure 3.11I). This increase in 
VSV RNA in the presence of BI 2536 is comparable to the observed phenotype of VSV-infected 
Ifnar1-/- animals (Iannacone et al., 2010). Because in the VSV model used here type I IFNs are 
produced by both infected CD169+ subcapsular sinus macrophages and pDCs (Iannacone et 
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al., 2010), we cannot distinguish whether Plk inhibition affects macrophages, pDCs, or both. 
Nevertheless, our results confirm the physiological importance of Plks in the host antiviral 
response in both ex vivo primary MLFs and in vivo mouse lymph nodes. 
 
3.10. Plks Affect the Phosphorylation of Dozens of Proteins Post-LPS Stimulation, 
Including Known and Candidate Antiviral Regulators 
We next sought to discover the signaling pathways between Plks and antiviral gene 
transcription. Notably, the only signaling molecule previously reported as shared across well-
known IFN-inducing pathways is TRAF3 (Oganesyan et al., 2006), which links TLR or RLR 
adaptors (i.e., MYD88, TRIF, MAVS) to downstream kinase cascades and the transcription of 
type I IFNs (Blasius and Beutler, 2010; Takeuchi and Akira, 2010). We used MicroWestern 
Arrays (MWAs) (Ciaccio et al., 2010) to measure changes in the phosphorylation levels of 20 
signaling phosphoproteins (using 23 phosphosite-specific antibodies) of the TLR pathway 
(Experimental Procedures). We also measured total protein levels for 6 proteins. We 
measured phosphorylation and protein levels in BMDCs at each of 12 combinations of four time 
points (0, 20, 40, 80 min after LPS stimulation) and three perturbations (vehicle control, BI 2536, 
and SP 600125, a JNK inhibitor serving as a negative control). Although, LPS stimulation alone 
led to the expected changes in phosphorylation states and protein levels, compared to pre-
stimulation levels (e.g., early peak of phosphorylation for ERK1/2, p38, and Mapkapk2, and 
rapid degradation of IκBα; Figure 3.13A), BI 2536 treatment did not cause any significant 
changes in the phosphorylation levels of any of these 20 proteins, compared to vehicle or to the 
negative control JNK inhibitor SP 600125 (Figure 3.13A and Figure 3.14A and 3.14B). This 
may reflect the paucity of known phospho-proteins and phospho-sites in these pathways, and 
consequently the limited number of available phospho-specific antibodies targeting known TLR 
signaling nodes. We therefore hypothesized that Plks could affect previously unrecognized 
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regulators of IFN-inducing pathways and/or known regulators with no existing antibodies to 
specific phosphosites. 
 
To test this hypothesis and overcome the limited availability of phospho-specific antibodies, we 
used SILAC-based unbiased phosphoproteomics (Villen and Gygi, 2008) to identify any proteins 
whose phosphorylation depends on Plks in response to TLR stimulation (Figure 3.13B top). We 
compared the levels of phospho-tyrosine, -threonine and -serine peptides following stimulation 
with LPS (for 30 or 120 min) in BMDCs pre-treated with BI 2536 versus those treated with 
vehicle (DMSO). We identified and quantified 5,061 and 5,997 phosphopeptides after 30 and 
120 minutes, respectively, for a total of 10,236 individual phosphosites (Figure 3.13B). BI 2536 
treatment led to a significant (P < 0.001) increase or decrease in the level of 510 
phosphopeptides, reflecting 413 distinct proteins (Figure 3.13B). Thus, BI 2536-mediated 
inhibition of Plks had a substantial effect on the TLR phosphoproteome of DCs. 
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Figure 3.13. Unbiased Phosphoproteomics Identifies a Plk-Dependent Antiviral Pathway 
(A) BI 2536 does not affect phosphorylation and protein levels of known TLR signaling nodes. Shown are 
representative MicroWestern Array (MWA; see Experimental Procedures) blots (left) obtained from 
analyzing lysates from BMDCs pre-treated with DMSO, BI 2536 (1 µM), or SP 600125 (5 µM) and 
stimulated with LPS for 0, 20, 40, 80 min. Blots were analyzed using indicated antibodies (left most), and 
fold change in fluorescence signals was quantified relative to t = 0 (right; see Experimental Procedures). 
Error bars are the standard error of the mean of triplicate MWA blots. 
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Figure 3.13 (Continued) 
(B) BI 2536 affects protein phosphorylation levels during LPS stimulation. Top: Schematic depiction of 
experimental workflow. From left to right: LPS-stimulated BMDCs cultured in “heavy” or “light” SILAC 
medium were pre-treated with BI 2536 (1 µM) or DMSO, respectively. Protein lysates were mixed (1:1) 
and digested into peptides with trypsin, before phospho-serine, -threonine and -tyrosine (pS/T/Y) peptide 
enrichment, and LC-MS/MS analysis. Bottom: Shown are the differential phosphorylation levels (average 
log2 ratios of two independent experiments; Y axis) of all 5061 and 5997 phosphopeptides respectively 
identified and quantified by LC-MS/MS (X axis) at 30 min (top) and 120 min (bottom) post-LPS 
stimulation. Dark grey: phosphopeptides with a significant change (Punadjusted < 0.001 for both time points; 
FDR30min = 0.05; FDR120min = 0.03; left: induced; right: repressed). Average ratios from phosphopeptides 
identified and quantified in two independent experiments are depicted. 
(C) Eleven Plk-dependent phosphoproteins significantly affect the expression of TLR signature genes. 
Shown are significant changes in expression of the TLR signature genes (rows) following knockdown of 
each of the 11 phosphoproteins (columns), following stimulation with LPS for 6 h. Red and blue mark 
significant hits (as presented in Figure 3.3) and are shown only for genes where the effect was consistent 
between two independent experiments. 
(D) Functional characterization based on similarity of perturbation profiles. Shown is a correlation matrix 
of the perturbation profiles from C (grey), and those from Figure 2B including canonical (purple) and 
candidate (blue) signaling components as well as core antiviral (green) and inflammatory (orange) 
transcriptional regulators. Yellow: positive correlation; purple: negative correlation; black: no correlation. 
(E) A Plk-dependent pathway in antiviral sensing. Shown is a diagram of a model of the Plk-dependent 
pathway of IFN induction in innate immunity. Out of the 11 Plk-dependent proteins described in C and D, 
only the 5 showing a phenotype with 2 independent shRNAs are depicted. 
 
Of note, 35% (2489/7018) of the phospho-sites we identified were recently reported in mouse 
bone marrow-derived macrophages treated with LPS (Figure 3.14C, left) (Weintz et al., 2010), 
and 483 of our phosphosites were among 1858 sites (26%) reported in a phosphoproteomic 
study of LPS signaling in a macrophage cell line (Figure 3.14C, left) (Sharma et al., 2010). A 
comparison of the phosphosites of known kinases showed similar overlaps between the three 
studies (Figure 3.14C, right). This level of agreement across these two studies, despite 
differences in cell types, timepoints, and experimental procedures, supports our results. 
 
The Plk-dependent phosphoproteins include several known regulators of antiviral pathways 
(e.g., Prdm1, Fos, Unc13d) (Crozat et al., 2007; Keller and Maniatis, 1991; Takayanagi et al., 
2002), as well as many additional protein candidates with no previously known function in viral-
sensing (Figure 3.13B). Notably, proteins involved in the TBK1/IKK-ε/IRF3 axis were detected 
and quantified but did not show any significant change in phosphorylation levels upon Plk 
inhibiton, consistent with the MicroWestern array data. Conversely, Plk inhibition with BI 2536 
 91 
decreased the phosphorylation levels of cell cycle regulators of the Jun family of transcriptional 
regulators (i.e., Jund) that we recently reported as co-opted by antiviral pathways (Amit et al., 
2009). BI 2536 treatment also decreased the phosphorylation levels of the mitotic kinases Nek6 
and Nek7  (Figure 3.13B). The recent observation that the phosphorylation Nek6 substrates are 
increased following LPS stimulation in macrophages indirectly corroborates our finding that 
Nek6 may be active in the TLR signal flow (Weintz et al., 2010). To test the role of these new 
candidates, we returned to our shRNA perturbation-based approach. 
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Figure 3.14. Plk Inhibition Does Not Affect Known TLR Signaling Components but Affects Eleven 
Newly Identified Plk-Dependent Phosphoproteins 
(A, B) BI 2536-mediated Plk inhibition does not affect protein and/or phosphorylation levels of known TLR 
signaling nodes. (A) Shown are representative MicroWestern Array (MWA; see Experimental Procedures) 
blots obtained from analyzing lysates from BMDCs pre-treated with DMSO, BI 2536 (1 µM), or SP 600125  
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Figure 3.14 (Continued) 
(5 µM) and stimulated with LPS for 0, 20, 40, 80 min. Blots were analyzed using indicated antibodies (left 
most), and fold change in fluorescence signals was quantified relative to t = 0 (right; see Experimental 
Procedures). Error bars are the standard error of the mean of triplicate MWA blots. (B) Shown are the 
differential protein and phosphorylation levels (fold change; Y axis) of 6 proteins and 23 phosphosites in 
BMDCs treated with BI 2536 (red line), control JNK inhibitor (SP 600125; green line), or DMSO vehicle 
(blue line), and stimulated with LPS (0, 20, 40, 80 min; X axis). Band intensities on MWA blots were 
quantified using Li-cor Odyssey analysis software (Experimental Procedures). For each antibody, data 
was normalized to β-actin levels; error bars are the standard error of the mean of triplicate MWA blots. 
(C, D) 11 Plk-dependent phosphoproteins are critical for TLR-mediated antiviral responses in DCs. 
Shown are mRNA levels (qPCR; relative to non-targeting control shRNAs, Ctrl) for knockdown (KD) 
efficiency (left), Ifnb1 (middle), and Cxcl10 (right) in BMDCs following LPS stimulation. Genes with one 
and two shRNAs are shown in C and D, respectively. Three replicates in each experiment; error bars are 
the standard error of the mean. 
(E) Comparison of phosphosites identified in our study and in two recent reports (Weintz et al., and 
Sharma et al.). Shown are proportional Venn diagrams of the total unique phosphosites identified by the 3 
studies (left), and the phosphosites harbored by kinases only (right). Total numbers of unique 
phosphosites per study are indicated in parentheses. 
 
3.11. Plk-Dependent Phosphoproteins Affect the Antiviral Response 
We tested 25 novel Plk-dependent phosphoproteins, using shRNA perturbation in BMDCs 
followed by both qPCR and the 118 TLR gene signature measurements. These 25 candidates 
satisfied three criteria: (1) there was no prior knowledge of their function in viral-sensing 
pathways; (2) their phosphoprotein levels were consistently up- or down-regulated upon BI 2536 
treatment (in two independent experiments); and (3) they had detectable mRNA expression 
and/or differential expression upon stimulation. 
 
Of the 18 phosphoproteins showing efficient knockdown, 11 caused a significant decrease in 
Ifnb1 mRNA levels with a single shRNA (Sash1, Dock8, Nek6, Nek7, Nfatc2, and Ankrd17; 
Figure 3.14D), or with two independent shRNAs (Tnfaip2, Samsn1, Arhgap21, Mark2, and 
Zc3h14; Figure 3.14E). Decrease in Cxcl10 expression was less prominent, consistent with our 
previous observations of BI2536’s weaker effect on this cytokine during LPS stimulation (Figure 
3.14D and 3.14E, far right panels). Each of the 11 Plk-dependent phosphoproteins tested 
affected at least 9 targets in the 118-gene signature (on average, 39 targets ± 30 SD; Figure 
3.13C), and 9 affected more than 10% of the targets in the TLR gene signature (Figure 3.13C). 
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9 of the 11 Plk-dependent phosphoproteins affected the TLR signature comparably to major 
antiviral regulators (Figure 3.13D). For example, the profiles of newly identified Samsn1, Dock8, 
and Sash1 were closely correlated to those of Stat and Irf family members (Figure 3.13D). The 
profile of the Plk2/4 double knockdown was most correlated to those of Tnfaip2 and Zc3h14, 
proteins without a known molecular function. Interestingly, Tnfaip2 has been associated with 
rheumatoid arthritis and autoimmune myocarditis in recent genome-wide association studies 
(Consortium, 2007; Kuan et al., 1999). Our findings provide a potential molecular context for this 
disease association.  
 
Taken together, these results establish a previously unrecognized role for Plks in pathways 
inducing type I IFNs ex vivo in several primary cell types (i.e., DCs, MLFs), and in vivo in a 
mouse VSV infection model, likely by controlling the phosphorylation and activity of a new 
module of at least 11 components (Figure 3.13E). 
 
3.12. Discussion 
Therapeutic targeting of TLR pathways to dampen or enhance immune responses is an area of 
intense investigation in infectious disease, vaccine development, and autoimmune disorders 
(Hennessy et al., 2010; Kanzler et al., 2007; Ulevitch, 2004). Using an integrative strategy that 
combines transcriptional profiling, genetic and small molecule perturbations, and 
phosphoproteomics, we discovered 19 new signaling regulators not previously implicated in the 
TLR network (including 8 based on mRNA changes – 7 of 17 initial candidates together with 
Plk4; and 11 based on phosphorylation changes). Among these new regulators, we further 
explored the roles of Crkl and Plks and uncovered their critical roles as antiviral regulators. In 
particular, using the Plk inhibitor BI 2536, we demonstrated a significant role for Plks in host 
 95 
defense against viral infections in vitro and in vivo in mice. We showed that Plks are essential 
for all well-described IFN-inducing pathways (i.e., TLR- and RLR-mediated), and control a 
previously uncharacterized module of at least eleven members, including a functionally 
uncharacterized gene (i.e., Tnfaip2), that has been genetically associated with two autoimmune 
diseases (Figure 3.15). 
 
 
Figure 3.15. Graphical Summary of the Approach and Main Results from Chapter 3 
 
Crkl is an SH2- and SH3-adaptor protein from the Crk family of phosphotyrosine adaptors, and 
plays a known role in cell proliferation, cell adhesion, and regulation of gene expression (Birge 
et al., 2009). Crk adaptors have been linked with immune signaling in both normal (e.g., 
lymphocyte activation, IFN signaling) and pathological (e.g., diabetes) conditions (Birge et al., 
2009; Laloraya et al., 2006). We report a new role for Crkl in modulating the antiviral arm of 
TLR4 signaling. This may explain recent findings that Crkl is targeted by the non-structural 
protein 1 (NS1) of influenza A virus (Heikkinen et al., 2008; Hrincius et al., 2010). We also find 
that in response to DC stimulation, Crkl is phosphorylated on Tyrosine 132, a known 
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phosphorylation site in other responses (Ballif et al., 2008). Future studies are needed to 
characterize the role of this phosphorylation site in Crkl-dependent regulation of antiviral 
responses, to determine its molecular targets, and to find the upstream tyrosine kinase. Both the 
similarity of perturbational profiles and previous observations (Birge et al., 2009; Hrincius et al., 
2010) suggest that Jnk2 is a likely candidate partner for Crkl in the TLR system.  
 
We find that Plk2 and 4 – typically associated with cell cycle regulation and proliferation – have 
been co-opted in differentiated DCs to serve as major regulators of antiviral pathways. This is 
consistent with our earlier finding of the role of cell cycle transcription factors in the antiviral 
responses (Amit et al., 2009). In addition, we find that two other cell cycle kinases, Nek6 and 
Nek7, regulate IFN transcription. Given the 85% homology between the kinase domain of Nek6 
and Nek7, they may have partially redundant roles in regulating TLR pathway substrates, and 
hence, combinatorial perturbation of these two kinases might reveal different and critical 
aspects of their roles in the TLR system.  
 
Despite substantial progress in elucidating the role of Plk1 in the regulation of mitotic events, the 
functions of its paralogs – Plk2, 3, and 4 – remain poorly defined (Strebhardt, 2010). Plk2, 3, 
and 4 participate in cell cycle processes to a lesser extent than Plk1, and their new roles in non-
dividing cells have begun to emerge, especially in the nervous system (Archambault and 
Glover, 2009; Seeburg et al., 2005). In immune DCs, we show that Plk2 and 4 have redundant 
functions in the control of antiviral responses, illustrating the importance of epistasis analysis of 
mammalian signaling networks. Such redundancies might be obscuring additional roles for Plks, 
Neks, and other kinase families across multiple systems. However, genetic interactions 
currently cannot be found by genome-wide screens in mammalian cells. Thus, a more 
systematic computational and experimental approach is required in order to predict and test 
them. 
 97 
 
BI 2536 blocked the nuclear translocation of the IRF3 transcription factor without affecting its 
phosphorylation level (based on MicroWestern arrays and phosphoproteomics). Similar 
observations have very recently been reported in innate immune pathways. Indeed, the sodium-
potassium ATPase inhibitor bufalin inhibits the nuclear translocation of NF-κB upon TNF 
stimulation without affecting its phosphorylation level (Ye et al., 2011). Our results with BI 2536 
thus demonstrate that IRF3 translocation is likely to be regulated by a mechanism that does not 
impact phosphorylation. 
One of the goals of our work was to identify signaling nodes with clear regulatory functions that 
could be potential therapeutic targets. We find that Plk inhibition suppresses type I IFN 
production in vivo during viral infection, a finding that has potential clinical implications. For 
example, IFN receptor knockouts have reduced symptoms in a mouse model of Systemic Lupus 
Erythematosus (SLE) (Santiago-Raber et al., 2003), and disease activity in patients correlates 
with IFN expression signatures (Banchereau and Pascual, 2006). Furthermore, TLR7 and 9 
expressed by pDCs and B cells are well-known to be involved in SLE pathogenesis, and a 
bifunctional inhibitor (IRS 954) of both TLR7 and 9 increases the survival of lupus-prone animals 
(Barrat and Coffman, 2008). Our in vitro experiments demonstrate that Plk inhibition strongly 
suppresses both TLR7 and 9 responses in pDCs. Thus, testing the effect of BI 2536 on a 
mouse model of lupus, such as (NZB×NZW)F1 mice, will be critical in assessing the potential 
therapeutic implications of Plk inhibition for SLE. Inhibiting Plks might also be relevant to other 
disorders with TLR7- and TLR9-driven components such as psoriasis (Lande et al., 2007) and 
AIDS (Mandl et al., 2008). 
 
Our study demonstrates how an integrative strategy – combining transcriptomics, genetic and 
chemical perturbations, and unbiased phosphoproteomics – can be used to discover and place 
new components of signaling networks. This approach may also be broadly applicable for 
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characterizing the functions of genes reported in genome-wide association studies (e.g., 
Tnfaip2), for uncovering new potential therapeutic targets (e.g., Plks), and for re-purposing 
existing small molecules in new physiological contexts (e.g., using the cancer drug BI 2536 to 
repress innate immune responses). The vast public compendia of microarray data could serve 
as starting points for identification of relevant signaling components in diverse biological 
systems, followed by perturbations and signature measurements. Nevertheless, since the 
mRNAs corresponding to many pathway components do not change upon pathway activation, 
our approach is far from exhaustive. Combination of our perturbation-based approach with 
large-scale biochemical measurements (e.g., post-translational modifications, protein-protein 
interactions), will lead to more comprehensive, integrated maps of signaling and transcriptional 
networks. 
 
3.13. Experimental Procedures 
Preparation of dendritic cells 
Bone marrow-derived dendritic cells (BMDCs) were generated from 6-8 week old female 
C57BL/6J mice (Jackson Laboratories). Bone marrow cells were collected from femora and 
tibiae and plated at 106 cells/mL on non-tissue culture treated petri dishes in RPMI-1640 
medium (Gibco), supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, MEM non-
essential amino acids, HEPES, sodium pyruvate, β-mercaptoethanol, and murine GM-CSF (15 
ng/mL; Peprotech) or human Flt3L (100 ng/mL; Peprotech). GM-CSF-derived BMDCs were 
used directly for all RNAi experiments unsing lentiviral shRNAs. For all other experiments, 
floating cells from GM-CSF cultures were sorted at day 5 by MACS using the CD11c (N418) 
MicroBeads kit (Miltenyi Biotec). Sorted CD11c+ cells were used as GM-CSF-derived BMDCs, 
and plated at 106 cells/mL and stimulated at 16 h post sorting. For Flt3L culture, floating cells 
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were harvested at day 6-8 and used as Flt3L-derived BMDCs by plating them at 106 cells/mL 
and stimulating 16 h later. 
 
For SILAC experiments, GM-CSF-derived BMDCs were grown in media containing either 
normal L-arginine (Arg-0) and L-lysine (Lys-0) (Sigma) or L-arginine 13C6-15N4 (Arg-10) and L-
lysine 13C6-15N2 (Lys-8) (Sigma Isotec). Concentrations for L-arginine and L-lysine were 42 
mg/L and 40 mg/L, respectively. The cell culture media, RPMI-1640 deficient in L-arginine and 
L-lysine, was a custom media preparation from Caisson Laboratories (North Logan, UT) and 
dialyzed serum was obtained from SAFC-Sigma. We followed all standard SILAC media 
preparation and labeling steps as previously described (Ong and Mann, 2006). 
 
Preparation of primary lung fibroblasts 
Mouse lung fibroblasts (MLFs) were derived from lung tissue from 6-8 week old female 
C57BL/6J mice (Jackson Laboratories). MLFs were isolated as previously described (Tager et 
al., 2004). Briefly, lungs were digested for 45 min at 37°C in collagenase and DNase I, filtered, 
washed, and cultured in DMEM supplemented with 15% FBS. Cells were used for experiments 
between passages 2 and 5. 
 
Genetically modified mice 
Bone marrow from Plk2-/- mice and their wild-type littermates were obtained from Elan 
Pharmaceuticals (Inglis et al., 2009). Ifnar1-/- mice on a C57BL/6J background were a gift from 
Kate Fitzgerald (originally from Jonathan Sprent based on Müller et al., 1994). Heterozygous 
Crkl+/- mice on a C57BL/6J background were obtained from the Jackson Laboratory. Crkl+/- 
C57BL/6J mice were crossed to wild-type Black Swiss mice from Taconic, as Crkl-/- mice on a 
pure C57BL/6J genetic background have been reported to be embryonic lethal (Guris et al., 
2001; Hemmeryckx et al., 2002). Heterozygous Crkl+/- offspring were backcrossed to Crkl+/- 
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C57BL/6J mice to obtain Crkl-/- mice. Mice were kept in a specific pathogen-free facility at MIT. 
Animal procedures were in accordance with National Institutes of Health Guidelines on animal 
care and use, and were approved by the MIT Committee on Animal Care (Protocol #0609-058-
12). 
 
Viruses 
Sendai virus (SeV), strain Cantell, and Encephalomyocarditis virus (EMCV), strain EMC, were 
from ATCC. Newcastle disease virus (NDV), strain Hitchner B1 was from Aldolfo Garcia-Sastre 
(Mount Sinai School of Medicine), and vesicular stomatitis virus (VSV), strain Indiana was from 
Ulrich von Andrian (Harvard Medical School). Influenza A virus strain A/PR/8/34 and ∆NS1 were 
grown in Vero cells (which allow efficient growth of the ∆NS1 virus) in serum-free DMEM 
supplemented with 10% BSA and 1 mg/ml TPCK trypsin. Viral titers were determined by 
standard MDCK plaque assay. To measure the amount of VSV RNA present in infected tissues, 
we used previously reported qPCR primers: VSV Forward 5’-
TGATACAGTACAATTATTTTGGGAC-3’, and VSV Reverse 5’-
GAGACTTTCTGTTACGGGATCTGG-3’ (Hole et al., 2006). Viruses were handled according to 
CDC and NIH guidelines with protocols approved by the Broad Institutional Biosafety 
Committee. 
 
Reagents 
TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coli K12 LPS, ODN 1585 CpG type 
A, and ODN 1668 CpG type B) and Enzo Life Sciences (poly(I:C)), and were used at the 
following concentrations: Pam3CSK4 (250 ng/mL), poly(I:C) (10 µg/mL), LPS (100 ng/mL), 
CpG-A (10 µg/mL), CpG-B (10 µg/mL). Heat-killed Listeria monocytogenes (HKLM) was from 
Invivogen. Polo-like kinase inhibitors were from Selleck (BI 2536; (Steegmaier et al., 2007), 
Sigma (GW843682X, also known as compound 1 and GSK461364; (Lansing et al., 2007), and 
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Chembridge (Poloxipan; (Reindl et al., 2009). SP 600125 (Jnk inhibitor) was from Enzo Life 
Sciences. Image-iT FX Signal Enhancer, DAPI, and Alexa Fluor Labeled Secondary Antibodies 
were obtained from Invitrogen. For immunofluorescence, antibodies against IRF3 (4302S) and 
NF-κB P65 (4764S) were obtained from Cell Signaling Technology. For cell viability assays, 
Alamar Blue was from Invitrogen and CellTiter-Glo from Promega. 
 
Virus titering of MLF supernatant 
293T cells were seeded and transfected with a vRNA luciferase reporter plasmid as previously 
described (Shapira et al., 2009). Briefly, at 24 h post-transfection, 104 transfected reporter cells 
were re-seeded in white Costar plates. Supernatants from influenza-infected MLFs were added 
to reporter cells and incubated for 24 h. Reporter activity was measured with firefly luciferase 
substrate (Steady-Glo, Promega). Luminescence activity was quantified with the Envision 
Multilabel Reader (Perkin Elmer). 
 
Cell cycle analysis 
Cells were fixed in ethanol, washed, and stained for 30 min at room temperature (RT) with 
propidium iodide (100 µg/mL) prepared in PBS (calcium- and magnesium-free) supplemented 
with RNAse A (2 mg/mL; Novagen) and triton X-100 (0.1%). Samples were analyzed for DNA 
content using an Accuri C6 flow cytometer (Accuri) and data was processed using the FlowJo 
software (Treestar). 
 
ELISA 
Cell culture supernatants were assayed using a sandwich ELISA kit for mouse IFN-β (PBL 
Biomedical Laboratories). 
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mRNA isolation 
Total RNA was extracted with QIAzol reagent following the miRNeasy kit’s procedure (Qiagen), 
and sample quality was tested on a 2100 Bioanalyzer (Agilent). RNA was reverse transcribed 
with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). For experiments 
with more than 12 samples, we harvested polyA+ RNA in 96- or 384-well plates with the 
Turbocapture mRNA kit (Qiagen) and reverse transcribed with the Sensiscript RT kit (Qiagen). 
 
qPCR measurements 
Real time quantitative PCR reactions were performed on the LightCycler 480 system (Roche) 
with FastStart Universal SYBR Green Master Mix (Roche). Every reaction was run in triplicate 
and GAPDH levels were used as an endogenous control for normalization. 
 
shRNA knockdowns 
High titer lentiviruses encoding shRNAs targeting genes of interest were obtained from The 
RNAi Consortium (TRC; Broad Institute, Cambridge, MA, USA) (Moffat et al., 2006). Bone 
marrow cells were infected with lentiviruses as described (Amit et al., 2009). For each gene of 
interest, we tested five shRNAs for knock down efficiency using qPCR of the target gene. We 
selected shRNAs with >75% knockdown efficacy. For combinatorial knockdown, two 
independent mixtures of two lentiviruses encoding validated shRNAs against Plk2 and 4, 
respectively, were used to infect bone marrow cells (two Plk2- and two Plk4-specific shRNAs 
were used to generate these mixtures). Lentivirus-infected cells were composed of ~90% 
CD11c+ cells, which was comparable to sorted BMDCs and to our previous observations (Amit 
et al., 2009). 
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mRNA measurements on nCounter 
Details on the nCounter system are presented in full in (Geiss et al., 2008). We used a custom 
CodeSet constructed to detect a total of 128 genes (including 10 control genes whose 
expression remain unaffected by TLR stimulation) selected by the GeneSelector algorithm (Amit 
et al., 2009) as described below. ~5 × 104 bone marrow-derived DCs were lysed in RLT buffer 
(Qiagen) supplemented with 1% β-mercaptoethanol. 10% of the lysate was hybridized for 16 
hours with the CodeSet and loaded into the nCounter prep station followed by quantification 
using the nCounter Digital Analyzer following the manufacturer’s instructions. 
 
Custom Nanostring CodeSet construction using the GeneSelector algorithm 
We used the CodeSet that we previously used and described in (Amit et al., 2009). Briefly, to 
choose a set of genes that will capture as much as possible of the information on the expression 
of all genes, we used an information-theoretic approach. We modeled the expression levels X 
given the experimental condition C with a naive Bayes model where the expression of gene i 
under condition c follows a normal distribution . In this model, the 
expression levels of all genes depend on the experimental condition C, and we selected genes 
that are highly informative about C. Formally, for a set of genes Y we used the conditional 
entropy  as a measure of the 
remaining uncertainty in C once the expression levels Y are known. We then used this measure 
and a greedy procedure to select multiple disjoint gene sets, Y1, ... ,Yk such that for each set Yi, 
 (we set η = 0.5). In the greedy procedure, we select genes one at a time, and with 
each selected gene re-compute the entropy given the genes already selected in the current set. 
Once a set is complete (the remaining conditional entropy is below the threshold η), we add all 
the genes to the selected set, and repeat the procedure (excluding all the selected genes from 
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consideration). We stop when the number of selected genes has reached a user-defined 
threshold, set by the number of genes feasible for the experimental assay. 
To select a time point, we used the same approach. Here, we measured entropy under all time 
points for multiple randomly selected gene sets of several sizes and plotted the average entropy 
for each timepoint (see (Amit et al., 2009)). We chose the time point with the minimal entropy 
(i.e., 6 h post-simulation). 
 
nCounter data analysis 
After normalization by internal Nanostring controls (spike-normalization following manufacturer’s 
instructions), we normalized the data relying on three control genes (Ndufa7, Tbca, Tomm7) 
that are the least affected by shRNAs and LPS stimulation. Next, we log-transformed the 
expression values (Bengtsson and Hossjer, 2006). Five signature genes (Cxcl5, Fos, Fst, Ereg, 
and Egr2) that were highly variable across control shRNA samples were removed from 
subsequent analysis. To score target genes whose expression is significantly affected by 
perturbations, we used a fold threshold corresponding to a false discovery rate (FDR) of 2%. 
For a given shRNA perturbation, a target gene was called as significantly affected when the 
ratio of the log-expression of this gene upon shRNA knockdown to the average log-expression 
of this gene in control shRNA samples was below (or above) a threshold (1/threshold), chosen 
such that, on average, no more than 2 hits (out of 128 genes in the Nanostring codeset) per 
control shRNA sample were called. Heatmaps and distance matrix analyses were generated 
using the software Gene-E (http://www.broadinstitute.org/cancer/software/GENE-E/). 
 
Microarray hybridization and processing 
For oligonucleotide microarray hybridization, 1 µg of RNA were labeled, fragmented, and 
hybridized to an Affymetrix Mouse Genome 430A 2.0 Array. After scanning, the expression 
value for each gene was calculated with RMA (Robust Multi-Array) normalization. The average 
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intensity difference values were normalized across the sample set. Probe sets that were absent 
in all samples according to Affymetrix flags were removed. All values below 50 were floored to 
50. 
 
Detection of regulated signaling genes 
To identify differentially regulated signaling components (i.e., kinases, phosphatases, and 
signaling adaptors or scaffolds), we defined regulated probesets for each condition (TLR 
agonist) as probesets displaying at least 1.7-fold up- or down-regulation in both duplicates of at 
least one time point, compared to unstimulated controls, using our previously published 
microarray dataset available in the NCBI Gene Expression Omnibus under the accession 
number GSE17721 (Amit et al., 2009). Differentially regulated probesets were intersected with 
lists of kinases, phosphatases, and signaling adaptors and scaffolds. These gene sets were 
generated combining data from publicly available databases: Panther 
(http://www.pantherdb.org), Gene Ontology (http://www.geneontology.org), and DAVID 
(http://david.abcc.ncifcrf.gov). Regulated signaling genes were hierarchically clustered using the 
Cluster software (Eisen et al., 1998). 
 
 
Antiviral versus inflammatory gene enrichment 
Genes whose expression changed upon BI 2536 treatment in microarrays were evaluated for 
their enrichment with genes involved in the antiviral and inflammatory programs. When multiple 
probesets were available for a given gene on the microarray, only the probeset with maximum 
value was kept for analysis. Thus, the complete microarray consisted of 14088 genes, among 
which 804 and 550 genes were identified as part of antiviral and inflammatory programs, 
respectively (Amit et al., 2009). We performed a hypergeometric test on genes whose 
expression changed at least 3-fold upon BI 2536 treatment compared to vehicle control 
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(DMSO), in either LPS or poly(I:C) samples. In addition, genes whose expression changed upon 
BI 2536 treatment in microarrays in response to LPS and/or poly(I:C) stimulation were analysed 
for enrichment of Gene Ontology (GO) processes and canonical pathways from curated 
databases using the Molecular Signature Databse (MSigDB; 
http://www.broadinstitute.org/gsea/msigdb/index.jsp). 
 
Nanowire-mediated drug delivery and microscopy 
BMDCs were plated on top of etched silicon nanowires (Si NWs) coated with small molecules 
(Shalek et al., 2010). After 24 hours, cells were stimulated with LPS or poly(I:C), and then fixed 
in 4% formaldehyde in PBS (RT, 10 min). After fixation, each sample was permeabilized with 
0.25% Triton-X 100 in PBS (RT, 10 min), incubated with Image-iT FX Signal Enhancer (RT, 30 
min), and then blocked with 10% goat serum and 0.25% Triton-X 100 in PBS (RT, 1 hour). After 
washing, the samples were placed in 3% IgG-Free BSA & 0.25% Triton-X 100 in PBS that 
contained primary antibodies against either IRF3 or NF-κB P65 (1:175 dilution) and then rocked 
overnight at 4 °C. The following day, the samples were washed with PBS and then incubated 
with an Alexa Fluor labeled secondary antibody (1:250 dilution) in 3% IgG-Free BSA & 0.25% 
Triton-X 100 in PBS (RT, 60 min). After washing with PBS, the samples were counterstained 
with 300 ng/mL of DAPI in PBS (RT, 30 min). For each experiment, every stimulus-molecule 
combination was prepared in triplicate. Once fixed, samples were imaged using an upright 
confocal microscope (Olympus). For each captured image, the nuclear fraction of the 
fluorescent protein was calculated after identifying nuclear boundaries using DAPI. Finally, 
distributions for this quantity across different conditions were compared using a one-way 
ANOVA analysis. 
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In vivo BI 2536 experiments in a VSV infection model 
8-week old C57BL/6 male mice (from Charles River Laboratories) received 500 µg of BI 2536 
(or vehicle) intravenously, and 50 µg into the footpad 3 hours before and 2 hours after infection 
with 106 pfu of VSV, as previously described (Iannacone et al., 2010), into the footpad. Mice 
were sacrificed 6 hours post-infection and the draining popliteal lymph nodes were harvested in 
RNAlater solution (Ambion) before subsequent RNA analysis. All experimental animal 
procedures were approved by the Institutional Animal Committees of Harvard Medical School 
and IDI. All infectious work was performed in designated BL2+ workspaces, in accordance with 
institutional guidelines, and approved by the Harvard Committee on Microbiological Safety. 
 
MicroWestern Arrays 
The MicroWestern Array (MWA) method previously described (Ciaccio et al., 2010) was 
modified to accommodate a larger number of lysates. The lysates were printed in a ‘double-
block’ format with each MWA being 18 mm wide by 9 mm long. Twelve samples plus protein 
marker (Li-cor 928-40000) were printed with a non-contact piezoelectric arrayer (GeSiM NP2) 
along the top edge of the block, each block printed forty-eight times on the acrylamide gel. 
Electrophoresis, transfer, and antibody incubation were performed as previously described with 
the exception of using a modified 48-well gasket (The Gel Company MMH96) manually cut to 
have a larger block size in order to isolate antibodies on the nitrocellulose membrane per 
printed block. The antibodies used in this study were against β-ACTIN, GAPDH, β-TUBULIN, 
IκBα (clone L35A5), P65 (clone C22B4), STAT1, p-ABL(C-) (Y245), p-AKT (S473), p-AKT1/2/3 
(T308), p-ATF2 (T71), p-ERK1/2 (T202/Y204), p-IKBALPHA (S32), p-IKKA/B (S176/180), p-
IRF3 (S396), p-MAPKAPK2 (T222), p-MEK(1/2) (S217/221), p-MET (Y1234/1235), p-P38  
(T180/Y182), p-P65 (S536), p-P70S6K (S371), p-P70S6K (T389), p-P90RSK (S380), p-PI3K 
P85(Y458) P55(Y199), p-PKCD (Y311), p-SAPK/JNK (T183/Y185), p-SEK1/MKK4 (T261), p-
STAT1 (S727), p-STAT1 (Y701), p-STAT3 (S727). All antibodies were from Cell Signaling 
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Technology, except for β-ACTIN which was from Santa Cruz Biotechnology. Band intensities 
were quantified using Li-cor Odyssey analysis software (V3.0).  Circles were applied to the 
appropriate band on the scanned image and the net intensity was calculated by subtracting the 
background intensity from the trimmed mean intensity of each band. The net intensity was 
divided by the average net intensities of β-actin to control for lysate protein concentration. Fold 
Change was then calculated in relation to time of inhibitor application (time zero). 
 
Phosphotyrosine peptide analysis 
Tyrosine-phosphorylated peptides were prepared using a PhosphoScan Kit (Cell Signaling 
Technology) as previously described (Rush et al., 2005). Briefly, 100 million cells were lysed in 
lysis buffer (20 mM HEPES, 25 mM sodium pyrophosphate, 10 mM beta-glycerophosphate, 9 M 
urea, 1 mM ortho-vanadate, 1 Roche Ser/Thr phosphatase inhibitor tablet) assisted by 
sonication on ice using Misonix S-4000 sonicator with five 30-second bursts at 4 watts. Lysates 
were pre-cleared by centrifugation for 15 min at 20,000 g. ~10 mg of total proteins from each 
SILAC label were mixed, reduced with 10 mM dithiothreitol and alkylated with 25 mM 
iodoacetamide. After 4-fold dilution 200 µg sequencing grade modified trypsin (Promega, 
V5113) was added in an enzyme to substrate ratio of 1:100. The total peptide mixtures were 
then desalted using a tC18 SepPak cartridge (Waters, 500 mg, W AT036790) and resuspended 
in IAP buffer (50 mM MOPS/NaOH pH 7.2, 10 mM Na2HPO4, 50 mM NaCl). Peptide 
immunoprecipitation was performed with protein-G agarose bead-bound anti-phosphotyrosine 
antibodies pY100. Peptides captured by phosphotyrosine antibodies were eluted under acidic 
conditions (0.15% trifluoroacetic acid). The IP eluate was analyzed by data-dependent LC-
MS/MS using a Thermo LTQ-Orbitrap instrument.  
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Global serine, threonine, and tyrosine phosphorylation analysis 
Quantitative analysis of serine, threonine and tyrosine phosphorylated peptides was performed 
essentially as described (Villen and Gygi, 2008) with some modifications. After stimulation, cells 
were lysed for 20 min in ice-cold lysis buffer (8 M Urea, 75 mM NaCl, 50 mM Tris pH 8.0, 1 mM 
EDTA, 2 µg/ml Aprotinin (Sigma, A6103), 10 µg/ml Leupeptin (Roche, #11017101001), 1 mM 
PMSF, 10 mM NaF, 2 mM Na3VO4, 50 ng/ml Calyculin A (Calbiochem, #208851), Phosphatase 
inhibitor cocktail 1 (1/100, Sigma, P2850) and Phosphatase inhibitor cocktail 2 (1/100, Sigma, 
P5726). Lysates were precleared by centrifugation at 16,500 g for 10 min and protein 
concentrations were determined by BCA assay (Pierce). We obtained 3 mg total protein per 
label out of 30 million cells. Cell lysates were mixed in equal amounts per label and proteins 
were reduced with 5 mM dithiothreitol and alkylated with 10 mM iodoacetamide. Samples were 
diluted 1:4 with HPLC water (Baker) and sequencing-grade modified trypsin (Promega, V5113) 
was added in an enzyme to substrate ratio of 1:150. After 16 h digest, samples were acidified 
with 0.5% trifluoroacetic acid (final concentration). Tryptic peptides were desalted on reverse 
phase tC18 SepPak columns (Waters, 500 mg, WAT036790) and lyophilized to dryness. 
Peptides were reconstituted in 500 µl strong cation exchange buffer A (7 mM KH2PO4, pH 2.65, 
30% MeCN) and separated on a Polysulfoethyl A column from PolyLC (250 x 9.4 mm, 5 µm 
particle size, 200 A pore size) using an Akta Purifier 10 system (GE Healthcare). We used an 80 
min gradient with a 20 min equilibration phase with buffer A, a linear increase to 30% buffer B (7 
mM KH2PO4, pH 2.65, 350 mM KCL, 30% MeCN) within 33 min, 100% B for 7 min and a final 
equilibration with Buffer A for 20 min. The flow rate was 3 ml/min and the sample was injected 
after the initial 20 min equilibration phase. Upon injection, 3 ml fractions were collected with a 
P950 fraction collector throughout the run. 60 fractions were collected of which 3-4 adjacent 
fractions were combined to obtain 12 samples. Pooling of SCX fractions was guided by the 
UV214-trace and fractions were combined starting where the first peptide peak appeared. The 
12 samples were desalted with reverse phase tC18 SepPak columns (Waters, 100 mg, 
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WAT036820) and lyophilized to dryness. SCX-separated peptides were subjected to IMAC 
(immobilized metal affinity chromatography) as described (Villen and Gygi, 2008). Briefly, 
peptides were reconstituted in 200 µl IMAC binding buffer (40% MeCN, 0.1% FA) and incubated 
for 1 h with 5 µl of packed Phos-Select beads (Sigma, P9740) in batch mode. After incubation, 
samples were loaded on C18 StageTips (Rappsilber et al., 2007), washed twice with 50µl IMAC 
binding buffer and washed once with 50µl 1% formic acid. Phosphorylated peptides were eluted 
from the Phos-Select resin to the C18 material by loading 3 times 70 µl of 500 mM K2HPO4 (pH 
7.0). StageTips were washed with 50 µl of 1% formic acid to remove phosphate salts and eluted 
with 80 µl of 50% MeCN / 0.1 % formic acid. Samples were dried down by vacuum 
centrifugation and reconstituted in 8 µl 3% MeCN / 0.1 % formic acid. 
 
NanoLC-MS/MS analysis 
All peptide samples were separated on an online nanoflow HPLC system (Agilent 1200) and 
analyzed on a LTQ Orbitrap Velos (Thermo Fisher Scientific) mass spectrometer. 4 µl of peptide 
sample were autosampled onto a 14 cm reverse phase fused-silica capillary column (New 
Objective, PicoFrit PF360-75-10-N-5 with 10 µm tip opening and 75 µm inner diameter) packed 
in-house with 3 µm ReproSil-Pur C18-AQ media (Dr. Maisch GmbH). The HPLC setup was 
connected via a custom-made electrospray ion source to the mass spectrometer. After sample 
injection, peptides were separated at an analytical flowrate of 200 nL/min with an 70 min linear 
gradient (~ 0.29 %B/min) from 10% solvent A (0.1% formic acid in water) to 30% solvent B 
(0.1% formic acid/90% acetonitrile). The run time was 130 min for a single sample, including 
sample loading and column reconditioning. Data-dependent acquisition was performed using 
the Xcalibur 2.1 software in positive ion mode. The instrument was recalibrated in real-time by 
co-injection of an internal standard from ambient air (“lock mass option”) (Olsen et al., 2005). 
Survey spectra were acquired in the orbitrap with a resolution of 60,000 and a mass range from 
350 to 1750 m/z. In parallel, up to 16 of the most intense ions per cycle were isolated, 
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fragmented and analyzed in the LTQ part of the instrument. Ions selected for MS/MS were 
dynamically excluded for 20 s after fragmentation. For the second biological replicate analysis 
peptides observed to be regulated in the first analysis were loaded into a global parent mass 
inclusion list and 4 MS/MS scans were reserved for precursors from the inclusion list whereas 
12 were performed on the most intense ions per duty cycle. 
 
Identification and quantification of peptides and proteins 
Mass spectra were processed using the Spectrum Mill software package (Agilent Technologies) 
v4.0 b that includes in-house developed features for SILAC-based quantitation and phoshosite 
localization and also with the MaxQuant software package (version 1.0.13.13) (Cox and Mann, 
2008), which was used in combination with a Mascot search engine (version 2.2.0, Matrix 
Science). For peptide identification in Spectrum Mill an International Protein Index protein 
sequence database (IPI version 3.60, mouse) was used which was reversed on-the-fly at 
search time. In MaxQuant a concatenated forward and reversed IPI protein sequence database 
(version 3.60, mouse) was queried. The mass tolerance for precursor ions and for fragment ions 
was set to 7 ppm and 0.5 Da, respectively. Cysteine carbamidomethylation was searched as a 
fixed modification, whereas oxidation on methionine, N-acetylation (Protein) and 
phosphorylation on serine, threonine or tyrosine residues were considered as variable 
modifications. The enzyme specificity was set to trypsin and cleavage N-terminal of proline was 
allowed. The maximum of missed cleavages was set to 3. For peptide identification the 
maximum peptide FDR was set to 1%. The minimum identification score was to 5 in Spectrum 
Mill and to 10 in MaxQuant. SILAC ratios were obtained from the peptide export table in 
Spectrum Mill and the evidence table in MaxQuant. Arginine to Proline conversion was 
determined to be 3.42% and 5.55% for both biological replicates, respectively. The conversion 
was calculated by defining Arg-10 as a fixed modification and by quantifying the ratio between 
peptides containing normal L-proline (Pro-0) and 13C5-15N1-labeled proline (Pro-6) with 
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MaxQuant. Each peptide SILAC ratio was corrected for arginine to proline conversion by the 
formula r[c] = r[o]/((1-p)^n), where r[c] is the corrected ratio, r[o] the observed ratio, p the 
conversion rate and n the number of proline residues per peptide. The median ratios of all non-
phosphorylated peptides were used to normalize the M/L and H/L ratios of all phosphorylated 
peptides. To allow better peptide grouping, phosphosite localization information obtained from 
SpectrumMill and MaxQuant were further simplified. Probability scores greater or equal 0.75 
were called fully localized and designated with (1.0), scores smaller 0.75 and greater or equal to 
0.5 were called ambiguously localized and designated with (0.5), whereas scores smaller than 
0.5 were called non-localized and the total number of phosphorylation sites per peptide was 
designated with an underscore after the peptide sequence. Median SILAC ratios of 
phosphopeptides for each experiment were calculated over all versions of the same peptide 
including different charge states and methionine oxidation states. The highest scoring versions 
of each distinct peptide were reported per experiment. Overlapping data between SpectrumMill 
and MaxQuant as well as between different biological replicates was analyzed for discrepancies 
by calculating the mean and standard deviation over all residuals for different ratios of the same 
phosphopeptide. Residuals were calculated by subtracting the two values for each 
phosphopeptide derived by SpectrumMill or MaxQuant as well as by two different biological 
replicates. All peptides were filtered from the data set that had residuals greater than 3 standard 
deviations distant from the mean as they were not reproducible between two biological 
replicates or between SpectrumMill and MaxQuant. Data derived from both software packages 
was combined and MaxQuant data was reported when the same phosphopeptide was identified 
and quantified by both programs. Log2 phosphopeptide ratios of BI-2536 treated vs untreated 
dendritic cells followed a normal distribution that was fitted using least squares regression. 
Mean and standard deviation values derived from the Gaussian fit were used to calculate p-
values. An FDR-based measure was used to assess significance of the findings (Storey and 
Tibshirani, 2003). 
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Accession numbers and supplementary tables 
Complete microarray data sets are available in the NCBI Gene Expression Omnibus under the 
accession number GSE28520. The proteomics raw data (.raw files) associated with this 
manuscript were submitted to the Tranche data repository and can be downloaded from: 
https://proteomecommons.org/tranche/, using the following hash: 
HTWY5ZeSLM1hyYEyfEiJREkgLXs6BZxCczuixy9XjULsync5HCkXx/8gB7nZKpGocwOnt8vOk/
Q3cpbPh/ycD/2LT0AAAAAAAAAuEg== 
and passphrase:  
SpSTB6vceSUKeNqefq59 
All 7 supplementary tables containing the datasets presented in this Chapter are available with 
the online version of this published work (Chevrier et al., 2011). 
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Chapter 4 – Integrative Analysis of Signaling-to-Transcription 
Events Reveals the Organization of the TLR Network 
 
4.1. Author Contributions 
- Nicolas Chevrier conceived the study, designed and performed all experiments, 
analyzed and interpreted data, and wrote the manuscript draft. 
- Philipp Mertins optimized the phosphoproteomics protocol, assisted with designing and 
optimizing the affinity purification protocol, assisted with execution of proteomics 
experiments, operated the mass spectrometer, and processed raw data files. 
- Nir Yosef contributed to the statistical analyses of the following data sets: proteomics, 
NanoString, and ChIP-seq (from an independent study). 
- Karl Clauser assisted with computational analysis of the mass spectrometry raw data 
sets. 
- Ido Amit assisted with the design of the temporal phosphoproteomics profiling. 
- Aviv Regev supervised computational analyses. 
- Steven A. Carr supervised the mass spectrometry-based work. 
- Nir Hacohen supervised the project. 
 
4.2. Introduction 
The studies reported in Chapter 3 demonstrate how a systematic strategy – combining 
transcriptomics, genetic and chemical perturbations, and unbiased phosphoproteomics – can be 
used to discover and position new components of signaling networks. In particular, we relied on 
changes in mRNA levels upon stimulation to identify candidate regulators. Although this 
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approach can lead to significant advances in deciphering signaling networks, it is far from 
exhaustive. Indeed, components with unchanged mRNA levels are missed; direct enzyme-
substrate relationships cannot be established; interactions from components can be inferred 
from co-phenotypes (i.e., similar knockdown effect on the TLR gene signature), but remain to be 
tested; and (4) the mechanistic links within and between the signaling and transcriptional 
regulatory layers are not established. To address start addressing these limitations, we 
reasoned that combination of our perturbation-based approach (Chapter 2 and 3) with large-
scale biochemical measurements (e.g., post-translational modifications, protein-protein 
interactions), will lead to more comprehensive, integrated maps of signaling and transcriptional 
networks (Figure 4.1). The two main goals of this study are: (i) to uncover modules of signaling 
regulators controlling TLR-dependent gene expression, and (ii) to extract organizational rules 
driving the ‘signaling-to-transcriptional’ TLR network by intersecting functional and physical 
interactions among the signaling and transcriptional regulatory layers. 
 
 
Figure 4.1. An Integrated Approach to Dissect Intracellular Networks from Signaling to 
Transcriptional Events  
Shown is a schematic depicting the strategy consisting of four steps (from left to right): (1) extract 
candidate signaling regulators from temporal phosphoproteomic profiles; (2) perturb candidates with 
shRNAs and measure the effect on the expression of signature genes; (3) place each regulator within 
their functional context by dissecting protein complexes and kinase-substrate relationships; (4) integrate 
orthogonal datasets into a dynamic, physical model connecting signaling (e.g., phosphorylation, binding) 
and downstream transcriptional events (e.g., TF binding to genomic loci). 
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4.3. A Temporal Phosphoproteomic Analysis Reveals Numerous Known and 
Candidate Regulators of the TLR Pathways 
We reasoned that large-scale measurements of the changes in protein phosphorylation in DCs 
would help characterize the TLR signaling network (Choudhary and Mann, 2010). Our rationale 
was two-fold: (1) TLR signaling has been shown to rely on multiple kinases (e.g., MAP kinases, 
IRAKs, IKKs, TBK1, IKK-ε) and phosphorylation of key transcription factors (e.g., NF-κB and 
IRF families, Jun, Fos) (Takeuchi and Akira, 2010), and (2) we (Chevrier et al., 2011) and others 
(Weintz et al., 2010) have previously shown that phosphoproteomic measurements in DCs or 
macrophages treated with TLR agonist allowed the identification of functional components of the 
TLR system. We measured large-scale changes in phosphorylation in a time course of LPS-
stimulated DCs using SILAC for quantification, leading to the identification of 61299 
phosphopeptides corresponding to 29783 phosphosites on 9648 distinct proteins (False 
Discovery Rate (FDR) 1%) (Figure 4.2A and Experimental Procedures). For all identical 
phosphosites occurring in different peptides (e.g., trypsin miscleavage), we collapsed the values 
by averaging the data points measured more than once. To identify differentially expressed 
phosphopeptides at each time point, we computed the fold-change values compared to 
unstimulated samples and used for subsequent analyses the extreme points of the resulting 
Gaussian distributions (p < 0.001, Figure 4.2B). We identified 32150 and 12332 
phosphopeptides with a significant fold-change in at least one time point and two consecutive 
time points, respectively. These phosphopeptides matched 7928 and 3194 proteins, 
respectively. 
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Figure 4.2. Identification of the LPS-Regulated Phosphoproteome in DCs 
(A) Overview of the experimental strategy to measure large-scale changes in phosphorylation. GM-CSF-
induced BMDCs were grown in different SILAC media (triplex experiments), and lysed upon stimulation 
with LPS at different time points. Protein lysates were mixed (1:1:1 ratio), digested into peptides with 
trypsin, and processed for phosphopeptide enrichment using SCX/IMAC (see Experimental Procedures) 
before LC-MS/MS analysis. Numbers on the right are (grey box), from top to bottom: the total number of 
phosphopeptides identified, the total number of phosphosites, and the total number of corresponding 
phosphoproteins. 
(B) Frequency plots showing the distribution of the SILAC ratios (LPS/unstimulated) for each of the 8 time 
points measured after LPS stimulation. 
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Clustering analysis of the temporal data sets revealed interesting features that we exploited to 
identify the pathways and biological processes and functions that are enriched, and to select 
candidate regulators for functional characterization. To avoid potential artifacts, we focused our 
clustering analysis on the 3627 phosphopeptides (matching 1277 proteins) that satisfied the 
following criteria: (1) significantly regulated in two consecutive time points; (2) quantified in at 
least 6 time points out of the 8 measured; and (3) matching a protein whose mRNA was 
expressed based on microarray measurements. We used k-means clustering to partition the 
temporal profiles of these 3627 phosphopeptides into 15 clusters, which was the minimal k 
number of clusters providing optimal similarity (Euclidean metric) within each cluster (Figure 
4.3A). 
 
Enrichment analyses of the pathways and molecular functions significantly over-represented (p 
< 10-5) among these 1277 LPS-regulated proteins revealed canonical members of pathogen-
sensing pathways (TLR, p = 5.96 x 10-7; NOD-like receptor, p = 2.75 x 10-7; RIG-I-like receptor, 
p = 2.19 x 10-7), and associated pathways such as MAP kinases (p = 5.78 x 10-9) (Figure 4.3B). 
In addition, molecular functions associated with signal transduction were highly enriched, 
including protein kinase activity (p = 6.33 x 10-13), transcription factor binding (p = 9.5 x 10-8), 
and GTPases and their regulators (e.g., GTPase regulator activity, p = 2.3 x 10-25; small 
GTPase regulator activity, p = 1.23 x 10-14) (Figure 4.3B). Other enriched gene sets pointed to 
nascent areas of TLR biology (Barton and Kagan, 2009; Lee et al., 2012), such as the 
organization and regulation of the TLR system within the framework of intracellular organelles 
and structures (e.g., endocytosis, p = 6.59 x 10-6; cytoskeletal protein binding, p = 1.03 x 10-10; 
phospholipid binding, p = 3.79 x 10-6). Interestingly, comparing changes in phosphorylation 
(Figure 4.3C) and mRNA levels (Figure 4.3D) for known TLR pathway members suggested a 
more comprehensive coverage of the TLR pathways using phosphoproteomics. Altogether, 
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these results indicate the predictive potential of the data in identifying functional components of 
the TLR network. 
 
Figure 4.3. Clustering and Enrichment Analyses Reveals the Predictive Potential of the TLR 
Phosphoproteome in Identifying Regulators 
(A) Heatmap of all the phosphopeptides (row) significantly regulated (up or down) in at least 2 
consecutive time points (column). Data were clustered using k-means (left-most color-coded clusters), 
and only phosphopeptides measured in at least 6 out of 8 time points are shown. Missing values were 
imputed as the average between the two surrounding values), and ratios at time point 0 were set to 1 for 
clustering. 
(B) Gene-set enrichment analysis on the 1277 phosphoproteins belonging to the 15 k-means clusters 
from (A). Significantly enriched genesets (GO terms, KEGG pathways; p value < 10-5) are represented in 
a network-based view whereby each set is a node and edges represent gene overlap between sets. The 
size of nodes and edges is proportional to geneset sizes and the degrees of overlap, respectively. 
Enrichments were generated using DAVID, and the network view was created in Cytoscape using the 
‘Enrichment Map’ plugin (Experimental Procedures). 
(C-D) Examples of temporal phosphorylation (C) and mRNA (D) profiles of selected known TLR pathway 
members. Rows correspond to phosphopeptides (C) and mRNA transcripts (D) from indicated genes, and 
columns to time point after LPS stimulation. 
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4.4. A Perturbation Strategy Uncovers Components Participating in the Control of 
TLR Signature Gene Expression 
The results of these temporal (Figure 4.3A) and enrichment (Figure 4.3B) analyses were used 
to focus the scope of the subsequent identification and characterizations of candidate signaling 
regulators. First, we focused our attention on the four largest k clusters in numbers of 
phosphopeptides: k clusters 3, 4, 8, and 11, collectively containing ~36% of all phosphoproteins 
present in our dataset (Figure 4.4A). These four clusters encompass phosphopeptides with an 
early peak in induction at 30 min after LPS stimulation, which is not due to changes in total 
protein levels that remained largely unchanged during the course of stimulation (Figure 4.4A). 
We reasoned that focusing on these early clusters would favor the identification of candidate 
regulators directly downstream of TLR4, thus avoiding feedbacks through transcription and 
autocrine/paracrine signaling. Furthermore, practically speaking, focusing on a single, early time 
point (i.e., 30 min), helps narrowing down the scope of our subsequent functional assays 
(detailed below). Using molecular function annotations, we selected from these four k clusters 
(2033 phosphopeptides corresponding to 833 proteins) all 203 enzymes (e.g., kinases, 
GTPases) and enzyme binders and regulators (e.g., GTPase regulators) as candidate 
regulators of the TLR system (Figure 4.4B).  
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Figure 4.4. Candidate Signaling Regulators Were Selected Based on Molecular Function 
Annotations 
(A) Heatmap of the phosphopeptides belonging to clusters 3, 4, 8, and 11 (left-most bar) as represented 
in Figure 4.3A, and matching the selected 203 candidate regulators. Bar graphs on the right indicate the 
total protein levels upon LPS stimulation for 2 and 6 h (as SILAC ratios between 2/0 h, and 6/0 h, from left 
to right; a ratio of 1 indicates no change in protein level). 
(B) Functional enrichment of the molecular functions present in the proteins from all 15 k-means clusters 
(comprising 1277 phosphoproteins; left column), from k-means clusters 3, 4, 8, and 11 (comprising 811 
phosphoproteins; middle column), and from selected candidate regulators (comprising 203 
phosphoproteins; right column). Numbers in parenthesis on the top of each column indicate the total 
number of proteins in each case. The color-coded (blue) legend indicates p-values (hypergeometric test). 
 
To assess the function of these 203 phosphoproteins, we measured the impact of genetic 
perturbations on a representative set of 230 TLR-induced genes, referred to as TLR signature 
genes (Figure 4.5). Out of the 203 candidates initially selected, 156 were efficiently knocked 
down using shRNAs, among which 30 led to a significant decrease in TLR signature genes 
(Figure 4.5). These 30 phosphoproteins included well-described TLR signaling components, 
such as TRIF, TBK1, and IRAK2, as well as a host of phosphoproteins not previously 
associated with the TLR system. Interestingly, known and candidate components had similar 
effects on the TLR gene signature (Figure 4.6A). By measuring the pairwise similarity (Pearson 
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correlation) among these 30 perturbation profiles, we observed three clusters of signaling 
regulators (Figure 4.6B). These genetic interactions suggest that the TLR4 pathways leading to 
transcriptional regulation are likely to be organized around at least three overlapping pathways 
or modules. Indeed, while some genes such as TRIF (Ticam1) led a near-complete abrogation 
of TLR signature gene induction, MYD88 only affected inflammatory gene expression (e.g., 
Cxcl1, Cxcl2, Il1a, Il1b, Il6, Tnf, Il12b). 
 
 
Figure 4.5. Genetic Perturbations of Candidate Regulators Affect TLR Signature Gene Expression  
Shown are perturbation profiles of the 156 regulators with efficient shRNA-mediated knockdown (out of 
203 initially selected), as indicated by % of remaining transcript compared to control shRNAs (bar graph 
on top). The heatmap shows each perturbed regulator (columns) and their statistically significant effects 
on each of 230 TLR signature genes (rows). Blue: target gene expression decreased following 
perturbation; red: target gene expression increased following perturbation; white: no significant effect. 
Rows and columns were hierarchically clustered (Pearson’s correlation). 
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Figure 4.6. Functional Characterization Based on Similarity of Perturbation Profiles Reveals 
Genetic Interactions Among 30 Signaling Regulators 
(A) Shown are perturbation profiles of the 30 regulators with significant effects on TLR signature genes 
(extracted from the matrix in Figure 4.5). 
(B) Shown is a correlation matrix of the perturbation profiles from the 30 candidate regulators that 
significantly affected TLR signature gene expression (from Figure 4.5). Pearson’s correlation was used to 
compute pairwise correlation coefficients among all 30 profiles. Red: maximum correlation; blue: negative 
correlation. 
 
These observations raised two related questions: (1) what are the roles of these 30 regulators 
and how do they function together, and (2) what is the overall organization of the ‘signaling-to-
transcription’ TLR network? The following sections 4.4 and 4.5 present preliminary data and 
analyses that start to address these questions. 
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4.5. Systematic Functional Characterization of 30 Candidate Regulators Affecting 
TLR Signature Gene Expression 
Next, we sought to systematically characterize the function of these 30 candidate regulators. To 
this end, we designed and applied in DCs three complementary proteomics-based assays to: 
(1) connect a regulator with downstream phosphorylation events, (2) identify the substrates of 
kinases, and (3) place each component within its functional context by identifying its binding 
partners (Figure 4.7). 
 
 
Figure 4.7. Functional Assays for Mechanistic Characterization of Candidate Regulators 
Overview of the experimental workflow used for each large-scale biochemical assays described in the 
text on: (1) dissecting protein complexes, (2) measuring the impact of individual gene knockdown on the 
phosphoproteome, and (3) connecting kinases with their downstream substrates. 
 
First, to connect each candidate regulators with downstream phosphorylation events (direct and 
indirect), we will genetically perturb each gene and measure the impact on the DC 
phosphoproteome upon LPS stimulation at a single time point (30 min) (Figure 4.7, panel 1). 
We and others have demonstrated in DCs (Chevrier et al., 2011), and in other mammalian or 
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yeast models (Bodenmiller et al., 2010; Grosstessner-Hain et al., 2011; Hsu et al., 2011; Koch 
et al., 2011; Santamaria et al., 2011), the validity of this approach in determining functional 
pathway components downstream of a given network node. Second, for the 10 protein kinases 
present among the 30 candidate regulators, we will determine their direct substrates using a 
massively parallel in vitro kinase assay, relying on purified recombinant kinases incubated with 
DC protein lysates followed by phoshoproteomic measurements (Figure 4.7, panel 2). 
Preliminary datasets using recombinant Tbk1 protein kinase demonstrated the feasibility of this 
method by identifying its known substrate motif (data not shown). Finally, we will place each 
component within their functional context in DCs by pulling them down, and identifying their 
binding partners upon stimulation (Figure 4.7, panel 3). The first two assays delineated above 
are part of ongoing efforts, and we will focus on the preliminary results obtained for the pull-
down experiments. 
 
To start investigating the precise molecular mechanisms of action of interesting signaling nodes 
or modules emanating from the results mentioned above, we used affinity purification followed 
by mass spectrometry (AP-MS). V5-tagged open reading frames (ORFs) were expressed in 
DCs using a lentiviral vector. For preliminary development of the methodology, we focused on 
Myd88, well-described proximal adaptor in the TLR4 signaling cascade (Figure 4.8A). 
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Figure 4.8. Myd88 Affinity-Purification Followed by Mass Spectrometry (AP-MS) Reveals Known 
and Candidate Interaction Partners 
(A) Overview of the experimental workflow. V5-tagged Myd88 ORF was overexpressed in BMDCs using 
lentiviral delivery followed by blasticidin selection. Verification of ORF expression and size was done by 
Western blot using anti-V5 mAb (panel 1). For AP-MS experiments, cells were grown in SILAC media for 
quantification (“light” for GFP-V5, and “heavy” for Myd88-V5) and stimulated with LPS for 30 min before 
lysis and separate IPs (for each ORF-V5) using magnetic beads covalently linked to anti-V5 mAb. After 
washes, on-bead protein complexes from each IP (GFP-V5 and Myd88-V5) were mixed, digested into 
peptides, and analyzed by mass spectrometry. 
(B) DCs overexpressing V5-tagged ORFs normally respond to LPS. BMDCs were infected with GFP-V5 
lentivirus and selected with blasticidin. Shown are immunofluorescence images of GFP-V5-expressing 
BMDCs before (top) and after (bottom) LPS stimulation for 4 h. 
(C-D) Independent AP-MS experiments identify high-confidence Myd88-associated proteins. Shown are 
density plots of the SILAC ratios (Myd88/GFP) of two independent experiments (C), and a plot of the 
SILAC ratios for proteins identified in both of these experiments (D, proteins in the top-right corner 
representing high-confidence Myd88-associated proteins). 
 
DCs subjected to lentiviral ORF delivery and expression exhibited normal responsiveness to 
LPS stimulation (Figure 4.8B). Following immunoprecipitation of Myd88-V5 and GFP-V5 (as a 
control) in parallel in DCs stimulated with LPS for 30 min, we identified high-confidence binding 
partners that include known interactors (Tirap, Irak family) as well as potential new ones (Tbk1) 
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(Figure 4.8C and 4.8D). Importantly, immunoprecipitation of endogenous Myd88 in DCs led to 
comparable results, including the identification or Iraks and Tbk1 as Myd88 interaction partners 
(data not shown). Furthermore, immunoprecipitation of Irak2-V5 led to the identification of 
endogenous Myd88 as well as most of the other Myd88-associated proteins identified by 
Myd88-V5 AP-MS (data not shown). These preliminary datasets reinforce the validity of using 
our AP-MS approach to obtain mechanistic clues about the function of known and candidate 
TLR pathway components. 
 
4.6. Integrative Analysis of Physical and Functional Interactions to Model 
‘Signaling-to-Transcription’ Events in TLR Responses 
Finally, to investigate the organization of the ‘signaling-to-transcription’ pathways controlling 
TLR responses, the orthogonal datasets detailed above will be integrated into a statistical 
model. The goal of this integrative analysis is two-fold. First, our data-driven model will help 
extracting the general organization of the overlapping pathways suggested by the genetic 
interactions observed in Figure 4.6. For example, it will inform whether these pathways cross 
talk via shared components or complexes, what are the sequence of events from ligand 
recognition to transcription initiation, or what are the hierarchical relationships between signaling 
components. Second, it will provide mechanistic clues regarding the roles of signaling regulators 
in the control of TLR-induced transcripts. For example, it will generate specific hypotheses 
about the mechanisms of action of a new component or module within the TLR network, or even 
directly pinpoint this mechanism in certain cases. Because this work is ongoing, we simply 
present a preliminary workflow for data integration, together with preliminary results on an 
example of integrating functional and physical datasets. 
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In a nutshell, our data-driven modeling approach relies on the integration of physical and 
functional interactions emanating from the measurements reported above (Figure 4.9A). 
Physical interactions (Figure 4.9A) comprise measurements of phosphorylation (Figure 4.2), 
protein binding (AP-MS; Figure 4.7 and 4.8), kinase substrates (Figure 4.7, panel 2), and 
transcription factor (TF) binding sites (Garber et al., unpublished). Functional interactions 
(Figure 4.9A) include the effects of genetic perturbations on the TLR-induced transcripts 
(Figure 4.5) and phosphoproteome (Figure 4.7, panel 1). To integrate these orthogonal 
datasets into a model, we will apply a stepwise procedure: stimulus-dependent phosphorylation 
events identify signaling components and provide clues on temporality (i.e., order of events) 
(Figure 4.9B, panel 1); effects of genetic perturbations on TLR-induced transcripts establish 
functional relationship for a given component and between signaling components (Figure 4.9B, 
panel 2); effects of genetic perturbations on the TLR-induced phosphoproteome together with 
kinases’ substrates connect modules of components acting in a sequential signaling path 
(Figure 4.9B, panel 3); and protein-protein and protein-DNA interactions will inform the physical 
relationships between components and downstream gene regulation (Figure 4.9B, panel 4). 
Furthermore, if proven necessary to expand or increase the confidence of the resulting model 
network, we will complement our observed interactions using a custom database of >50,000 
physical interactions with experimental evidence retrieved from several public repositories 
(BioGrid, HPRD, PhosphoSite, SPIKE, and NetPath). 
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Figure 4.9. An Integrative Analysis to Dissect the Rules of ‘Signaling-to-Transcription’ 
Downstream of TLR4 
(A) Schematic summary of the data types and measurements of this study. Datasets are categorized into 
functional and physical interactions, and corresponding measurement types and associated figures are 
listed on the right. 
(B) Schematic overview of the proposed analytic framework to integrate functional and physical 
interactions into a model. From left to right: (1) Identification – candidate regulators are identified by  
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Figure 4.9 (Continued) 
phosphoproteomic measurements (Figure 4.2, 4.3, and 4.4); (2) Functionality – regulators participating in 
the control of TLR signature genes are determined by functional genomics (Figure 4.5); (3) Connectivity 
– regulators are connected between themselves and with downstream effectors using functional 
phosphoproteomics and massively parallel in vitro kinase assay (Figure 4.7, panel 1 and 2); and (4) 
Interactivity – Physical interactions are determined for regulator-associated proteins (Figure 4.8) and for 
transcription factors (TFs) bound to promoter regions of TLR signature genes (Garber et al., unpublished 
data). 
(C) An example of integrative analysis of functional and physical interactions to connect TLR signaling 
and transcriptional regulatory layers. Top matrix: shown are the 30 signaling regulators (columns) and 
TFs (rows) showing significant overlap (hypergeometric test) in terms of TLR signature genes affected by 
knockdown and bound at promoter regions, respectively. Green: significant correlation; white: no 
correlation. Bottom matrix: Shown are perturbation profiles of the signaling regulators from the top matrix. 
The heatmap shows each perturbed signaling regulator (columns, order identical as top matrix) and their 
statistically significant effects on each of 230 TLR signature genes (rows). Blue: target gene expression 
decreased following perturbation; red: target gene expression increased following perturbation; white: no 
significant effect. 
 
As an initial example of the analyses described above, we show connections between the 
signaling and transcriptional layers of the TLR system. To connect these regulatory layers, we 
previously relied on genetic interactions inferred from similar perturbation profiles (Chapter 3, 
section 3.3). Here we go further by measuring overlaps (hypergeometric test) between the 
genes whose promoters are bound by 19 TFs of the TLR response (Garber et al., unpublished), 
and the genes whose transcripts were significantly impacted by knockdown of the 30 signaling 
regulators (Figure 4.5). By intersecting these physical and functional interactions, we identify 
significant overlaps highlighting that signaling regulators with similar perturbation profiles lie 
upstream of the same set of TFs (Figure 4.9C). For example, Myd88 clearly lies upstream of 
NF-κB family members Crel and Relb, and Ticam1-dependent genes significantly overlap with 
both inflammatory and antiviral TFs, such NF-κB and IRFs, respectively (Figure 4.9C). These 
observations are consistent with previous knowledge of the TLR pathways (Takeuchi and Akira, 
2010). Further analyses following the preliminary framework delineated above will help to 
uncover the intermediate effectors and mechanistic events between the TLR signaling and 
transcriptional regulatory layers. 
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4.7. Discussion 
By integrating functional and physical interactions about signaling and transcriptional regulatory 
layers, we uncovered a set of 30 TLR signaling regulators that control downstream 
transcriptional changes. Ongoing mechanistic characterization of these 30 regulators and 
integrative analysis of the resulting datasets are likely to help uncover modules and 
organizational rules driving the ‘signaling-to-transcriptional’ TLR network in DCs. Furthermore, 
the approach, datasets, and ongoing analyses reported here suggest multiple avenues for 
future exploration; we highlight below a handful of them.  
 
The temporal phosphoproteomic datasets have been specifically mined for extraction of 
candidate signaling regulators. However, these highly information-rich data are likely to be 
useful for multiple other analytic, mining, and hypothesis-generating purposes. For example, 
intersecting phosphorylation data with other post-translational modifications (PTMs; e.g., 
ubiquitinylation, acetylation) might help uncover regulatory codes on proteins harboring unique 
or combinations of these PTMs in response to LPS, as suggested by the p53 example (Sims 
and Reinberg, 2008). While we focuses on enriched enzymes and enzyme regulators likely to 
be active in signaling events in this work, our data uncovered multiple other classes of 
regulators that may be nominated as candidates such as TFs and other transcriptional 
regulators. Previous studies in macrophages (Weintz et al., 2010) or T cells (Navarro et al., 
2011) have demonstrated that changes in phosphorylation may indeed be indicative of 
functional transcriptional regulators. Another potential avenue for future mining of these 
temporal phosphoproteomic data might come from searching for regulators of the positive and 
negative feedback regulatory loops involved in the TLR system (Rothlin et al., 2007).  
 
Our perturbation analyses focused on measuring the effects of a given regulator knockdown on 
selected, downstream transcriptional targets. As sequencing costs keep decreasing, applying 
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the same approach to genome-wide readouts (e.g., using RNA-seq) might help uncovering 
further modular subdivisions in the architecture of the signaling-to-transcription TLR circuits. For 
example, it might help further refine the various and overlapping branches of signaling events 
that culminate with changes in given sets of target genes. 
 
Many candidate regulators did not have a significant impact on the TLR gene signature. Some 
of the possible explanations to this phenomenon include: (1) technical issues (e.g., knockdown 
efficiency not sufficient), (2) redundancies (e.g., PLK example from Chapter 3), and (3) potential 
importance of these genes not in controlling downstream transcription, but rather, other aspects 
of DC biology (e.g., antigen processing and presentation, cell shape and motility, etc.), as 
exemplified in recent work by others (Neefjes et al., 2011; Paul et al., 2011). These results 
suggest the importance of conducting systematic analyses of epistatic interactions, as 
demonstrated in yeast for example (Collins et al., 2007; Roguev et al., 2008). 
 
4.8. Experimental Procedures 
Preparation of dendritic cells 
Bone marrow-derived dendritic cells (BMDCs) were generated from 6-8 week old female 
C57BL/6J mice (Jackson Laboratories). Bone marrow cells were collected from femora and 
tibiae and plated at 106 cells/mL on non-tissue culture treated petri dishes in RPMI-1640 
medium (Gibco), supplemented with 10% FBS, L-glutamine, penicillin/streptomycin, MEM non-
essential amino acids, HEPES, sodium pyruvate, β-mercaptoethanol, and murine GM-CSF (15 
ng/mL; Peprotech) or human Flt3L (100 ng/mL; Peprotech). GM-CSF-derived BMDCs were 
used directly for all RNAi experiments unsing lentiviral shRNAs. For all other experiments, 
floating cells from GM-CSF cultures were sorted at day 5 by MACS using the CD11c (N418) 
MicroBeads kit (Miltenyi Biotec). Sorted CD11c+ cells were used as GM-CSF-derived BMDCs, 
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and plated at 106 cells/mL and stimulated at 16 h post sorting with 100 ng/mL ultra-pure E. coli 
K12 LPS (Invivogen). 
 
Metabolic labeling of cells 
For stable isotope labeling of amino acids in cell culture (SILAC) experiments, GM-CSF-derived 
BMDCs were grown for seven days in media containing either normal L-arginine (Arg-0) and L-
lysine (Lys-0) (Sigma) or L-arginine 13C6-15N4 (Arg-10) and L-lysine 13C6-15N2 (Lys-8) (Sigma 
Isotec). Concentrations for L-arginine and L-lysine were 42 mg/L and 73 mg/L, respectively. To 
prevent metabolic conversion of L-arginine to L-proline we added 200 mg/L L-proline to the cell 
culture medium. The cell culture media, Roswell Park Memorial Institute-1640 (RPMI) deficient 
in L-arginine and L-lysine, was a custom media preparation from Caisson Laboratories (North 
Logan, UT) and dialyzed serum was obtained from SAFC-Sigma. We followed all standard 
SILAC media preparation and labeling steps as previously described (Ong and Mann, 2006). 
 
Global serine, threonine, and tyrosine phosphorylation analysis 
BMDCs grown in SILAC media were stimulated with LPS, and lysed and processed for 
enrichment of phosphopeptides as described in full in Chapter 3 (section 3.12). 
 
Analysis of relative protein expression 
BMDCs grown in SILAC media were left untreated or stimulated with LPS for 2 and 6 h. After in 
solution digest and desalting, 100 µg of total peptides were separated using an Agilent 3100 
Offgel fractionator (Agilent, G3100A) as described in the manual. For separation into 12 
fractions, we used Immobiline DryStrips, 13cm, pH 3-10 (GE Healtcare, 17-6001-14) that were 
rehydrated in a 1:50 dilution of IPG buffer, pH 3-10 (GE Healthcare, 17-6000-87) containing 5% 
glycerol. Peptides were reconstituted in IPG buffer (1:50 dilution) containing 5% glycerol and 
focused for 20kV*h with a maximum current of 50 µA and power of 200 mW. After separation, 
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fractions were acidified by adding 1% formic acid and desalted using StageTips. Peptide 
samples were analyzed on a LTQ Orbitrap Velos instrument. 
 
Analysis of phosphoproteomic data 
For supervised k-means clustering to partition the differentially expressed phosphopeptides, we 
set the parameter k (number of clusters) as the minimal number of clusters that provided a 
sufficient level of within-cluster similarity. For every cluster we define the within-cluster similarity 
as the average r2 between the members of the cluster and the centroid of the cluster. We used 
the following cutoffs for: the minimum within-cluster similarity (across all clusters) to be >0.7, 
and the average (across all clusters) to be >0.75. 
Pathway enrichment analyses were performed using the following databases and online 
resources: Panther (http://www.pantherdb.org), DAVID (http://david.abcc.ncifcrf.gov), MSigDB 
(http://www.broadinstitute.org/gsea/msigdb). Data were displayed using the Enrichment Map 
plugin (Merico et al., 2011) in Cytoscape (http://www.cytoscape.org/), and the software Gene-E 
(http://www.broadinstitute.org/cancer/software/GENE-E/) 
 
shRNA knockdowns 
High titer lentiviruses encoding shRNAs targeting genes of interest were obtained from The 
RNAi Consortium (TRC; Broad Institute). Bone marrow cells were infected with lentiviruses and 
processed for RNA extraction and measurments as described in Chapter 3 (section 3.12). 
 
mRNA counting and data analysis 
Samples were processed as described in Chapter 3 (section 3.12). We used a custom CodeSet 
constructed to detect a total of 267 genes (including 16 control genes whose expression remain 
unaffected by TLR stimulation) selected using the GeneSelector algorithm and manually 
populated for DC- or TLR-related genes of interest. 
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Multiplex mRNA count data analysis 
For normalization, we divide the nCounter (NanoString) mRNA count values for each gene by 
the sum of counts obtained for the 16 control genes present in our custom nCounter CodeSet. 
To determine significantly affected signature genes, a fold-change ratio is computed for each 
pairwise comparison of a knockdown sample versus a set of control samples (i.e., non-targeting 
shRNA; at least 10 per experimental batch). As a threshold, we require a substantial fold-
change (above a threshold value t) in the same direction (up- or down-regulation) in more than 
half of the pairwise comparisons sample vs. control shRNA. The threshold value t is determined 
as max (q, d), d being the mean + 1.645 times the standard deviation in the fold change shown 
by the control genes (corresponding to p = 0.05, under the assumption of normality). The 
threshold q is similar for all comparisons and is based on the noise level estimated from the 
control shRNA samples. Specifically, we compute gene expression fold changes in all possible 
pairs of control shRNA samples (which are supposed to be consistent). We set the threshold q 
such that 95% of the comparisons exhibit lower fold change than q. The resulting value of q is 
1.961. Notably, we ignore all pairwise comparisons in which both control and knockdown 
samples had low counts before normalization (<50). All heatmaps and distance matrix analyses 
were generated using the software Gene-E, referenced above. 
 
Affinity purification followed by mass spectrometry 
Analysis of interaction partners of V5-tagged proteins was performed using a fast and low-
stringency single-step purification procedure (to retain weak binders and potentially transient 
interactions) previously decribed by Matthias Mann’s group (Hubner et al., 2010; Hubner and 
Mann, 2011), with several modifications to fit our experimental system. 2 x 106 bone marrow 
cells were plated in SILAC complete medium supplemented with 15 ng/mL GM-CSF in 10-cm 
Petri dishes, and infected two days later with lentiviruses (MOI ~10-20) containing V5-tagged 
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ORFs (Yang et al., 2011) in 10-cm Petri dishes. 2-4 h after infection, cells were fed with GM-
CSF-containing complete medium. Two days post-infection, GM-CSF-containing complete 
medium supplemented with blasticidin (10 µg/mL) was added to cells, which were further 
incubated for 3 days. ORF expression and size was validated using standard Western blotting 
with anti-V5 antibody (Invitrogen). 
For immunoprecipitation (IP) of protein complexes, BMDCs expressing a V5-tagged ORF 
encoding MYD88 were stimulated with LPS for 30 min, scraped on ice and washed in ice-cold 
PBS. Cell pellets were lysed for 30 min on ice in a lysis buffer containing 150 mM NaCl, 50 mM 
Tris pH 7.5, 5% Glycerol, 1% IGPAL-CA-630 (Sigma, #I8896), and freshly added protease and 
phosphatase inhibitors (Roche). After centrifugation at 4°C for 10 min at 14,000 g, protein 
concentration in supernatants was measured by BCA (Pierce), and equal amounts (~2.5-3 mg) 
of lysates from each SILAC samples were used for subsequent IP. Cell lysates were incubated 
for ~16 h at 4°C on a roller with anti-V5 tag antibody covalently bound to magnetic beads (MBL). 
Beads were then washed twice with wash buffer (150 mM NaCl, 50 mM Tris pH 7.5, 5% 
Glycerol) containing 0.05% 1% IGPAL-CA-630, and twice with wash buffer alone. Beads from 
each SILAC state were combined after the first wash. Purified protein complexes were then 
eluted non-specifically by direct on-bead digestion with trypsin using a buffer containing 2 M 
urea, 50 mM Tris pH 7.5, 1 mM DTT, and 5 µg/mL Trypsin. After elution, samples were reduced 
(4 mM DTT) and alkylated (10 mM iodoacetamide) following standard procedures, and further 
digested with trypsin overnight. Digestion were stopped by adding 1% TFA, and peptides were 
desalted purified on C18 StageTips. 
Desalted peptide samples were separated on an online nanoflow UHPLC system (Proxeon 
EASY-nLC 1000) and analyzed on a Q Exactive (Thermo Fisher Scientific) mass spectrometer. 
We used a 13 cm reversed phase fused-silica capillary column (New Objective, PicoFrit PF360-
75-10-N-5 with 10 µm tip opening and 75 µm inner diameter) packed in-house with 3 µm 
ReproSil-Pur C18-AQ media (Dr. Maisch GmbH) and separated peptides at a flow rate of 200 
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nL/min in a 82 min linear gradient from 6 to 30% composition of solvent A (3% acetonitrile /0.1% 
formic acid) and solvent B (90% acetonitrile /0.1% formic acid). The Q Exactive was operated at 
a spray voltage of 2 kV, a capillary temperature of 250 C and a S-lens RF level of 50. Data was 
acquired in positive ion mode, with MS1 scans at a resolution of 70,000 at m/z=200, a mass 
range from 300-1800, AGC target of 1e6 and 5 ms maximum ion time. Up to 12 of the most 
intense ions per duty cycle were isolated using an isolation window of 2.5 m/z and fragmented 
by HCD at a NCE of 25 with an underfill ratio set at 5%. For data dependent MS2 scans we 
used a resolution of 17,500, an AGC target of 5e4 and a maximum ion time of 120ms. All ions 
selected for MS2 scans were dynamically excluded for 20 s after fragmentation. 
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Chapter 5 – Concluding Remarks 
The approaches and results presented here set the ground for further developments from both 
systems biological and immunological standpoints. For example, immediate applications of 
these approaches can be foreseen with the use of additional data sources for candidate 
regulator nomination (e.g., genes emanating from genome-wide association studies). 
Furthermore, the study of additional regulatory layers embedded within the TLR system (e.g., 
see Appendix A) will be key to reach a more detailed understanding of how it operates, and to 
potentially gain insights into basic cell biology. Equally important will be the integration of these 
regulatory layers with variables such as context (e.g., diseases) and space (e.g., intracellular 
structures). Furthermore, while the studies presented here focused on the TLR system, it is 
clear that many inter-dependencies exist among pathogen-sensing pathways (e.g., interplay 
between TLRs and NLRs). Conducting systematic analyses of these interactions to identify their 
levels of interface and functional relevance will be key to crack the code of innate immune 
sensing and activation. Finally, a deeper understanding of pathogen-sensing pathways will not 
be reached unless placed in the context of evolutionary constraints and organism-level immune 
responses. 
The advent of systems approaches has propelled biology in an era of accelerated discovery. 
Furthermore, a quantitative understanding of biological systems at a high level of resolution is 
likely to be within reach in the not too distant future. Some of the challenges for the next decade 
are to fully realize the vision and promise of systems approaches by leveraging their potential to 
catalyze the generation of refined hypotheses and precise cellular networks about the 
mechanisms of health and disease. Resulting knowledge will undoubtedly help (i) in 
manipulating biological systems either by rationale targeting of components or pathways, alone 
or in combination, and (ii) in building biological systems de novo. 
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Appendix A – Large Non-Coding RNAs as a Putative Regulatory 
Layer of the Toll-Like Receptor System 
 
A.1. Introduction 
In this appendix, we provide preliminary evidence that large non-coding RNAs (ncRNAs) might 
represent a previously unrecognized layer of regulation in the TLR system. The idea that RNA 
molecules would be well adapted for regulatory roles emerged more than 50 years ago (Eddy, 
2001; Jacob and Monod, 1961). Initial discovery of functional RNAs included small nuclear (sn) 
and nucleolar (sno) RNAs, involved in ribosome biogenesis, and ribosomal RNAs and transfer 
RNAs. A few decades later, the first examples of functional, mRNA-like, large ncRNAs were 
discovered. While they resembled mRNAs in terms of length and structure (i.e., capped, 
exonic), these large ncRNAs did not possess any protein-coding potential. For example, Xist 
has been shown to function in imprinting and X chromosome inactivation (Brown et al., 1991; 
Penny et al., 1996). Another example of functional, large ncRNA comes from T cell biology: 
NRON (noncoding repressor of NFAT) prevents NFAT from transclocating into the nucleus, 
therefore blocking NFAT-induced gene expression (Willingham et al., 2005). 
 
Large-scale studies have focused on better characterizing eukaryotic transcripts present in a 
given cell or tissue under multiple conditions. Using massive shotgun sequencing of mouse 
complementary DNAs (cDNAs), a consortium study highlighted a broader transcriptional activity 
than anticipated (Carninci et al., 2005). Another approach relied on the development of high-
density tiling arrays. These arrays were designed to represent genomic DNA at various 
sequence resolutions regardless of known gene annotations, thus providing a powerful and 
unbiased tool to investigate transcribed sequences of genomic chromosomes or loci (Bertone et 
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al., 2005). Through the interrogation of tiling arrays, thousands of new transcribed regions of the 
human genome were identified (Bertone et al., 2004). More recently, the combination of direct 
high-throughput sequencing of cDNAs and the use of tiling arrays allowed for the detection of 
widespread transcriptional activity in more than 90% of the genome of the yeast 
Schizosaccharomyces pombe (Wilhelm et al., 2008). Altogether, these datasets and those of 
others (Birney et al., 2007) demonstrated that eukaryotic genomes are almost entirely 
transcribed, producing multiple small (<200 nucleotides) and large ncRNAs (>200 nucleotides) 
transcripts. An important question arising from these datasets is whether these large ncRNAs 
represent simple transcriptional noise, or are part of a larger set of RNAs with regulatory roles in 
cells, similarly to the few examples of functional large ncRNAs mentioned above (Ponting et al., 
2009). 
 
A.2. Chromatin Maps Identify Large Intergenic Non-Coding RNAs 
A recent study brought experimental evidence of the existence of a class of long ncRNAs, 
referred to here as long intergenic ncRNAs (lincRNAs) (Guttman et al., 2009). This work reports 
the identification of ~1600 lincRNAs in the mouse genome based on genome-wide modified-
chromatin immunoprecipitation (ChIP) followed by massive parallel sequencing (ChIP-seq) in 
four cell types. This experimental approach rests on the observation that genes actively 
transcribed by polymerase (Pol) II are marked by Histone 3-Lysine 4 trimethylation (H3K4me3) 
at their promoter, and Histone 3-Lysine 36 trimethylation (H3K36me3) along the length of the 
transcribed region (Mikkelsen et al., 2007). These modified-chromatin domains (K4/K36 
domains) are found in both protein-coding genes and well-known ncRNAs such as miRNAs. 
Here we asked whether these lincRNAs might play a role in regulating TLR responses of DCs. 
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A.3. A Set of LincRNAs is Differentially Regulated upon TLR Stimulation in DCs 
First, we designed custom tiling arrays with probes tiling across the K4/K36 domains of recently 
identified lincRNAs and the 3’ regions of ~300 protein-coding genes, which are differentially 
regulated in TLR-activated BMDCs (Amit et al., 2009). Both protein-coding genes known to be 
involved in the TLR pathways (data not shown) and a set of 24 lincRNAs followed three similar 
patterns of induction (Figure A.1A). Interestingly, some of our lincRNA candidates lie in the 
genome in the neighboring regions of IRF family members (Figure A.1A). Moreover, some of 
the promoter regions of these lincRNAs have binding sites for IRF2, IRF3 and STAT6 
transcription factors (data not shown). However, only a small number of these lincRNAs were 
reproducible by qRT-PCR, which is likely due to: (1) the use of tiling array probes for lincRNA 
exonic regions identified in non-immune cells and that may not be relevant to DCs, and (2) the 
intrinsic limitations of tiling array platforms (e.g., poor reproducibility, high background, cross-
hybridization). 
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Figure A.1. Identification of DC-specific large intergenic noncoding RNAs (lincRNAs) 
(A) Heatmap of lincRNA exons differentially regulated in DCs stimulated with LPS for indicated times. 
cDNA was hybridized on custom tiling arrays with probes for both lincRNA and protein-coding gene 
exons. Groups of two contiguous columns represent duplicates processed independently with dye swap 
(Cy3 or Cy5). On the right are indicated chromosomal location (Chr. loc.), and closest neighboring gene 
(downstream) for each lincRNA exon.  
(B-D) RNA-seq of cDNA from BMDCs stimulated for 0, 2, 4, and 6 h with LPS. Massively parallel 
sequencing (Illumina platform) was performed on poly(A)+ mRNA, with 76-base paired-ends. Data 
analysis and transcriptome reconstruction were performed using the Scripture algorithm. Shown are 
expression levels of two well-known TLR-inducible genes (Cxcl1 and Cxcl2) as measured by number of 
reads (B), splicing information on Iigp1, an LPS-inducible gene (C), and an example of a differentially 
regulated lincRNA in DCs (i.e., not expressed in MEFs, MLFs, NPCs, or ESCs) (D). 
 
To address these problems, we moved to a different approach using RNA-seq. RNA-seq 
technologies have recently emerged as an unbiased way to precisely identify, quantify, and map 
the transcriptome of a cell (Wang et al., 2009). We generated poly(A)+ RNA from a time course 
of LPS stimulated DCs, and sequenced 50 million 76-base paired-end reads on the Illumina 
GAII platform. Analyzing this data, we were able to identify known protein-coding genes (Figure 
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A.1B), their isoforms (Figure A.1C), as well as a set of DC-specific lincRNAs (Figure A.1D). 
Quantification based on RNA-seq read numbers closely mirrored what we previously observed 
for protein-coding genes using microarrays or qRT-PCR (data not shown). 
 
We are now finalizing a list of ~25 most differentially regulated lincRNAs that are specific to DCs 
(i.e., not expressed in other mouse cell types such as ESCs, MEFs, NPCs, MLFs). Using RNA-
seq data for the study of lincRNAs, or other ncRNA species in general, has two major 
advantages: (1) it gives greater confidence in calling true positive hits in terms of differential 
expression upon stimulation, and (2) it precisely delimits intron-exon boundaries as well as 
potential splice variants. Having this dataset at hand will greatly facilitate experimental queries 
of the functions of lincRNAs in the TLR system (e.g., shRNA design for knockdowns, cloning for 
overexpression). 
 
Among the lincRNAs identified in these studies, we found linc-Ptgs2 next to the Cox-2 locus 
(Figure A.2A). Interestingly, it shares a similar pattern of induction as Cox-2 mRNA upon LPS 
stimulation in BMDCs (Figure A.2B). The differential expression between linc-Ptgs2 and Cox-2 
across mouse tissues suggests that these 2 loci do not entirely share the same transcriptional 
regulators (Figure A.2C). Nonetheless both Cox-2 and linc-Ptgs2 are under the control of NF-
κB in DCs. Indeed, knockdown of individual NF-κB family members leads to a decrease in linc-
Ptgs2 and Cox2 transcripts upon perturbation of Nfkb1, Rela, and Relb, but not Rel and Nfkb2 
(Figure A.2D). RNA fluorescence in situ hybridization (FISH) localized linc-Ptgs2 to the nucleus 
of LPS-treated BMDCs (Figure A.2E). Whether linc-Ptgs2 and the other DC-specific lincRNAs 
are functional, and if so, what are their mechanisms of action, remains to be determined. 
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Figure A.2. linc-Ptgs2 is regulated by NF-κB family and preferentially localize to the nucleus 
(A) linc-Ptgs2 does not exhibit any coding potential, as opposed to its closest neighboring gene Ptgs2. 
Shown are the codon substitution frequency (CSF) score, a positive score being indicative of protein-
coding potential whereas a negative one indicates a lack thereof, for the Ptgs2 and linc-Ptgs2 loci. 
(B) linc-Ptgs2 and Ptgs2 mRNA follow a similar pattern of induction following LPS, but not p(I:C). Shown 
are RNA expression levels (qPCR; normalized to Gapdh mRNA and relative to t = 0) of linc-Ptgs2 and 
Ptgs2 in DCs upon stimulation with LPS at indicated time points. 
(C) linc-Ptgs2 expression pattern across mouse tissues. Shown are linc-Ptgs2 RNA levels in indicated 
tissues (qPCR; normalized to Gapdh mRNA). 
(D) Identical NF-κB family members regulate both Ptgs2 and linc-Ptgs2 induction. Shown are RNA 
expression levels (qPCR; normalized to Gapdh mRNA) in DCs stimulated for 6 h with LPS in which 
indicated NF-κB members have been knocked down using shRNAs. 
(E) linc-Ptgs2 preferentially localized to the nucleus. Shown are micrographs of RNA fluorescence in situ 
hybridizations (FISH) with probes for linc-Ptgs2 (top) and IL-6 mRNA (bottom) in LPS-treated DCs. 
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and/or structural similarities; (2) what are the features characterizing protein-lincRNA 
interactions (e.g., sequence and/or structural motifs); (3) if lincRNAs modify the functional 
properties of their protein binding partner, how do they achieve doing so (e.g., allostery); and (4) 
what are the subcellular (e.g., nucleus vs. cytosol) and suborganellar (e.g., specific nuclear 
locations) localizations characterizing lincRNAs and their biological roles? 
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Unbiased Reconstruction of a
Mammalian Transcriptional Network
Mediating Pathogen Responses
Ido Amit,1,2,3,4 Manuel Garber,1* Nicolas Chevrier,2,3* Ana Paula Leite,1,5* Yoni Donner,1*
Thomas Eisenhaure,2,3 Mitchell Guttman,1,4 Jennifer K. Grenier,1 Weibo Li,2,3 Or Zuk,1
Lisa A. Schubert,6 Brian Birditt,6 Tal Shay,1 Alon Goren,1,7 Xiaolan Zhang,1 Zachary Smith,1
Raquel Deering,2,3 Rebecca C. McDonald,2,3 Moran Cabili,1 Bradley E. Bernstein,1,3,7
John L. Rinn,1 Alex Meissner,1 David E. Root,1 Nir Hacohen,1,2,3†‡ Aviv Regev1,4,8‡
Models of mammalian regulatory networks controlling gene expression have been inferred from
genomic data but have largely not been validated. We present an unbiased strategy to
systematically perturb candidate regulators and monitor cellular transcriptional responses.
We applied this approach to derive regulatory networks that control the transcriptional response
of mouse primary dendritic cells to pathogens. Our approach revealed the regulatory functions
of 125 transcription factors, chromatin modifiers, and RNA binding proteins, which enabled the
construction of a network model consisting of 24 core regulators and 76 fine-tuners that help
to explain how pathogen-sensing pathways achieve specificity. This study establishes a broadly
applicable, comprehensive, and unbiased approach to reveal the wiring and functions of a
regulatory network controlling a major transcriptional response in primary mammalian cells.
Regulatory networks controlling gene ex-pression serve as decision-making circuitswithin cells. For example, when immune
dendritic cells (DCs) are exposed to viruses,
bacteria, or fungi, they respond with transcrip-
tional programs that are specific to each pathogen
(1) and are essential for establishing appropriate
immunological outcomes (2). These responses
are initiated through specific receptors, such as
Toll-like receptors (TLRs), that distinguish broad
pathogen classes and are propagated through
well-characterized signaling cascades (2). How-
ever, little is known about how the transcriptional
network is wired to produce specific outputs.
Two major observational strategies have as-
sociated regulators with their putative targets on
a genome scale (3): Cis-regulatory models rely
on the presence of predicted transcription factor
binding sites in the promoters of target genes
(3–5), whereas trans-regulatory models are based
on correlations between regulator and target ex-
pression (3–6). Because promoter binding sites
and correlated expression are weak predictors of
functional regulator-target linkages, such approaches
are limited in their ability to produce reliable
models of transcriptional networks (3). A com-
plementary strategy is to systematically perturb
every regulatory input and measure its effect on
the expression of gene targets. This strategy has
been successfully used in yeast (7–9) and sea
urchin (10), but not in mammals.
A perturbation-based strategy for network
reconstruction. We developed a perturbation
strategy for reconstructing transcriptional net-
works in mammalian cells and used it to deter-
mine a network controlling the responses of DCs
to pathogens (Fig. 1). First, we profiled gene ex-
pression at nine time points after stimulation with
five pathogen-derived components and identi-
fied specific and shared genes that respond to
each stimulus (fig. S1A). We used these profiles
to identify 144 candidate regulators whose ex-
pression changed in response to at least one
stimulus (11) (fig. S1B, top). We also identified
a signature of 118 marker genes (fig. S1B, bot-
tom) that captures the complexity of the re-
sponse. We generated a validated lentiviral short
hairpin RNA (shRNA) library for 125 of the
144 candidate regulators (fig. S1C, top), used it
to systematically perturb each of the regulators
in DCs, stimulated the cells with a pathogen com-
ponent, and profiled the expression of the 118-
gene signature (12) (fig. S1C, bottom). Finally,
we used the measurements from the perturbed
cells to derive a validated model of the regula-
tory network (fig. S1D).
Gene expression programs in response to
TLR agonists. We measured genome-wide ex-
pression profiles in DCs exposed to PAM3CSK4
(PAM), a synthetic mimic of bacterial lipopep-
tides; polyinosine-polycytidylic acid [poly(I:C)], a
viral-like double-stranded RNA; lipopolysaccharide
(LPS), a purified component from Gram-negative
Escherichia coli; gardiquimod, a small-molecule
1Broad Institute of MIT and Harvard, 7 Cambridge Center,
Cambridge, MA 02142, USA. 2Center for Immunology and
Inflammatory Diseases, Massachusetts General Hospital,
149 13th Street, Charlestown, MA 02129, USA. 3Harvard
Medical School, Boston, MA 02115, USA. 4Department of
Biology, Massachusetts Institute of Technology, Cambridge, MA
02142, USA. 5Computational and Systems Biology, Mas-
sachusetts Institute of Technology, Cambridge, MA 02139,
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RNAi perturbation Develop network model
based on data
Measure states Gene selection Network perturbation Construct network
Measure mRNA levels 
of signature genes
Stimulation
Genomewide mRNA 
expression
Select candidate regulators
Select representative
signature of output genes
Fig. 1. A systematic strategy for network reconstruction. The strategy consists of four steps (left to right): state measurement using arrays; selection of regulators
and response signatures; network perturbation with shRNAs against each regulator, followed by measurement of signature genes; and network reconstruction from
the perturbational data.
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agonist; and CpG, a synthetic single-stranded
DNA. These compounds are known agonists of
TLR2, TLR3, TLR4, TLR7, and TLR9, respective-
ly. Poly(I:C) also activates the cytosolic viral RNA
sensor MDA-5, and LPS can also act through co-
receptors such as CD14; we therefore refer to the
ligands rather than their receptors for clarity. On
the basis of pilot experiments (fig. S2) (11), we
measured mRNA expression at 0.5, 1, 2, 4, 6, 8,
12, 16, and 24 hours after stimulation with these
pathogen components.
The observed transcriptional responses were
classified into a “PAM-like” program and a
“poly(I:C)-like” program, as well as a shared re-
sponse [24.5% shared by PAM, poly(I:C), and
LPS]. The LPS response (Fig. 2 and fig. S3) was
largely the union of the “PAM-like” and “poly(I:C)-
like” programs. This is partly explained by the
known signaling pathways activated by these
agonists. PAM binds TLR2 and signals through
the MYD88 pathway; poly(I:C) binds TLR3 and
MDA-5 and signals mostly through the TRIF
and IPS-1 pathways, respectively; and LPS binds
TLR4 and co-receptors and uses the MYD88 and
TRIF pathways (13). It is also consistent with the
known induction of an antiviral response by poly
(I:C) and LPS (14). The “PAM-like” program is
enriched for targets of the transcription factor
NF-kB and for inflammatory responsive genes
(P < 6.1 × 10−8), whereas the “poly(I:C)-like”
program is enriched for interferon regulatory
factors (IRFs) and for viral- and interferon-
responsive genes (ISGs; P < 8.3 × 10−24). We
thus term them the “inflammatory-like” and
“antiviral-like” programs. A small number of
genes are specific to a single stimulus. For
example, ~250 genes are poly(I:C)-specific
(1250 are shared with LPS), including several
type I interferons (e.g., IFNA2, IFNA4; Fig.
2A). Surprisingly, 82% of the gardiquimod
(TLR7) and CpG (TLR9) response was shared
with the LPS response, but with a weaker
antiviral component (fig. S4). This observation
is unexpected given their different signaling
mechanisms (15), but is highly reproducible and
robust (fig. S4) (11).
Identification of candidate regulators and a
response signature. To select potential regula-
tors that mediate the observed transcriptional
response, we focused on regulator genes whose
expression changes during pathogen sensing [a
reasonable assumption for many mammalian
responses (16, 17), including pathogen sensing
(1, 4)]. First, we reconstructed an observational
trans-model of gene regulation (fig. S1B, top,
and fig. S5A) (11) that associated 80 modules of
co-regulated genes with 608 predictive regula-
tors (fig. S5B) (4, 11, 18, 19) automatically
chosen out of a curated list of 3287 candidate
regulators (11). Filtering identified 117 regula-
tors above a minimal expression signal in at
least one experiment (fig. S5B). These included
known regulators from the NF-kB, STAT, and
IRF families, as well as unexpected candidates
such as the circadian regulator Timeless and
the DNA methyltransferase Dnmt3a. Second,
we added five constitutively expressed regula-
tors whose cis-regulatory elements are en-
riched in the responsive genes (11). Third, to
capture delayed responses or nonlinear rela-
tions, we incorporated 22 regulators whose ex-
pression changed by at least a factor of 2. This
resulted in 144 candidate regulators, with a dis-
tribution of expression patterns similar to the
general response (figs. S6 to S8 and table S1).
The regulators’ expression under LPS was con-
served between DCs and functionally similar
macrophages (Pearson correlation r = ~0.9 at
1 hour; fig. S9A) as well as between human mac-
rophages and mouse DCs (r = ~0.6 at 2 hours;
fig. S9B), supporting the functional relevance of
the regulators’ transcription.
To identify highly informative reporter genes
for monitoring the effects of perturbing regu-
lators, we devised GeneSelector (fig. S10A and
table S2) (11). GeneSelector incrementally chooses
genes (from our full expression data set) whose
expression profile improves our discrimination
of stimuli given the previously chosen genes.
Using this approach, we identified the optimal
time point (6 hours after activation; fig. S10B)
and a set of 81 genes that distinguished the stim-
uli (11). We added 37 candidate regulators with
Time (hours)
24120.5 161 2 4 6 8
Complete response
pIC
specific
Inflam
m
atory
A
LPS pIC PAM CpG GRDCt
rl.
+
–
Tlr4
Tlr3 Tlr2
Plasma
membrane
Nuclear
envelope
GRN1 GRN2
Anti-viral program Inflammatory program
B
Anti-viral
Shared
LPS
PAMpIC
Fig. 2. Gene expression response to pathogen
components. (A) mRNA profiles of the 1800
genes whose expression was induced by a
factor of at least 1.7 from baseline level in
both duplicates of at least one time point in
CD11c+ DCs stimulated with the indicated
pathogen component across a time course of 0,
0.5, 1, 2, 4, 6, 8, 12, 16, or 24 hours (tick marks;
pIC, poly(I:C); GRD, gardiquimod). Replicates
were collapsed and genes hierarchically
clustered (rows, genes; columns, experiments;
red, induced from baseline; blue, repressed
from baseline; white, unchanged from
baseline). (B) Model illustrating the differential
gene regulatory networks controlling the
antiviral [“poly(I:C)-like”] and inflammatory
(“PAM-like”) programs.
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detectable expression at the 6-hour time point,
creating a signature of 118 genes. Finally, we
added 10 control genes whose expression levels
were unchanged under all stimuli, but whose
(constant) basal levels varied from very low to
high.
Perturbations, profiling, and modeling. We
generated validated lentiviral shRNAs that knocked
down the expression of 125 of our 144 candi-
date regulators in bone marrow DCs by at least
75% (fig. S11 and table S3) (11) and 32 shRNAs
with no known gene targets as controls (figs. S12
and S13 and table S4) (11). To carry out our
perturbational study, we selected a single treat-
ment, LPS, that activates the majority of both the
“inflammatory-like” and “antiviral-like” programs.
After stimulation of shRNA-perturbed DCs with
LPS for 6 hours, we used nCounter (12) to count
transcripts of the 118 reporter and 10 control
genes.
The changes in signature gene expression re-
sulting from infection with each shRNA were
used to construct a model that associated regu-
lators to their targets. We expected increases in
the transcript levels of reporter genes whose re-
pressors are targeted by knockdown, and decreases
in reporters whose activators are targeted. Our
false discovery rate (FDR) model estimates the
statistical significance of a change in transcripts
in DCs infected with a given shRNA (11). We
controlled for gene-specific noise by comparing
to changes in the expression of each gene after
perturbation with the control shRNAs (Fig. 3A),
and for shRNA-specific noise by comparing to
changes in the expression of the control genes
after a given shRNA perturbation (Fig. 3B). We
estimated the sensitivity of our calls from the 37
regulators, which are also included as target
reporters (fig. S14) (11).
On the basis of these results, we identified a
densely overlapping network with 2322 signif-
icant regulatory connections, including 1728 ac-
tivations and 594 repressions (Fig. 3B, red and
blue, respectively, at 95% confidence; tables S5
to S7). Of the 125 tested regulators, we confi-
dently identified 100 with at least four targets.
Among those were 24 hub regulators that were
predicted to regulate more than 25% of the 118
genes measured, as well as 76 specific regulators
each affecting the expression of 4 to 25 genes.
On average, ~14 (T8; SD) regulators activated a
target gene, and 5 (T5.8) regulators repressed it.
Indirect effects may account for the large number
of regulators we observed for each target.
Our perturbational model captured known
regulatory features of the response, but also iden-
tified novel regulators. The reporter genes parti-
tioned into two main clusters according to their
response to perturbations (Fig. 3B and fig.
S15A), consistent with the expression data: the
“antiviral poly(I:C)–like” program reporters (e.g.,
Cxcl10, Isg15, and Ifit1) and the “inflammatory
(PAM)–like” program reporters [e.g., IL1b,
Cxcl2, IL6, and IL12b). We also found many
known regulatory relations—for example, the
NF-kB family of transcription factors (Rel, Rela,
Relb, Nfkb1, Nfkb2, and Nfkbiz) regulating their
known inflammatory gene targets. Our network
provided evidence for the involvement of at
least 68 additional regulators in the response to
pathogens, of which 11 were hubs not previ-
ously associated with this system. Interestingly,
12 of the identified regulators (e.g., Hhex, Fus,
Bat5, and Pa2g4) are in linkage disequilibrium
with single-nucleotide polymorphisms (SNPs)
associated with autoimmune and related diseases
in genome-wide association studies (table S8).
The core inflammatory and antiviral pro-
grams. We next addressed how each regulator
contributes to the generation of specific cell
states. We first automatically defined the two
major states induced by the five pathogen com-
ponents with the use of non-negative matrix
factorization (NMF) (20) and the original array
data (11). This procedure identified two major
expression components (termed “metagenes”):
one predominantly determined by genes from
the “inflammatory-like” program and the other
by genes from the “antiviral-like” programs (Fig.
2A). Next, we quantified the effects of each reg-
ulator’s knockdown on these two states (Fig.
3B, fig. S15A, and table S9) by classifying the
nCounter expression measurements after a reg-
ulator’s perturbation (20, 21).
Finally, we used a regulator ranking score
(11) to assign 33 (8 known) genes as regulators
of the inflammatory state and 33 (15 known)
genes as regulators of the antiviral state. This
accurately classified the known activators of the
inflammatory response (e.g., the NF-kB factors
Rela, Nfkbiz, and Nfkb1; Fig. 3C, yellow in the
inflammatory metagene) and of the antiviral
response (e.g., Stat1, Stat2, Stat4, Irf8, and Irf9;
Fig. 3C, yellow in the viral metagene). Al-
though all perturbation experiments were con-
ducted only under LPS stimulation (a bacterial
component), we correctly classified factors known
to mediate the response to other stimuli. Because
34 additional regulators were associated with both
responses, it is possible that a single regulator
can control genes in either state, depending on
the differential timing of regulator activation, its
level, or combinatorial regulation. Notably, for
12 of the transcription factors examined, we
found an enriched cis-regulatory element in the
appropriate metagene (11).
On the basis of the NMF scores (table S9),
we identified an inflammatory subnetwork (fig.
S15B), an antiviral subnetwork (Fig. 4A and fig.
S15C), and several fine-tuning subnetworks that
affect smaller numbers of genes from both re-
sponses (figs. S15D and S16) (11). The inflam-
matory subnetwork (fig. S15B) consisted of three
regulatory modes: dominant activators (Cebpb,
Bcl3, and Cited2) that induce more inflamma-
tory targets than antiviral ones; cross-inhibitors
(Nfkbiz, Nfkb1, Atf4, and Pnrc2) that induce in-
flammatory genes while repressing antiviral ones;
and specific activators (Runx1 and Plagl2) that
almost entirely target inflammatory genes. We
observed that dominant activators mostly regulate
effectors, whereas regulators are primarily
controlled by cross-inhibitors.
Focusing on the network architecture, we
found multiple feedforward circuits in this re-
sponse, where an upstream regulator controls
a target gene both directly and indirectly through
a secondary regulator (22) (e.g., Fig. 4B and
tables S10 and S11). The majority (76%, 4892 of
6444) of these feedforward circuits were found
to be coherent (22), having the same direct and
indirect effect on the regulated gene. The vast
majority (80%) are type I loops (23) (Fig. 4B)
with all-positive regulation (e.g., Nfkbiz activates
E2f5 and both activate IL-6). Such feedforward
circuits respond to persistent rather than transient
stimulation, protecting the system from respond-
ing to spurious signals, as was shown for one
circuit in LPS-stimulated macrophages (24). Our
finding suggests that coherent feedforward loops,
especially class I (22), are a general design prin-
ciple in this system and may have a physiolog-
ical impact on this response.
In the antiviral subnetwork, we identified a
two-tiered regulatory circuit combining feed-
forward and feedback loops (Fig. 4A and table
S11). This circuit has at the top the antiviral reg-
ulators Stat1 and Stat2, which regulate a full
complement of antiviral reporters. The second-
tier regulators Timeless, Rbl1, and Hhex are con-
trolled by Stat1 and Stat2 and most likely form
coherent feedforward loops that target specific
subsets of genes. Timeless, Rbl1, and Hhex also
feed back and promote the expression of the Stat
regulators. This circuit is repressed through the
cell cycle regulator and RNA binding protein Fus
(25), acting as a single dominant inhibitor of 43
viral genes.
Finally, we derived a core network incor-
porating the regulators with the most substantial
impact on each response, on the basis of the
number, magnitude, and logic of targets that each
regulator affects (11). The core network (Fig. 4C)
has 24 regulators, 13 of which have previously
been identified as key factors regulating the in-
flammatory or antiviral responses; the other 11
have not been previously implicated in either re-
sponse. Of these 24 regulators, 19 are transcrip-
tion factors, three are chromatin modifiers, and
two are RNA binding proteins. The regulators
apparently distinguish the two programs through
cross-inhibition (Fig. 4C, gray lines) or domi-
nant activation (Fig. 4C). The core network also
explains how differential expression of secreted
factors is specified, leading to the activation and
migration of appropriate cell types for different
pathogens (11, 26) (fig. S17).
Embedded within the many known regula-
tors of the antiviral response (Fig. 4C and fig.
S15C), we found a large set of regulators not
previously associated with this response. These
included several known regulators of the cell cycle
and the circadian rhythm, including Rbl1, Jun, Rb,
E2f5, E2f8, Nmi, Fus, and Timeless, several of
which were placed in our core network. This
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Fig. 3. Gene regulatory programs controlling the response to pathogen
components. (A and B) A strategy to minimize the false discovery rate
(FDR) calls of significant changes in an output target gene resulting from
knockdown of a regulator gene. (A) The first FDR procedure (top)
compares the expression of the gene after a perturbation with a regulator
shRNA (right) to its expression upon perturbation with 32 nontargeting
shRNAs (left). The dashed lines identify the gene-specific FDR-based
thresholds for induction (blue line) and repression (red line). A discrete
vector of significant calls (bottom) is derived from the raw data (blue,
regulator represses the target gene; red, regulator induces the target
gene). (B) A second FDR procedure (top) compares the expression of the
target gene to that of eight control (target) genes upon perturbation with
the same shRNA. In the example shown, the gene’s induction (left) was
significant relative to the variation in expression among the control target
genes, resulting in a high score (bottom, dark blue), but its repression did
not significantly differ from the controls, resulting in a lower score
(bottom, weaker red). (C) All significant (95% confidence)
relations between regulators (columns) and targets (rows),
colored as in (B). The gray bar (right) represents the NMF-
based calls for each target gene; black, antiviral program; dark
gray, inflammatory program; light gray, control genes. The
bottom bar shows the degree of effect by the regulator on
each program as determined by the NMF projection of the
regulator’s perturbation profile (yellow, high; green, low).
9 OCTOBER 2009 VOL 326 SCIENCE www.sciencemag.org260
RESEARCH ARTICLES
 o
n 
M
ay
 1
0,
 2
01
2
ww
w.
sc
ien
ce
m
ag
.o
rg
Do
wn
loa
de
d 
fro
m
 
 161 
 
 
 
 
 
suggests that a cell cycle regulatory circuit was
co-opted to function in the antiviral response in
DCs (with no observable effect on cell cycle pro-
gression; fig. S18). Because we identified these
antiviral regulatory relations in perturbation ex-
periments using DCs stimulated with the bacte-
rial component LPS, we silenced four regulators
(Timeless, Rbl1, Jun, and Nmi) after exposure
to the viral component poly(I:C). Each of the
four regulators had a strong impact on the anti-
viral program, more than was observed under
LPS stimulation (Fig. 4D), and on affected genes
(e.g., type I IFNs) whose expression is poly(I:C)-
specific. Nmi affected a smaller set of genes,
consistent with the model’s prediction. These
results demonstrate our ability to correctly predict
function in unobserved conditions.
Although most antiviral genes are induced
after stimulation with the bacterial component
LPS, a few critical ones are expressed specifically
in poly(I:C) stimulation or follow distinct pat-
terns in each stimulus. For example, in response
to viral infection, cells induce the production of
interferon b1 (Ifnb1), a crucial mediator of the
antiviral response. Because high levels of Ifnb1
may be deleterious to the host if infected by
specific bacteria (27), we predicted that specific
mechanisms insulate Ifnb1’s regulation from the
response to LPS. Indeed, although Ifnb1 expres-
sion was induced in the first 2 hours of stimulation
with LPS, this expression declined at subsequent
time points, in contrast to its sustained induction
after poly(I:C) treatment (Fig. 5A). Our model
suggested that three regulators known to affect
chromatin remodeling (25, 28, 29) are Ifnb1
repressors in LPS (Fig. 5B): the Polycomb com-
plex subunit Cbx4 (28), Fus (25), and the DNA
methyltransferase Dnmt3a (29). Cbx4 appeared
to confer antiviral specificity to Ifnb1 induction
because it was induced within the first 2 hours
of PAM and LPS treatment but not by poly(I:C)
(Fig. 5C), and Cbx4 knockdown caused induc-
tion of Ifnb1 mRNA and protein during LPS
treatment (Fig. 5D and fig. S19A) but had no
effect on the induction of the chemokine Cxcl10,
a poly(I:C)- and LPS-induced gene (fig. S19B).
Cbx4 knockdown did not affect Ifnb1 during
PAM activation (Fig. 5E), when the antiviral re-
sponse is not induced. Combined with evidence
for chromatin changes around the Ifnb1 locus
and its closest neighbor gene, Ptplad2 (fig. S20A),
which has a similar dependence on Cbx4, these
data are consistent with an effect by Cbx4 on
local chromatin organization (fig. S20, B and C).
Cbx4 knockdown affected few genes (~120
up-regulated and ~120 down-regulated genome-
wide; table S12). Because most up-regulated
Fig. 4. The core regulatory circuits controlling the inflammatory and antiviral
responses. (A) The antiviral subnetwork shows regulatory relations between the
core antiviral regulators (blue nodes, top), their targets (boxes, bottom), each
other, and inflammatory regulators (green node, top right). The two top
regulators, Stat1 and Stat2, activate all antiviral targets (dashed blue arrows).
The second-tier regulators activate subsets of targets (dashed purple arrows).
(B) Examples of feedforward loop classes identified in the network, with fraction
of each class. (C) A core regulatory network of the inflammatory and antiviral
programs, consisting of the most distinct regulators, and their relation to
ligands and receptors (top). Pointed arrows, induction; blunt arrows, repression;
green ovals, inflammatory regulators; blue ovals, antiviral regulators. Example
target genes are noted. (D) nCounter expression profiles for the target genes
(rows) upon perturbation with shRNAs against a subset of viral regulators
(columns) and followed by stimulation with LPS (left) or poly(I:C) (right). All
values are normalized by expression in cells infected with a control shRNA and
under the same stimulus (shCtl).
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genes show a precise temporal pattern in un-
perturbed cells akin to that of Cbx4—they are
induced quickly and return to basal level by 2
to 4 hours (fig. S21, A to F)—we conclude that
a chromatin modifier can act like a transcription
factor controlling the precise expression of spe-
cific genes in the regulatory program.
Taken together, our results suggest a model
of a transcriptional negative feedback loop, con-
trolling Ifnb1 expression in LPS stimulation,
wherein the induced proinflammatory regulator
and chromatin modifier Cbx4 represses transcrip-
tion by modifying the chromatin in the Ifnb1
locus, generating the specificity needed to drive
the inflammatory versus the antiviral response
(Fig. 5F). The type III coherent feedforward
loop formed by Cbx4 and Dnmt3a (Fig. 4B) is
consistent with a delayed repression of Ifnb1.
Because neither regulator carries a sequence-
specific DNA binding domain, the factors re-
sponsible for their guidance to the Ifnb1 locus
remain unknown.
Discussion. A central goal of our study was
to address the mechanistic basis for pathogen-
specific responses. Consistent with previous
studies (14), we distinguished two key programs,
a PAM (TLR2)–like inflammatory response and
a poly(I:C) (TLR3/MDA-5)–like antiviral re-
sponse, which are together induced by LPS, a
Gram-negative bacterial component and a TLR4
ligand. These programs reflect both qualitative
and quantitative differences between the required
functional responses, and are consistent with the
cross-protection between certain bacteria and
virus infections (14). The broad effect of LPS
allowed us to focus on a single stimulus and time
point, but screens with other stimuli may identify
additional unique regulators.
We found that these two responses are con-
trolled by two corresponding regulatory arms,
uncovering a mechanistic basis for the observed
transcriptional responses. These two arms are
integrated into a core network of 24 regulators
that balance specific and shared responses through
dominant activation and cross-inhibition. In the
inflammatory response, we found several feed-
forward loops, which may ensure response to
only persistent and not sporadic signals. In the
antiviral response, we discovered a two-tiered cir-
cuit involving feedback and feedforward loops,
implicating a module of cell cycle regulators (Jun,
Rbl1, Timeless, and Nmi), which we directly
validated. More than 75 additional genes work
to further fine-tune the regulation of gene targets.
This perturbational model identifies many regu-
latory relations that would have been missed by
nonsystematic approaches.
Our work establishes an unbiased, straight-
forward, and general framework for network
reconstruction in mammalian cells (11), includ-
ing several strategies to leverage shRNA for the
study of gene regulation. This approach can be
executed at substantial scale and reasonable cost,
and is compatible with the challenge of decipher-
ing the multiple regulatory systems that operate
in mammals. It can be expanded to derive in-
creasingly detailed models and to distinguish
direct from indirect targets.
Our study will facilitate the development of
new computational approaches to infer regulatory
models. Although many computational ap-
proaches have attempted to derive observational
models, their quality has been difficult to evaluate
(3). The data generated here include expression
profiles for training a model, as well as a pertur-
bational unbiased screen for testing its quality
(ftp://ftp.broadinstitute.org/pub/papers/dc_network).
When we compared the perturbational model to
our observational model, we found that many
candidate regulators were correctly identified
in both (figs. S5 and S22). However, there were
also numerous false positive relations in the
observational model, attributable to the fact that
both the correct regulator and many others have
indistinguishable expression (figs. S22 and S23).
The high-resolution map we constructed has
important biomedical implications. By identifying
regulators that mediate the differential control
of specific gene pairs (e.g., IL-23 versus IL-12,
fig. S17) and entire regulatory arms (e.g., viral
versus inflammatory), it opens the way for ther-
apeutic targeting of specific pathways to control
disease or enhance vaccine efficacy. Further-
more, 12 of our regulators reside in genetic loci
that were in linkage disequilibrium with SNPs
associated with autoimmune and related dis-
eases. The identified genes and their impact on
DCs provide hypotheses to help explain how
alleles of genes in a cascade may alter suscep-
tibility to specific infections or immune disor-
ders in humans.
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Mapping Excited-State Dynamics
by Coherent Control of a Dendrimer’s
Photoemission Efficiency
Daniel G. Kuroda,1* C. P. Singh,1† Zhonghua Peng,2 Valeria D. Kleiman1‡
Adaptive laser pulse shaping has enabled impressive control over photophysical processes in
complex molecules. However, the optimal pulse shape that emerges rarely offers straightforward
insight into the excited-state properties being manipulated. We have shown that the emission
quantum yield of a donor-acceptor macromolecule (a phenylene ethynylene dendrimer tethered to
perylene) can be enhanced by 15% through iterative phase modulation of the excitation pulse.
Furthermore, by analyzing the pulse optimization process and optimal pulse features, we
successfully isolated the dominant elements underlying the control mechanism. We demonstrated
that a step function in the spectral phase directs the postexcitation dynamics of the donor
moiety, thus characterizing the coherent nature of the donor excited state. An accompanying
pump-probe experiment implicates a 2+1 photon control pathway, in which the optimal pulse promotes
a delayed excitation to a second excited state through favorable quantum interference.
Since ancient times, humans have been try-ing to control the transformation of mat-ter. For more than a century, absorption of
light has been used to initiate photochemical
reactions. It is only in the past 20 years, how-
ever, that researchers have devised techniques
to steer the ensuing dynamics through modula-
tion of the optical excitation field. Such quan-
tum, or coherent, control schemes (1–3) use
laser-derived electric fields to direct the motion
of wave packets along excited-state potential
energy surfaces (4–6). In principle, the phases
and amplitudes in the applied field necessary
to achieve a given outcome can be obtained from
the field’s coupling to the molecular Hamilto-
nian. In practice, rational design of the requisite
pulse shapes remains an insurmountable prob-
lem for large molecules in condensed phase:
The complete Hamiltonian is either unknown or
too complex to be used in electric field calcula-
tions. Instead, researchers have relied on empirical
methods whereby pulse shapes are determined
through iterative optimization using the desired
product (e.g., fluorescence quantum yield) as a
feedback parameter (7). Thus, photoinduced
processes can be actively manipulated without
previous knowledge of the Hamiltonian and the
light-matter couplings (8–11).
This closed-loop feedback technique has
proven powerfully versatile. For example, mod-
ulation of isomerization yield in the natural pho-
toreceptor bacteriorhodopsin (11), and control of
quantum efficiency in both natural and artificial
photosynthetic antennae by tuning spectral am-
plitude and phase in resonant linear excitation
(9, 12), were shown. Nonetheless, very few closed-
loop experiments have yielded optimal pulse
shapes that can be directly explained in terms of
known molecular properties of the system under
investigation (9, 11, 13–15). Major hindrances
to attain such insight are the often intricate rela-
tionship between the variables to be optimized
and the molecular response; the large number of
parameters used for the generation of arbitrarily
modulated pulses; and the often arbitrary, ran-
dom pathways to optimization generated by the
iteration algorithms. A major goal in the field is
thus to develop a procedure for gleaning molec-
ular insight from coherent control, especially in
systems where the photophysical or photochem-
ical pathways are presently unknown. For ex-
ample, using optimal control, Branderhorst et al.
(15) were able to identify wave packets with min-
imum position variance as candidates to minimize
coupling to the bath and thus increase coherence
robustness.
Our approach toward this end is to search for
a confined set of parameters that directly govern
the optimization. The idea is to express all the
independent electric field parameters obtained
from the collection of closed-loop optimization
data as a combined set, filtering out those var-
iables with redundant or negligible effects on
the molecular response (16–20). Ideally, it ought
to be more straightforward to associate these fewer
parameters with a physical property.
We apply this approach to coherent control
studies of the emissive properties of the phenylene
ethynylene dendrimer 2G2-m-Per (Fig. 1) (21),
designed to mimic natural light harvesting sys-
tems (22). Phenylene ethynylene dendrimers
are rigid macromolecules with a high quantum
yield for energy transfer from donor to ac-
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SUMMARY
Deciphering the signaling networks that underlie
normal and disease processes remains a major chal-
lenge. Here, we report the discovery of signaling
components involved in the Toll-like receptor (TLR)
response of immune dendritic cells (DCs), including
a previously unkown pathway shared across
mammalian antiviral responses. By combining tran-
scriptional profiling, genetic and small-molecule
perturbations, and phosphoproteomics, we uncover
35 signaling regulators, including 16 known regula-
tors, involved in TLR signaling. In particular, we find
that Polo-like kinases (Plk) 2 and 4 are essential
components of antiviral pathways in vitro and in vivo
and activate a signaling branch involving a dozen
proteins, among which is Tnfaip2, a gene associated
with autoimmune diseases but whose role was
unknown. Our study illustrates the power of
combining systematic measurements and perturba-
tions to elucidate complex signaling circuits and
discover potential therapeutic targets.
INTRODUCTION
Signaling networks detect and respond to environmental
changes, and defects in their wiring can contribute to diseases.
For example, Toll-like receptors (TLRs) sense microbial mole-
cules and trigger signaling pathways critical for host defense
(Takeuchi and Akira, 2010). Genetic defects in components of
the TLR and other pathogen-sensing pathways have been linked
to human diseases. Hence, rational targeting of these pathways
should help in better manipulating immune responses associ-
ated with infections, autoimmunity, and vaccines (Hennessy
et al., 2010).
However, despite extensive studies, many components of
TLR and other biological networks are unknown, and many
genes associatedwith disease have not been assigned to a func-
tion or a pathway. A key challenge is thus to systemically dissect
mammalian signaling networks, by determining the functions of
their components and placing themwithin pathways. Previously,
we introduced an integrated experimental and computational
approach to decipher the TLR transcriptional network of immune
dendritic cells (DCs) (Amit et al., 2009), allowing us to identify
transcriptional regulators and to define their impact on TLR
responses in DCs. For example, we found a host of cell-cyle
regulators—Rbl1, Rb, Myc, Jun, and E2fs—that are required
for antiviral transcriptional responses in nondividing DCs.
Here, we adapt and expand this approach to the discovery
and validation of TLR signaling components in DCs (Figure S1
available online). First, to identify candidate components, we
rely on transcriptional feedbacks, whereby a signaling circuit
regulates the transcript levels of genes encoding some, but not
all, of its components (Amit et al., 2007; Fraser and Germain,
2009; Freeman, 2000). Second, we perturb these candidates
with shRNAs and measure the effects on a representative
Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc. 853
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signature of >100 TLR-activated genes. Third, we use functional
phosphoproteomics to expand the pathway’s scope to com-
ponents whose mRNA levels may be unchanged upon TLR
activation. Applying this approach iteratively, we discovered 19
functional components, including a signaling arm mediated by
two Polo-like kinases (Plk2 and 4) that participate in regulating
well-established host antiviral pathways.
RESULTS
Transcripts for Signaling Components Are Regulated
upon TLR Stimulation
To identify candidate components of pathogen-sensing path-
ways, we used genome-wide mRNA profiles, previously mea-
sured at 10 time points along 24 hr following stimulation of
primary bone marrow-derived DCs (BMDCs) with lipopolysac-
charide (LPS; TLR4 agonist), polyinosinic:polycytidylic acid
(poly(I:C); recognized by TLR3 and the cytosolic viral sensor
MDA-5), or Pam3CSK4 (PAM; TLR2 agonist) (Amit et al., 2009).
These three TLRs activate transcriptional programs referred
to here as ‘‘inflammatory’’ (TLR2), ‘‘antiviral’’ (TLR3), or both
(TLR4) (Figure 1A) (Amit et al., 2009; Doyle et al., 2002).
Our analysis uncovered 280 genes annotated as known or
putative signaling molecules that were differentially expressed
followingstimulation:115kinases,69phosphatases,and96other
regulators, such as adaptors and scaffolds (Figure 1B, Table S1,
and Experimental Procedures). These 280 genes were enriched
for canonical pathways of the TLR network such as MAP kinase
(p < 1.22 3 10!15, overlap 25/87, hypergeometric test), TLR
(e.g., Myd88, Traf6, Irak4, Tbk1; p < 8.43 3 10!12, 21/86), and
PI3K (p < 2.58 3 10!8, 11/33) pathways, as well as the PYK2
pathway (p< 3.123 10!10, 12/29),whichwas recently associated
with the TLR system (Wang et al., 2010). Overall, 94 of the 280
genes (33%) were associated with the TLR network in the litera-
ture (Table S1), supporting the validity of our candidate selection
strategy. The remaining 186 genes (67%) represent candidate
TLR components. To test their putative function in TLR signaling,
we selected a subset of 23 candidates based on their strong
differential expression and to proportionally represent the five
main induced expression clusters (Figures 1B and 1C). We also
selected six canonical TLR components (Myd88, Mapk9, Tbk1,
Ikbke, Tank, andMap3k7) as benchmarks (Figures 1A and 1D).
A Perturbation Strategy Places Uncharacterized
Signaling Components within the Antiviral and
Inflammatory Pathways
We perturbed our 6 positive controls and 17 of the 23 candidates
in BMDCs using shRNA-encoding lentiviruses (6 candidates
showed poor knockdown efficiency) (Table S1). We stimulated
the cells with LPS and used a multiplex mRNA counting method
to measure the effect of gene silencing on the mRNA levels of
118TLR responsesignaturegenes, representing the inflammatory
and antiviral programs (Figure 2A). Notably, the expression of the
118 genes was not affected in BMDCs transduced with lentivirus
compared to untransduced cells (Amit et al., 2009). We deter-
mined statistically significant changes in the expression of signa-
ture transcripts upon individual knockdowns based on compar-
ison to 10 control genes, whose expression remains unchanged
upon TLR activation, and to control shRNAs (Experimental
Procedures). Finally, we associated signaling molecules and
downstream transcriptional regulators that may act in the same
pathway by comparing the perturbational profiles of the 23
signalingmolecules (6 canonical and 17 candidates) to each other
and to those of the 123 transcriptional regulators (including tran-
scription and chromatin factors and RNA-binding proteins) previ-
ously tested (Figures 2 and S2 and Table S2) (Amit et al., 2009).
Perturbing 5 of the 6 canonical signaling molecules strongly
affected the expression of TLR signature genes, consistent
with their known roles (Figure 2A and Table S2) and validating
our approach. For example, perturbing Myd88, a known inflam-
matory adaptor, specifically abrogated the transcription of
inflammatory genes (e.g.,Cxcl1, Il1a, Il1b, Ptgs2, Tnf; Figure 2A),
similar to perturbations of downstream inflammatory transcrip-
tion factors (e.g., Nfkb1, Nfkbiz; Figure 2B). In addition, Tank
acted as a negative regulator of a subset of antiviral genes (Fig-
ure 2A), as expected (Kawagoe et al., 2009), and Tbk1 knock-
down affected both antiviral and inflammatory outputs (Fig-
ure 2A), consistent with findings that Tbk1 regulates NF-kB
complexes (Barbie et al., 2009; Chien et al., 2006). Notably, Ikbke
(IKK-ε) knockdown did not affect our gene signature, consistent
with previous observations that IKK-ε!/! DCs respond normally
to LPS and viral challenges (Matsui et al., 2006). Thus, IKK-εmay
be either not functional or redundant in our system.
All of the 17 candidate signaling molecules tested, except Plk2
(discussed below), affected at least 6 of the 118 genes (on
average, 16.6 targets ± 10.4 standard deviation [SD]), and 12
affected more than 10% of the genes (Figures S2A and S2D).
Notably, perturbations of these 17 candidates did not affect
BMDC differentiation (88.3% ± 6.8% SD of CD11c+ cells;
Table S1). These effects are comparable to those of known
signaling molecules and transcriptional regulators in this system
(Figures S2B–S2E). For example, the receptor tyrosine kinase
Met, not previously associated with TLR signaling, affected
a number of signature genes similar to Tbk1 (Figures S2C
and S2D), in both the inflammatory and antiviral programs
(Figure 2A). Conversely, both the phosphatase Ptpre and the
adaptor Socs6 positively regulated the inflammatory program,
although negatively regulating some antiviral genes (Figure 2B).
Of the 17 candidates tested when we originally conducted this
screen, 10 have subsequently been reported in other studies
as functional in the TLR system (Table S1), providing an inde-
pendent confirmation. For example, here Map3k8 knockdown
affected both inflammatory and antiviral target genes (Figure 2A),
consistent with its reported role in the TLR pathways based on
Sluggish mice (Xiao et al., 2009).
We identified both primary (e.g., Myd88) and secondary
(e.g., Stat1) mediators of TLR responses. Although secondary
mediators are not part of the initial intracellular signaling
cascade, they are important physiological components of the
TLR response, and their pertubation can lead to phenotypic
outcomes similar to those of primary components. For example,
the receptor tyrosine kinase Mertk acted as both a positive and
negative regulator of some inflammatory and antiviral genes
(e.g., Ifnb1), respectively (Figure 2A), consistent with its reported
role as a secondary inhibitor of the TLR pathways (Rothlin et al.,
2007).
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Figure 1. mRNAs of Signaling Components Are Differentially Regulated upon TLR Stimulation
(A) Simplified schematic of the TLR2, 3, and 4 pathways (Takeuchi and Akira, 2010).
(B) mRNA expression profiles of differentially expressed signaling genes. Shown are expression profiles for 280 differentially expressed signaling genes (rows)
at different time points (columns): a control time course (no stimulation, Ctrl) and following stimulations with Pam3CSK4 (PAM), LPS, and poly(I:C). Tick marks:
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expression clusters.
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gene names highlights the corresponding expression clusters from the complete matrix from (A).
See also Figure S1 and Table S1.
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Crkl Modulates JNK-Mediated Antiviral Signaling
in the TLR Network
Among the 17 candidate signaling proteins, perturbation of the
tyrosine kinase adaptor Crkl decreased expression of 13% of
the signature genes, especially antiviral ones (Figures 2A and
S2D). Crkl belongs to several signaling pathways, including early
lymphocyte activation (Birge et al., 2009), but has not been asso-
ciated with the TLR network. Crkl’s perturbation profile closely
resembled those of known antiviral regulators, most notably
Jnk2 (Mapk9; Chu et al., 1999) (Figures 2A and 3A). Indeed,
when Crkl!/! DCs were stimulated with LPS, the expression of
antiviral cytokines (Cxcl10, Ifnb1) was strongly reduced (Fig-
ure 3B, left and middle), but that of an inflammatory cytokine
(Cxcl1) was unaffected (Figure 3B, right).
To test whether Crkl is a primary component of the TLR
pathway, we determined whether Crkl phosphorylation is rapidly
modified after TLR signaling initiation. Using SILAC-based (Ong
et al., 2002) quantitative phosphoproteomics, we identified and
quantified 62 phosphotyrosine (pTyr)-containing peptides from
BMDCs stimulated with LPS for 30 min (Figure 3C, Table S3,
and Experimental Procedures). Of these 62 phosphopeptides,
7 and 9 were significantly up- or downregulated, respectively
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knockdown of Plk2 and 4. Red and blue mark significant hits as in Figure 2, only for genes where the effect was consistent between the two independent
combinations of shRNAs.
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(Figure 3C and Table S3). A phosphopeptide derived from Crkl
(Y132)—one of the top 6 induced phosphopeptides—was
induced 2.1-fold (Figure 3C). This indicates that Crkl is likely acti-
vated directly downstream of TLR4 signaling.
Several lines of evidence suggest that Crkl acts through Jnk2
(Mapk9) signaling. First, the MAP kinase Jnk2 (Mapk9) is coregu-
lated at the phosphorylation level with Crkl upon LPS stimulation
(Figure 3C). Second, the Crk adaptor family—including CrkI,
CrkII, and Crkl—has been shown to modulate Jnk activity in
growth factor and IFN signaling (Birge et al., 2009; Hrincius
et al., 2010). Third, the perturbation profiles of Mapk9 and Crkl
are strikingly similar (Figure 3A). These observations suggest
that Crkl modulates Jnk-mediated antiviral signaling in the
TLR4 pathway, providing a possible explanation for why the
NS1 protein of influenza A virus may target Crkl (Heikkinen
et al., 2008; Hrincius et al., 2010).
Polo-like Kinases Are Critical Activators of the Antiviral
Program
To discover potential drug targets among our 17 candidates, we
next focused on Plk2, a well-known cell-cycle regulator and drug
target (Strebhardt, 2010). The roles of Plks in nondividing, differ-
entiated cells are poorly defined (Archambault and Glover, 2009;
Strebhardt, 2010).We have previously shown that transcriptional
regulators of cell-cycle processes (e.g., Rbl1, Rb, Myc, Jun,
E2fs) are co-opted to function in the antiviral responses in DCs
(Amit et al., 2009). However, neither knockdown (Figure 2A) nor
knockout (Figure S3A) of Plk2 in BMDCs had any effect on the
TLR response. We hypothesized that this could be due to func-
tional redundancy with another Plk, as Plk4 mRNA was induced
in DCs similarly to Plk2 (Figure 4A), albeit at a lower amplitude
(and thus was below our threshold for inclusion in the initial
candidate list). Interestingly, functional redundancy between
Plk2 and 4 has been suggested to account for the viability of
Plk2-deficient mice (Strebhardt, 2010), and Plk2 and 4 have
been reported to function together in centriole duplication
(Chang et al., 2010; Cizmecioglu et al., 2008).
To test our hypothesis, we simultaneously perturbed Plk2 and
4 in BMDCs using two independent mixes of different pairs of
shPlk2/shPlk4 (Figure S3B and Experimental Procedures). We
observed a significant and specific decrease in the expression
of 21 antiviral genes (Figure 4B). For example, the antiviral cyto-
kines Ifnb1 and Cxcl10 mRNAs were decreased, whereas the
expression of the inflammatory geneCxcl1 and almost all inflam-
matory signature genes remained unaffected (Figure 4C). Two
recent reports suggested a role for Plk1 alone as a negative regu-
lator of MAVS (Vitour et al., 2009) and NF-kB (Zhang et al., 2010)
in cell lines. However, knockdown of either Plk1 or 3 in BMDCs
did not affect the TLR transcriptional response (Figure S3C
and Table S2). Notably, BMDC viability was unaffected by lenti-
viral shRNA transduction targeting Plk1, 2, 3, or 4 individually or
Plk2 and 4 together (based on mRNA levels of control genes;
Table S2). Thus, in BMDCs, Plk2 and 4, but likely not Plk1 or 3,
are critical regulators of antiviral but not cell-cycle pathways.
A Small-Molecule Inhibitor of Plks Represses Antiviral
Gene Expression and IRF3 Translocation in DCs
We next targeted Plks in BMDCs using BI 2536, a commercial
pan-specific Plk small-molecule inhibitor (Steegmaier et al.,
2007). We compared genome-wide mRNA profiles from BMDCs
treated with either BI 2536 or DMSO vehicle before stimulation
with LPS or poly(I:C) (Experimental Procedures). BI 2536 treat-
ment repressed mostly antiviral gene expression compared to
DMSO (99/193 genes in response to poly(I:C), p < 1 3 10!71,
hypergeometric test; 67/194 in response to LPS; Table S4).
The 311 unique LPS- and/or poly(I:C)-induced genes that are
repressed by BI 2536 are significantly enriched for genes related
to cytokine signaling (e.g., IL-10, type I IFNs, IL-1), TLR signaling,
and DC signaling and for gene ontology (GO) processes related
to defense and immune responses (Figure S4A). Consistent with
the array data, BI 2536 strongly inhibited the expression of 12
well-studied antiviral genes, whereas inflammatory gene expres-
sion remained largely unaffected in DCs stimulated with LPS,
poly(I:C), or Pam3CSK4, as measured by qPCR (Figure 4D).
BI 2536 reduced the mRNA levels of Cxcl10 and Ifnb1 (by
qPCR) and of secreted IFN-b in a dose-dependent manner,
whereasCxcl1 expression was not significantly affected (Figures
S4B and S4C). Importantly, BI 2536 treatment prestimulation
impacted neither the viability nor the cell-cycle state of BMDCs
(Figures S4D and S4E), suggesting that Plk inhibition does not
act through cell-cycle effects. Consistent with our shRNA and
BI 2536 perturbations, two other pan-Plk inhibitors—structurally
unrelated to BI 2536—also repressed Ifnb1 and Cxcl10 expres-
sion without affecting Cxcl1 (Figure S4F). This strongly suggests
that the effects induced by these perturbations are due to
Plk inhibition and not off-target effects. Furthermore, we
observed a similar inhibitory effect of BI 2536 on Ifnb1 induction
in Ifnar1!/! and wild-type BMDCs, demonstrating that Plks
act directly downstream of TLR activation and not in an auto-
crine/paracrine feedback loop mediated by IFN receptor
signaling (Figure S4G). This is consistent with a recent phospho-
proteomic study reporting an enrichment for Plk substrates as
early as 15 min after LPS stimulation in macrophages (Weintz
et al., 2010).
We next used confocal microscopy to monitor the effect of BI
2536 on the subcellular localization of IRF3, a key antiviral tran-
scription factor. To more effectively deliver the drug, we plated
BMDCs on vertical silicon nanowires (Shalek et al., 2010) pre-
coated with BI 2536 prestimulation. Nanowires alone had no
effect on the TLR response (Figures 5A and S5A). BI 2536
(C) Double knockdown of Plk2 and 4 represses antiviral cytokine mRNAs. Shown are expression levels (qPCR) relative to control shRNAs (control) for two antiviral
cytokines (Ifnb1 and Cxcl10) and for an inflammatory cytokine (Cxcl1), following LPS stimulation in BMDCs using two independent combinations of shRNAs
(Plk2/4-1, Plk2/4-2). Three replicates for each experiment; error bars are the SEM.
(D and E) BI 2536 specifically abrogates transcription of antiviral genes without affecting inflammatory genes following stimulation with LPS, poly(I:C), or
Pam3CSK4. Shown aremRNA levels (qPCR; relative to t = 0) for 12 indicated antiviral (D) and 12 inflammatory (E) genes in BMDCs treatedwith BI 2536 (1 mM; dark
color bars) or DMSO vehicle (light color bars) and stimulated for 0, 2, or 4 hr with LPS (dark and light). Error bars represent the SEM.
See also Figures S3 and S4 and Table S4.
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inhibited IRF3 nuclear translocation in a dose-dependent
manner upon poly(I:C) or LPS stimulation, whereas the control
JNK inhibitor SP 600125 had no effect (Figures 5B, 5C, and
S5B). On the other hand, BI 2536 did not affect NF-kB p65 local-
ization (Figures 5D and 5E). Notably, IRF3 translocation was also
decreased when delivering BI 2536 in solution, but to a lesser
extent compared to nanowire-mediated delivery (Figure S5C),
highlighting the utility of highly efficient drug delivery methods
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Figure 5. BI 2536-Mediated Plk Inhibition Blocks IRF3 Nuclear Translocation in DCs
(A) DCs on NW undergo normal morphological changes upon LPS stimulation. Shown are electron micrographs of BMDCs plated on bare vertical silicon NW that
were left unstimulated (left; control) or stimulated with LPS (right). Scale bars, 5 mm.
(B–E) BI 2536 inhibits IRF3, but not NF-kB p65, nuclear translocation following TLR stimulation. (B and D) Shown are confocal micrographs of BMDCs plated on
vertical silicon NW precoated with vehicle control (DMSO; B and D), Plk inhibitor (BI 2536; B and D), or control Jnk inhibitor (SP 600125; B) and stimulated with
poly(I:C) for 2 hr (B) or LPS for 30 min (D) (reflecting peak time of nuclear translocation for IRF3 and NF-kB p65, respectively) or left unstimulated (B and D). Cells
were analyzed for DAPI (B and D), IRF3 (B), and NF-kB p65 subunit (D) staining. Scale bars, 5 mM. (C and E) Nuclear translocation (from confocal micrographs) of
IRF3 (C) and NF-kB p65 (E) was quantified using DAPI staining as a nuclear mask (purple circles; overlay in B and D) to determine the ratio of total versus nuclear
fluorescence (y axis) in BMDCs cultured on NW coated with different amounts of BI 2536 or SP 600125 or with vehicle control (DMSO; x axis). Three replicates in
each experiment; error bars are the SEM.
See also Figure S5.
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to induce homogeneous effects in single-cell assays. Altogether,
these results place Plk2 and 4 as critical regulators of the antiviral
program, upstream of a major antiviral transcription factor.
Plks Are Essential for Activation of All Well-Established
IFN-Inducing Pathways in Conventional and
Plasmacytoid DCs
DCs can be broadly categorized into two major subtypes—
conventional and plasmacytoid DCs—each relying on distinct
mechanisms to induce type I IFNs and antiviral gene expression
(Blasius and Beutler, 2010). In conventional DCs (cDCs), antiviral
responses are activated through TLR4/3 signaling (via TRIF) or
through the cytosolic sensors RIG-I or MDA-5 (via MAVS) (Fig-
ure 6A). In plasmacytoid DCs (pDCs; specialized IFN-producing
cells), the antiviral response depends solely on endosomal TLR7
and 9 that signal via MYD88 (Figure 6A) (Blasius and Beutler,
2010; Takeuchi and Akira, 2010).
BI 2536 treatment showed that Plks are essential for the viral-
sensing pathways in both cDCs and pDCs. In cDCs, BI 2536
inhibited the transcription of antiviral genes (Ifnb1 and Cxcl10)
upon infection with each of four viruses: vesicular stomatitis virus
(VSV; Figure 6B, top), Sendai virus (SeV; Figure S6A, top), New-
castle disease virus (NDV; Figure S6A, bottom) (all three sensed
through RIG-I), and encephalomyocarditis virus (EMCV), sensed
through MDA-5 (Figure 6B, bottom and Experimental Proce-
dures). Notably, BI 2536 neither affected the mRNA level of
Cxcl1 (an inflammatory cytokine) in any of the four cases nor
affected the response to heat-killed Listeria monocytogenes,
a natural TLR2 agonist (Figures 6B, S6A, and S6B). In pDCs, BI
2536 treatment nearly abrogated the transcription of mRNAs
for the antiviral cytokines Ifnb1, Ifna2, and Cxcl10 after stimula-
tion with type A CpG oligonucleotides (CpG-A) or infection with
EMCV, sensed by TLR9 and 7, respectively (Figures 6C and
S6C and Experimental Procedures). Conversely, in pDCs stimu-
lated with CpG-B—a ligand known to activate inflammatory
pathways but not IFN-inducing pathways—BI 2536 treatment
decreased Cxcl10 mRNA, while moderately increasing Cxcl1
mRNA (Figure 6C). Finally, of our 118 signature genes, BI 2536
repressed genes induced by CpG-A alone or by both CpG-A
and -B, although having aminor effect, if any, on CpG-B-specific
genes in pDCs (Figure 6D and Table S5). These findingsmay help
reveal the poorly characterized molecular determinants of IFN
production in pDCs (Reizis et al., 2011) and demonstrate a critical
role for Plks across all well-known IFN-inducing pathways.
Plks Are Essential in the Control of Host Antiviral
Responses
To assess the impact of Plk inhibition on the outcome of viral
infection, we infected primary mouse lung fibroblasts (MLFs)
with influenza virus. BI 2536-treated MLFs infected with influ-
enza failed to produce interferon (Figure 6E) and showed
elevated replication of both wild-type (PR8) and poorly repli-
cating mutant (DNS1) viruses (Figure 6F). The reduced interferon
response was not due to drug-induced toxicity (Figure 6G).
Next, we tested the effects of Plk inhibition in virally infected
mice. BI 2536 exhibits good tolerability in mice (Steegmaier
et al., 2007) and humans (Mross et al., 2008) and is currently in
phase II clinical trials as an antitumor agent in several cancers
(Strebhardt, 2010). Given its efficacy and safety in vivo, we tested
whether BI 2536 would also affect the response to viral infection
in animals. In mice infected with VSV, BI 2536 strongly sup-
pressed mRNA production in popliteal lymph nodes for type I
IFNs (Ifnb1, Ifna2) and Cxcl10 but did not affect Cxcl1 mRNA
induction (all compared to vehicle control; Figures 6H and
S6D). Concomitantly, VSV replication in the lymph node rapidly
increased as reflected by elevated VSV RNA levels (Figure 6I),
comparable to the observed phenotype of VSV-infected
Ifnar1!/!mice (Iannaconeet al., 2010). Because in theVSVmodel
used here type I IFNs are produced by both infected CD169+
subcapsular sinus macrophages and pDCs (Iannacone et al.,
2010), we cannot distinguish whether Plk inhibition affects
macrophages, pDCs, or both. Nevertheless, our results confirm
thephysiological importance of Plks in the host antiviral response
in both ex vivo primary MLFs and in vivo mouse lymph nodes.
Plks Affect the Phosphorylation of Dozens of Proteins
Post-LPS Stimulation, including Known and Candidate
Antiviral Regulators
Wenext sought to discover the signaling pathways between Plks
and antiviral gene transcription. We used microwestern arrays
(MWAs) (Ciaccio et al., 2010) to measure changes in the phos-
phorylation and protein levels of 20 and 6 TLR pathway proteins,
respectively, in BMDCs at each of 12 combinations of four time
points (0, 20, 40, 80 min after LPS stimulation) and three pertur-
bations (vehicle control, BI 2536, and negative control JNK inhib-
itor SP 600125) (Table S6). Although LPS stimulation alone led to
the expected changes (e.g., early peak of phosphorylation for
ERK1/2, p38, andMapkapk2 and rapid degradation of IkBa; Fig-
ure 7A), BI 2536 surprisingly did not cause any significant
changes (Figures 7A, S7A, and S7B). We therefore hypothesized
that Plks could affect previously unrecognized regulators of IFN-
inducing pathways and/or known regulators with no existing
antibodies to specific phosphosites.
Next, we used SILAC-based unbiased phosphoproteomics
(Figure 7B, top) (Ville´n and Gygi, 2008) to compare the levels
of phosphotyrosine, -threonine, and -serine peptides following
stimulation with LPS (for 30 or 120 min) in BMDCs pretreated
with BI 2536 versus those treated with vehicle (DMSO). We iden-
tified and quantified 5,061 and 5,997 phosphopeptides after
30 and 120 min, respectively, for a total of 10,236 individual
phosphosites (Figure 7B and Table S6). BI 2536 substantially
affected the TLR phosphoproteome, leading to a significant
(p < 0.001) change in the level of 510 phosphopeptides derived
from 413 distinct proteins (Figure 7B and Table S6). Further sup-
porting our results, 35% (2489/7018) of the phosphosites we
identified were recently reported in mouse bonemarrow-derived
macrophages treated with LPS (Figure S7C, left) (Weintz et al.,
2010), and 483 of our phosphosites were among 1,858 sites
(26%) reported in a phosphoproteomic study of LPS signaling
in a macrophage cell line (Figure S7C, left) (Sharma et al.,
2010). A comparison of the phosphosites of known kinases
showed similar overlaps between the three studies (Figure S7C,
right).
The Plk-dependent phosphoproteins include several known
regulators of antiviral pathways (e.g., Prdm1, Fos, Unc13d) (Cro-
zat et al., 2007; Keller and Maniatis, 1991; Takayanagi et al.,
Cell 147, 853–867, November 11, 2011 ª2011 Elsevier Inc. 861
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Figure 6. Plks Are Critical in the Induction of Type I Interferons In Vitro and In Vivo
(A) IFN-inducing pathways in cDCs and pDCs.
(B and C) BI 2536 inhibits mRNA levels for antiviral cytokines in response to diverse stimuli in cDCs and pDCs. Shown are Ifnb1, Cxcl10, and Cxcl1 mRNA
levels (qPCR; relative to t = 0) in cells treated with BI 2536 (1 mM; white bars) or DMSO vehicle (black bars) in cDCs (B) infected with VSV (multiplicity of infection
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2002), as well as many additional protein candidates with no
previously known function in viral sensing (Figure 7B and Table
S6). Notably, proteins involved in the TBK1/IKK-ε/IRF3 axis
were detected and quantified, but their phosphorylation levels
were unchanged upon Plk inhibiton (Table S6), consistent
with the MWA data. Conversely, Plk inhibition with BI 2536
decreased the phosphorylation levels of cell-cycle regulators
of the Jun family of transcriptional regulators (i.e., Jund) that
we previously found to be co-opted by antiviral pathways
(Amit et al., 2009). BI 2536 treatment also decreased the phos-
phorylation levels of the mitotic kinases Nek6 and Nek7 (Fig-
ure 7B). The recent observation that the phosphorylation of
Nek6 substrates is increased following LPS stimulation inmacro-
phages (Weintz et al., 2010) indirectly corroborates our finding
that Nek6may be active in TLR signaling. To test the role of these
Plk-dependent candidates, we returned to our shRNA perturba-
tion-based approach.
Plk-Dependent Phosphoproteins Affect
the Antiviral Response
We perturbed 25 Plk-dependent phosphoproteins (Table S7),
using shRNA perturbation in BMDCs followed by qPCR and TLR
gene signature measurements. These candidates satisfied three
criteria: (1) there was no prior knowledge of their function in
viral-sensing pathways; (2) their phosphoprotein levels were con-
sistently up- or downregulated upon BI 2536 treatment (in two
independent experiments); and (3) they had detectable mRNA
expression and/or differential expression upon stimulation.
Of the 18 phosphoproteins showing efficient knockdown, 11
caused a significant decrease in Ifnb1 mRNA levels with a single
shRNA (Sash1, Dock8, Nek6, Nek7, Nfatc2, and Ankrd17; Fig-
ure S7D) or with two independent shRNAs (Tnfaip2, Samsn1,
Arhgap21, Mark2, and Zc3h14; Figure S7E). Decrease in
Cxcl10 expression was less prominent, consistent with our
previous observations of BI 2536’s weaker effect on this cytokine
during LPS stimulation (Figures S7D and S7E, far right panels).
Each of the 11 Plk-dependent phosphoproteins tested affected
at least 9 targets in the 118-gene signature (on average, 39
targets ± 30 SD; Figure 7C), and 9 affected more than 10% of
the targets in the TLR gene signature (Figure 7C).
Nine of the 11 Plk-dependent phosphoproteins affected the
TLR signature comparably to major antiviral regulators (Fig-
ure 7D). For example, the knockdown profiles of Samsn1,
Dock8, and Sash1 were closely correlated to those of Stat and
Irf family members (Figure 7D), and those of Tnfaip2 and
Zc3h14 were most correlated to the Plk2/4 double knockdown.
Interestingly, Tnfaip2, a protein of unknown molecular function,
has been associated with rheumatoid arthritis and autoimmune
myocarditis in genome-wide association studies (Wellcome
Trust Case Control Consortium, 2007; Kuan et al., 1999). Our
findings provide a potential molecular context for this disease
association.
DISCUSSION
Using an integrative strategy combining transcriptomics,
genetic and chemical perturbations, and unbiased phosphopro-
teomics, we established a role for Plks in host defense pathways
inducing type I IFNs, likely by controlling the phosphorylation
and activity of a module of at least 11 components (Figure 7E).
Our findings and approach open up several avenues for future
investigations.
Consistent with our finding that cell-cycle transcription factors
play a role in antiviral responses (Amit et al., 2009), we identified
several cell-cycle kinases (Plks, Neks) as important regulators
of these responses. Despite extensive studies on the role of
Plk1 in mitosis, the functions of its paralogs—Plk2, 3, and 4—
are poorly defined (Strebhardt, 2010). Although they are less
essential than Plk1 in regulating cell division, their roles in nondi-
viding cells such as neurons are emerging (Archambault and
Glover, 2009; Seeburg et al., 2005). Interestingly, silencing of
both Plk2 and 4 was required to reveal their importance in
antiviral responses, highlighting the necessity of epistasis
analysis in studying mammalian signaling networks. Although it
is currently not feasible to screen for genetic interactions at
a genome-wide scale, it will be interesting to develop innovative
approaches to uncover them.
BI 2536 blocked the nuclear translocation of IRF3 without
affecting its phosphorylation level (based on MWAs and phos-
phoproteomics). A similar phenomenon has been reported for
NF-kB (Ye et al., 2011). This suggests that IRF3 translocation
in our system is likely to be regulated by a mechanism that
does not impact phosphorylation.
Furthermore, Plk inhibition suppresses type I IFN production
in vivo during viral infection—a finding that has potential clinical
implications. Indeed, disease activity in patients with Systemic
Lupus Erythematosus (SLE) correlates with IFN expression
signatures (Banchereau and Pascual, 2006), and lupus-prone
mice exhibit reduced symptoms upon treatment with a dual
inhibitor of TLR7 and 9 (Barrat and Coffman, 2008) or deletion
[moi] 1; B, top) or with EMCV (moi 10; B, bottom) and in pDCs (C) stimulated with CpG type A or B or infected with EMCV (moi 10). Three replicates in each
experiment; error bars are the SEM.
(D) BI 2536 inhibits the CpG-A response but has little effect on the CpG-B response. Shown are mRNA levels (nCounter) for the 118 TLR signature genes (rows) in
pDCs treated with DMSO vehicle or BI 2536 (1 mM) and left untreated (Ctrl) or stimulated with CpG-A or -B for 6 hr (columns). Three clusters of genes are shown:
CpG-A-specific (top), CpG-B-specific (bottom), and shared by CpG-A and -B (middle).
(E–G) BI 2536 inhibits IFN-b production in primary MLFs, leading to an increase in viral replication. MLFs treated with BI 2536 (1 mM; white bars) or vehicle control
(DMSO; black bars) were infectedwith influenzaDNS1 or PR8 strains at indicatedmois. Shown are Ifnb1mRNA levels measured by qPCR (relative to t = 0; E), viral
replication as measured by luciferase (Luc) activity in reporter cells (F), and cell viability measured by CellTiter-Glo assay (G). Error bars represent the SEM.
(H and I) BI 2536 inhibits antiviral cytokine mRNA production, while increasing viral replication during in vivo VSV infection. Shown are Ifnb1, Cxcl10, and Cxcl1
mRNA (H) and VSV viral RNA (I) levels (qPCR; relative to uninfected animals) from popliteal lymph nodes of mice injected with BI 2536 (white circles) or DMSO
vehicle (black circles) prior to and during the course of infection with VSV (intra-footpad). Nodes were harvested 6 hr post-infection. Each circle represents one
animal (n = 3). Data are representative of three independent experiments for each condition.
See also Figure S6 and Table S5.
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Figure 7. Unbiased Phosphoproteomics Identifies a Plk-Dependent Antiviral Pathway
(A) BI 2536 does not affect phosphorylation and protein levels of known TLR signaling nodes. Shown are representative MWA (see Experimental Procedures)
blots (left) obtained from analyzing lysates from BMDCs pretreated with DMSO, BI 2536 (1 mM), or SP 600125 (5 mM) and stimulated with LPS for 0, 20, 40, and
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of the IFN receptor (Santiago-Raber et al., 2003). Thus, testing
the effect of BI 2536 on a mouse model of lupus will be key to
assess the potential therapeutic implications of Plk inhibition
for SLE.
Our approach may be applicable for characterizing the func-
tions of genes reported in genome-wide association studies
(e.g., Tnfaip2), for uncovering potential therapeutic targets
(e.g., Plks), and for repurposing existing small molecules in
new physiological contexts (e.g., using the cancer drug BI
2536 to repress innate immune responses). The vast public
compendia of microarray data could serve as starting points
for identification of relevant signaling components in diverse
biological systems, followed by perturbations and signature
measurements. Nevertheless, because the mRNAs correspond-
ing to many pathway components do not change upon pathway
activation, our approach is far from exhaustive. Combination of
our perturbation-based approach with large-scale biochemical
measurements (e.g., posttranslational modifications, protein-
protein interactions) will lead to more comprehensive, integrated
maps of signaling and transcriptional networks.
EXPERIMENTAL PROCEDURES
Cells and Mouse Strains
BMDCs were generated from 6- to 8-week-old female C57BL/6J mice, Crkl
mutant mice (Jackson Laboratories), Plk2!/! mice (Elan Pharmaceuticals),
or Ifnar1!/! mice (gift from K. Fitzgerald). Primary MLFs were from C57BL/
6J mice.
Viruses
SeV strain Cantell and EMCV strain EMC (ATCC), NDV strain Hitchner B1 (gift
from A. Garcia-Sastre), and VSV strain Indiana (U. von Andrian) were used for
infections. Influenza A virus strain A/PR/8/34 and DNS1 were grown in Vero
cells, and virus titers from MLF supernatants were quantified using 293T cells
transfected with a vRNA luciferase reporter plasmid.
Reagents
TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coliK12 LPS, ODN
1585 CpG type A, and ODN 1668 CpG type B) and Enzo Life Sciences
(poly(I:C)). Heat-killed Listeria monocytogenes (HKLM) was from Invivogen.
Polo-like kinase inhibitors were from Selleck (BI 2536), Sigma (GW843682X),
and Chembridge (Poloxipan). SP 600125 (Jnk inhibitor) was from Enzo Life
Sciences.
mRNA Isolation, qPCR, and Microarrays
Total or poly(A)+ RNA was extracted and reverse transcribed prior to qPCR
analysis with SYBR Green (Roche) in triplicate with GAPDH for normalization.
For microarray analysis, Affymetrix Mouse Genome 430A 2.0 Array was used.
shRNA Knockdowns
High-titer lentiviruses expressing shRNAs were obtained from The Broad RNAi
Platform and used to infect BMDCs as previously described (Amit et al., 2009).
mRNA Measurements on nCounter
53 104 BMDCswere lysed in RLT buffer (QIAGEN) with 1% b-ME. Ten percent
of the lysate was used for mRNA counting using the nCounter Digital Analyzer
(NanoString) and a previously generated CodeSet of 118 genes (Amit et al.,
2009). To score target genes whose expression is significantly affected by
shRNA perturbations, we used a fold threshold corresponding to a false
discovery rate (FDR) of 2%. Heatmaps and distance matrix analyses were
generated using the Gene-E software (http://www.broadinstitute.org/cancer/
software/GENE-E/).
Detection of Regulated Signaling Genes
We identified differentially regulated signaling components (i.e., kinases,
phosphatases, and signaling adaptors or scaffolds) based on probesets
reproducibly displaying at least 1.7-fold up- or downregulation in at least
one time point, compared to unstimulated controls, using our previously
published microarray dataset (NCBI GEO GSE17721, Amit et al., 2009).
Nanowire-Mediated Drug Delivery and Microscopy
BMDCs were plated on top of etched silicon nanowires (Si NWs) coated with
small molecules. After 24 hr, cells were stimulated and processed for immuno-
fluorescence analysis by confocal microscopy.
VSV Infection Model
Eight-week-old C57BL/6 male mice received 500 mg of BI 2536 (or vehicle)
intravenously and 50 mg into the footpad 3 hr before and 2 hr after infection
with 106 pfu of VSV into the footpad. Mice were sacrificed 6 hr post-infection,
and the draining popliteal lymph nodes were harvested in RNAlater solution
(Ambion) before subsequent RNA extraction and qPCR analysis.
Microwestern Arrays
The MWA method previously described (Ciaccio et al., 2010) was modified to
accommodate a larger number of lysates.
Phosphotyrosine and Global Phospopeptide Analysis
Tyrosine-phosphorylated peptides from BMDC lysates were prepared using
a PhosphoScan Kit (Cell Signaling Technology) and analyzed by data-depen-
dent LC-MS/MS using a Thermo LTQ-Orbitrap. Quantitative analysis of
80 min. Blots were analyzed using indicated antibodies (leftmost), and fold change in fluorescence signals was quantified relative to t = 0 (right). Error bars are the
SEM of triplicate MWA blots.
(B) BI 2536 affects protein phosphorylation levels during LPS stimulation. Top: Schematic depiction of experimental workflow. From left to right: LPS-stimulated
BMDCs cultured in ‘‘heavy’’ or ‘‘light’’ SILAC medium were pretreated with BI 2536 (1 mM) or DMSO, respectively. Protein lysates were mixed (1:1) and digested
into peptides with trypsin, before phosphoserine, -threonine, and -tyrosine (pS/T/Y) peptide enrichment and LC-MS/MS analysis. Bottom: Shown are the
differential phosphorylation levels (average log2 ratios of two independent experiments; y axis) of all 5,061 and 5,997 phosphopeptides, respectively, identified
and quantified by LC-MS/MS (x axis) at 30 min (top) and 120 min (bottom) post-LPS stimulation. Dark gray: phosphopeptides with a significant change
(Punadjusted < 0.001 for both time points; FDR30min = 0.05; FDR120min = 0.03; left: induced; right: repressed). Average ratios from phosphopeptides identified and
quantified in two independent experiments are depicted.
(C) Eleven Plk-dependent phosphoproteins significantly affect the expression of TLR signature genes. Shown are significant changes in expression of the TLR
signature genes (rows) following knockdown of each of the 11 phosphoproteins (columns). Cells were stimulated with LPS for 6 hr. Red and blue mark significant
hits (as presented in Figure 2) and are shown only for genes where the effect was consistent between two independent experiments.
(D) Functional characterization based on similarity of perturbation profiles. Shown is a correlation (Pearson) matrix of the perturbation profiles from (C) (gray) and
those from Figure 2B including canonical (purple) and candidate (blue) signaling components as well as core antiviral (green) and inflammatory (orange) tran-
scriptional regulators. Yellow: positive correlation; purple: negative correlation; black: no correlation.
(E) A Plk-dependent pathway in antiviral sensing. Shown is a diagram of a model of the Plk-dependent pathway of IFN induction in innate immunity. Out of the 11
Plk-dependent proteins described in (C) and (D), only the 5 showing a phenotype with two independent shRNAs are depicted.
See also Figure S7 and Tables S6 and S7.
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serine-, threonine-, and tyrosine-phosphorylated peptides was performed
using SCX/IMAC as described (Ville´n andGygi, 2008) with somemodifications.
Peptide samples were analyzed on a LTQ-Orbitrap Velos (Thermo Fisher
Scientific). To identify and quantify peptides, mass spectra were processed
with Spectrum Mill software package (Agilent Technologies) v4.0b, including
in-house developed features for SILAC quantitation and phosphosite localiza-
tion, and with MaxQuant (v1.0.13.13) (Cox and Mann, 2008) and Mascot
search engine (v2.2.0, Matrix Science).
ACCESSION NUMBERS
Complete microarray datasets are available in the NCBI Gene Expression
Omnibus (accession number GSE28520). Proteomics raw data are in the the
Tranche data repository (https://proteomecommons.org/tranche/, hash:
HTWY5ZeSLM1hyYEyfEiJREkgLXs6BZxCczuixy9XjULsync5HCkXx/8gB7n
ZKpGocwOnt8vOk/Q3cpbPh/ycD/2LT0AAAAAAAAAuEg = =, and pass-
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Supplemental Information
EXTENDED EXPERIMENTAL PROCEDURES
Preparation of Dendritic Cells
BMDCs were generated from 6- to 8-week-old female C57BL/6J mice (Jackson Laboratories). Bone marrow cells were collected
from femora and tibiae and plated at 106 cells/ml on nontissue culture treated petri dishes in RPMI-1640 medium (GIBCO), supple-
mented with 10% FBS, L-glutamine, penicillin/streptomycin, MEM nonessential amino acids, HEPES, sodium pyruvate, b-mercap-
toethanol, and murine GM-CSF (15 ng/ml; Peprotech) or human Flt3L (100 ng/ml; Peprotech). GM-CSF-derived BMDCs were used
directly for all RNAi experiments. For all other experiments, floating cells from GM-CSF cultures were sorted at day 5 by MACS using
the CD11c (N418) MicroBeads kit (Miltenyi Biotec). Sorted CD11c+ cells were used as GM-CSF-derived BMDCs, and plated at
106 cells/ml and stimulated at 16 hr post sorting. For Flt3L culture, floating cells were harvested at days 6–8 and used as Flt3L-derived
BMDCs by plating them at 106 cells/ml and stimulating 16 hr later.
For SILAC experiments, GM-CSF-derived BMDCs were grown in media containing either normal L-arginine (Arg0) and L-lysine
(Lys0) (Sigma) or L-arginine 13C6-15N4 (Arg10) and L-lysine 13C6-15N2 (Lys8) (Sigma Isotec). Concentrations for L-arginine and
L-lysine were 42mg/l and 40mg/l, respectively. The cell culture media, RPMI-1640 deficient in L-arginine and L-lysine, was a custom
media preparation fromCaisson Laboratories (North Logan, UT) and dialyzed serumwas obtained fromSAFC-Sigma.We followed all
standard SILAC media preparation and labeling steps as previously described (Ong and Mann, 2006).
Preparation of Primary Lung Fibroblasts
MLFs were derived from lung tissue from 6- to 8-week-old female C57BL/6J mice (Jackson Laboratories). MLFs were isolated as
previously described (Tager et al., 2004). Briefly, lungs were digested for 45min at 37!C in collagenase and DNase I, filtered, washed,
and cultured in DMEM supplemented with 15% FBS. Cells were used for experiments between passages 2 and 5.
Genetically Modified Mice
Bone marrow from Plk2"/" mice and their wild-type littermates were obtained from Elan Pharmaceuticals (Inglis et al., 2009).
Ifnar1"/" mice on a C57BL/6J background were a gift from Kate Fitzgerald (originally from Jonathan Sprent based on Muller
et al., 1994). Heterozygous Crkl+/" mice on a C57BL/6J background were obtained from the Jackson Laboratory. Crkl+/" C57BL/
6J mice were crossed to wild-type Black Swiss mice from Taconic, as Crkl"/" mice on a pure C57BL/6J genetic background
have been reported to be embryonic lethal (Guris et al., 2001; Hemmeryckx et al., 2002). Heterozygous Crkl+/" offspring were back-
crossed to Crkl+/" C57BL/6J mice to obtain Crkl"/" mice. Mice were kept in a specific pathogen-free facility at MIT. Animal proce-
dures were in accordance with National Institutes of Health Guidelines on animal care and use and were approved by the MIT
Committee on Animal Care (Protocol #0609-058-12).
Viruses
SeV, strain Cantell, and EMCV, strain EMC, were from ATCC. NDV, strain Hitchner B1 was from Aldolfo Garcia-Sastre (Mount Sinai
School of Medicine), and VSV, strain Indiana was from Ulrich von Andrian (Harvard Medical School). Influenza A virus strain A/PR/8/
34 and DNS1 were grown in Vero cells (which allow efficient growth of the DNS1 virus) in serum-free DMEM supplemented with 10%
BSA and 1 mg/ml TPCK trypsin. Viral titers were determined by standard MDCK plaque assay. To measure the amount of VSV RNA
present in infected tissues, we used previously reported qPCR primers: VSV forward 50-TGATACAGTACAATTATTTTGGGAC-30, and
VSV reverse 50-GAGACTTTCTGTTACGGGATCTGG-30 (Hole et al., 2006). Viruses were handled according to CDC and NIH guide-
lines with protocols approved by the Broad Institutional Biosafety Committee.
Reagents
TLR ligands were from Invivogen (Pam3CSK4, ultra-pure E. coli K12 LPS, ODN 1585 CpG type A, and ODN 1668 CpG type B) and
Enzo Life Sciences (poly(I:C)), and were used at the following concentrations: Pam3CSK4 (250 ng/ml), poly(I:C) (10 mg/ml), LPS
(100 ng/ml), CpG-A (10 mg/ml), CpG-B (10 mg/ml). Heat-killed Listeria monocytogenes (HKLM) was from Invivogen. Polo-like kinase
inhibitors were from Selleck (BI 2536; Steegmaier et al., 2007), Sigma (GW843682X, also known as compound 1 and GSK461364;
Lansing et al., 2007), and Chembridge (Poloxipan; Reindl et al., 2009). SP 600125 (Jnk inhibitor) was from Enzo Life Sciences.
Image-iT FX Signal Enhancer, DAPI, and Alexa Fluor Labeled Secondary Antibodies were obtained from Invitrogen. For immunoflu-
orescence, antibodies against IRF3 (4302S) and NF-kB P65 (4764S) were obtained from Cell Signaling Technology. For cell viability
assays, Alamar Blue was from Invitrogen and CellTiter-Glo from Promega.
Virus Titering of MLF Supernatant
293T cells were seeded and transfected with a vRNA luciferase reporter plasmid as previously described (Shapira et al., 2009).
Briefly, at 24 hr post-transfection, 104 transfected reporter cells were reseeded in white Costar plates. Supernatants from influ-
enza-infected MLFs were added to reporter cells and incubated for 24 hr. Reporter activity was measured with firefly luciferase
substrate (Steady-Glo, Promega). Luminescence activity was quantified with the Envision Multilabel Reader (Perkin Elmer).
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Cell-Cycle Analysis
Cells were fixed in ethanol, washed, and stained for 30 min at room temperature (RT) with propidium iodide (100 mg/ml) prepared in
PBS (calcium- and magnesium-free) supplemented with RNase A (2 mg/ml; Novagen) and Triton X-100 (0.1%). Samples were
analyzed for DNA content using an Accuri C6 flow cytometer (Accuri) and data was processed using the FlowJo software (Treestar).
ELISA
Cell culture supernatants were assayed using a sandwich ELISA kit for mouse IFN-b (PBL Biomedical Laboratories).
mRNA Isolation
Total RNA was extracted with QIAzol reagent following the miRNeasy kit’s procedure (QIAGEN), and sample quality was tested on
a 2100 Bioanalyzer (Agilent). RNA was reverse transcribed with the High Capacity cDNA Reverse Transcription kit (Applied Bio-
systems). For experiments with more than 12 samples, we harvested Poly(A)+ RNA in 96- or 384-well plates with the Turbocapture
mRNA kit (QIAGEN) and reverse transcribed with the Sensiscript RT kit (QIAGEN).
qPCR Measurements
Real-time quantitative PCR reactions were performed on the LightCycler 480 system (Roche) with FastStart Universal SYBR Green
Master Mix (Roche). Every reaction was run in triplicate and GAPDH levels were used as an endogenous control for normalization.
shRNA Knockdowns
High-titer lentiviruses encoding shRNAs targeting genes of interest were obtained from The RNAi Consortium (TRC; Broad Institute,
Cambridge, MA, USA) (Moffat et al., 2006). Bone marrow cells were infected with lentiviruses as described (Amit et al., 2009). For
each gene of interest, we tested five shRNAs for knockdown efficiency using qPCR of the target gene. We selected shRNAs with
>75% knockdown efficacy. For combinatorial knockdown, two independent mixtures of two lentiviruses encoding validated shRNAs
against Plk2 and 4, respectively, were used to infect bone marrow cells (two Plk2- and two Plk4-specific shRNAs were used to
generate thesemixtures). Lentivirus-infected cells were composed of!90%CD11c+ cells, which was comparable to sorted BMDCs
and to our previous observations (Amit et al., 2009).
mRNA Measurements on nCounter
Details on the nCounter system are presented in full in (Geiss et al., 2008).We used a customCodeSet constructed to detect a total of
128 genes (including 10 control genes whose expression remain unaffected by TLR stimulation) selected by the GeneSelector algo-
rithm (Amit et al., 2009) as described below. 5 3 104 BMDCs were lysed in RLT buffer (QIAGEN) supplemented with 1% b-mercap-
toethanol. Ten percent of the lysate was hybridized for 16 hr with the CodeSet and loaded into the nCounter prep station followed by
quantification using the nCounter Digital Analyzer following the manufacturer’s instructions.
Custom Nanostring CodeSet Construction using the GeneSelector Algorithm
We used the CodeSet that we previously used and described in Amit et al., 2009. Briefly, to choose a set of genes that will capture as
much as possible of the information on the expression of all genes, we used an information-theoretic approach. We modeled the
expression levels X given the experimental condition C with a naive Bayes model where the expression of gene i under condition
c follows a normal distribution XijC= c ! Nðmic;s2i Þ. In this model, the expression levels of all genes depend on the experimental
conditionC, and we selected genes that are highly informative aboutC. Formally, for a set of genes Ywe used the conditional entropy
HðCjYÞ= $Pc pðC= cÞPy pðY = yjC= cÞlogpðC= cjY = yÞ as ameasure of the remaining uncertainty inC once the expression levels
Y are known.We then used thismeasure and a greedy procedure to select multiple disjoint gene sets, Y1,., Yk such that for each set
Yi, HðCjYiÞ<h (we set h = 0.5). In the greedy procedure, we select genes one at a time, and with each selected gene recompute the
entropy given the genes already selected in the current set. Once a set is complete (the remaining conditional entropy is below the
threshold h), we add all the genes to the selected set, and repeat the procedure (excluding all the selected genes from consideration).
We stopwhen the number of selected genes has reached a user-defined threshold, set by the number of genes feasible for the exper-
imental assay.
To select a time point, we used the same approach. Here, we measured entropy under all time points for multiple randomly
selected gene sets of several sizes and plotted the average entropy for each time point (see Amit et al., 2009). We chose the time
point with the minimal entropy (i.e., 6 hr post-simulation).
nCounter Data Analysis
After normalization by internal Nanostring controls (spike-normalization following manufacturer’s instructions), we normalized the
data relying on three control genes (Ndufa7, Tbca, Tomm7) that are the least affected by shRNAs and LPS stimulation. Next, we
log-transformed the expression values (Bengtsson and Hossjer, 2006). Five signature genes (Cxcl5, Fos, Fst, Ereg, and Egr2) that
were highly variable across control shRNA samples were removed from subsequent analysis. To score target genes whose expres-
sion is significantly affected by perturbations, we used a fold threshold corresponding to an FDR of 2%. For a given shRNA pertur-
bation, a target gene was called as significantly affected when the ratio of the log-expression of this gene upon shRNA knockdown to
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the average log-expression of this gene in control shRNA samples was below (or above) a threshold (1/threshold), chosen such that,
on average, no more than 2 hits (out of 128 genes in the Nanostring codeset) per control shRNA sample were called. Heatmaps and
distance matrix analyses were generated using the software Gene-E (http://www.broadinstitute.org/cancer/software/GENE-E/).
Microarray Hybridization and Processing
For oligonucleotide microarray hybridization, 1 mg of RNAwere labeled, fragmented, and hybridized to an Affymetrix Mouse Genome
430A 2.0 Array. After scanning, the expression value for each gene was calculated with RMA (Robust Multi-Array) normalization. The
average intensity difference values were normalized across the sample set. Probe sets that were absent in all samples according to
Affymetrix flags were removed. All values below 50 were floored to 50.
Detection of Regulated Signaling Genes
To identify differentially regulated signaling components (i.e., kinases, phosphatases, and signaling adaptors or scaffolds), we
defined regulated probesets for each condition (TLR agonist) as probesets displaying at least 1.7-fold up- or downregulation in
both duplicates of at least one time point, compared to unstimulated controls, using our previously published microarray dataset
available in the NCBI Gene Expression Omnibus under the accession number GSE17721 (Amit et al., 2009). Differentially regulated
probesets were intersected with lists of kinases, phosphatases, and signaling adaptors and scaffolds. These gene sets were gener-
ated combining data from publicly available databases: Panther (http://www.pantherdb.org), Gene Ontology (http://www.
geneontology.org), and DAVID (http://david.abcc.ncifcrf.gov). Regulated signaling genes were hierarchically clustered using the
Cluster software (Eisen et al., 1998).
Antiviral versus Inflammatory Gene Enrichment
Genes whose expression changed upon BI 2536 treatment in microarrays (Table S4) were evaluated for their enrichment with genes
involved in the antiviral and inflammatory programs. When multiple probesets were available for a given gene on the microarray, only
the probeset withmaximum value was kept for analysis. Thus, the complete microarray consisted of 14,088 genes, amongwhich 804
and 550 genes were identified as part of antiviral and inflammatory programs, respectively (Amit et al., 2009). We performed a hyper-
geometric test on genes whose expression changed at least 3-fold upon BI 2536 treatment compared to vehicle control (DMSO), in
either LPS or poly(I:C) samples. In addition, genes whose expression changed upon BI 2536 treatment in microarrays in response to
LPS and/or poly(I:C) stimulation were analyzed for enrichment of Gene Ontology (GO) processes and canonical pathways from
curated databases using the Molecular Signature Databse (MSigDB; http://www.broadinstitute.org/gsea/msigdb/index.jsp).
Nanowire-Mediated Drug Delivery and Microscopy
BMDCs were plated on top of etched silicon nanowires (Si NWs) coated with small molecules (Shalek et al., 2010). After 24 hr, cells
were stimulated with LPS or poly(I:C), then fixed in 4% formaldehyde in PBS (RT, 10 min). After fixation, each sample was permea-
bilized with 0.25% Triton X-100 in PBS (RT, 10 min), incubated with Image-iT FX Signal Enhancer (RT, 30 min), and then blocked with
10% goat serum and 0.25% Triton X-100 in PBS (RT, 1 hr). After washing, the samples were placed in 3% IgG-Free BSA & 0.25%
Triton X-100 in PBS that contained primary antibodies against either IRF3 or NF-kB P65 (1:175 dilution) and then rocked overnight at
4!C. The following day, the samples were washed with PBS and then incubated with an Alexa Fluor labeled secondary antibody
(1:250 dilution) in 3% IgG-Free BSA & 0.25% Triton X-100 in PBS (RT, 60 min). After washing with PBS, the samples were counter-
stained with 300 ng/ml of DAPI in PBS (RT, 30 min). For each experiment, every stimulus-molecule combination was prepared in trip-
licate. Once fixed, samples were imaged using an upright confocal microscope (Olympus). For each captured image, the nuclear
fraction of the fluorescent protein was calculated after identifying nuclear boundaries using DAPI. Finally, distributions for this quan-
tity across different conditions were compared using a one-way ANOVA analysis.
In Vivo BI 2536 Experiments in a VSV Infection Model
Eight-week-old C57BL/6malemice (fromCharles River Laboratories) received 500 mg of BI 2536 (or vehicle) intravenously, and 50 mg
into the footpad 3 hr before and 2 hr after infection with 106 pfu of VSV, as previously described (Iannacone et al., 2010), into the
footpad. Mice were sacrificed 6 hr post-infection and the draining popliteal lymph nodes were harvested in RNAlater solution (Am-
bion) before subsequent RNA analysis. All experimental animal procedures were approved by the Institutional Animal Committees of
Harvard Medical School and IDI. All infectious work was performed in designated BL2+ workspaces, in accordance with institutional
guidelines, and approved by the Harvard Committee on Microbiological Safety.
Microwestern Arrays
The MWAmethod previously described (Ciaccio et al., 2010) was modified to accommodate a larger number of lysates. The lysates
were printed in a ‘‘double-block’’ format with each MWA being 18 mm wide by 9 mm long. Twelve samples plus protein marker (Li-
Cor 928-40000) were printed with a noncontact piezoelectric arrayer (GeSiMNP2) along the top edge of the block, each block printed
forty-eight times on the acrylamide gel. The deck layout is included in Figure S7A. Electrophoresis, transfer, and antibody incubation
were performed as previously described with the exception of using a modified 48-well gasket (The Gel Company MMH96) manually
cut to have a larger block size in order to isolate antibodies on the nitrocellulose membrane per printed block. The antibodies used in
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this study were against b-ACTIN, GAPDH, b-TUBULIN, IkBa (clone L35A5), P65 (clone C22B4), STAT1, p-ABL(C-) (Y245), p-AKT
(S473), p-AKT1/2/3 (T308), p-ATF2 (T71), p-ERK1/2 (T202/Y204), p-IKBALPHA (S32), p-IKKA/B (S176/180), p-IRF3 (S396), p-
MAPKAPK2 (T222), p-MEK(1/2) (S217/221), p-MET (Y1234/1235), p-P38 (T180/Y182), p-P65 (S536), p-P70S6K (S371), p-P70S6K
(T389), p-P90RSK (S380), p-PI3K P85(Y458) P55(Y199), p-PKCD (Y311), p-SAPK/JNK (T183/Y185), p-SEK1/MKK4 (T261), p-
STAT1 (S727), p-STAT1 (Y701), p-STAT3 (S727). All antibodies were from Cell Signaling Technology, except for b-ACTIN which
was from Santa Cruz Biotechnology. Band intensities were quantified using Li-Cor Odyssey analysis software (V3.0). Circles were
applied to the appropriate band on the scanned image and the net intensity was calculated by subtracting the background intensity
from the trimmed mean intensity of each band. The net intensity was divided by the average net intensities of b-actin to control for
lysate protein concentration. Fold Change was then calculated in relation to time of inhibitor application (time zero).
Phosphotyrosine Peptide Analysis
Tyrosine-phosphorylated peptides were prepared using a PhosphoScan Kit (Cell Signaling Technology) as previously described
(Rush et al., 2005). Briefly, 100 million cells were lysed in lysis buffer (20 mM HEPES, 25 mM sodium pyrophosphate, 10 mM
beta-glycerophosphate, 9 M urea, 1 mM ortho-vanadate, 1 Roche Ser/Thr phosphatase inhibitor tablet) assisted by sonication on
ice using Misonix S-4000 sonicator with five 30 s bursts at 4 W. Lysates were precleared by centrifugation for 15 min at 20,000 g.
Approximately 10 mg of total proteins from each SILAC label were mixed, reduced with 10 mM dithiothreitol and alkylated with
25 mM iodoacetamide. After 4-fold dilution 200 mg sequencing grade modified trypsin (Promega, V5113) was added in an enzyme
to substrate ratio of 1:100. The total peptide mixtures were then desalted using a tC18 SepPak cartridge (Waters, 500 mg,
W AT036790) and resuspended in IAP buffer (50 mM MOPS/NaOH [pH 7.2], 10 mM Na2HPO4, 50 mM NaCl). Peptide immunopre-
cipitation was performed with protein-G agarose bead-bound anti-phosphotyrosine antibodies pY100. Peptides captured by phos-
photyrosine antibodies were eluted under acidic conditions (0.15% trifluoroacetic acid). The IP eluate was analyzed by data-depen-
dent LC-MS/MS using a Thermo LTQ-Orbitrap instrument.
Global Serine, Threonine, and Tyrosine Phosphorylation Analysis
Quantitative analysis of serine-, threonine-, and tyrosine-phosphorylated peptides was performed essentially as described (Ville´n
and Gygi, 2008) with some modifications. After stimulation, cells were lysed for 20 min in ice-cold lysis buffer (8 M Urea, 75 mM
NaCl, 50 mM Tris [pH 8.0], 1 mM EDTA, 2 mg/ml Aprotinin (Sigma, A6103), 10 mg/ml Leupeptin (Roche, #11017101001), 1 mM
PMSF, 10 mM NaF, 2 mM Na3VO4, 50 ng/ml Calyculin A (Calbiochem, #208851), Phosphatase inhibitor cocktail 1 (1/100, Sigma,
P2850) and Phosphatase inhibitor cocktail 2 (1/100, Sigma, P5726). Lysates were precleared by centrifugation at 16,500 g for
10 min and protein concentrations were determined by BCA assay (Pierce). We obtained 3 mg total protein per label out of 30 million
cells. Cell lysatesweremixed in equal amounts per label and proteins were reducedwith 5mMdithiothreitol and alkylatedwith 10mM
iodoacetamide. Samples were diluted 1:4 with HPLC water (Baker) and sequencing-grade modified trypsin (Promega, V5113) was
added in an enzyme to substrate ratio of 1:150. After 16 hr digest, samples were acidified with 0.5% trifluoroacetic acid (final concen-
tration). Tryptic peptides were desalted on reverse phase tC18 SepPak columns (Waters, 500 mg, WAT036790) and lyophilized to
dryness. Peptides were reconstituted in 500 ml strong cation exchange buffer A (7 mMKH2PO4, pH 2.65, 30%MeCN) and separated
on a Polysulfethyl A column from PolyLC (250 3 9.4 mm, 5 mm particle size, 200 A pore size) using an Akta Purifier 10 system (GE
Healthcare). We used an 80 min gradient with a 20 min equilibration phase with buffer A, a linear increase to 30% buffer B (7 mM
KH2PO4, pH 2.65, 350 mM KCL, 30% MeCN) within 33 min, 100% B for 7 min and a final equilibration with Buffer A for 20 min.
The flow rate was 3 ml/min and the sample was injected after the initial 20 min equilibration phase. Upon injection, 3 ml fractions
were collected with a P950 fraction collector throughout the run. 60 fractions were collected of which 3–4 adjacent fractions were
combined to obtain 12 samples. Pooling of SCX fractions was guided by the UV214-trace and fractions were combined starting
where the first peptide peak appeared. The 12 samples were desalted with reverse phase tC18 SepPak columns (Waters,
100 mg, WAT036820) and lyophilized to dryness. SCX-separated peptides were subjected to IMAC (immobilized metal affinity chro-
matography) as described (Ville´n and Gygi, 2008). Briefly, peptides were reconstituted in 200 ml IMAC binding buffer (40% MeCN,
0.1% FA) and incubated for 1 hr with 5 ml of packed Phos-Select beads (Sigma, P9740) in batch mode. After incubation, samples
were loaded on C18 StageTips (Rappsilber et al., 2007), washed twice with 50 ml IMAC binding buffer, and washed once with
50 ml 1% formic acid. Phosphorylated peptides were eluted from the Phos-Select resin to the C18 material by loading 3 times
70 ml of 500 mM K2HPO4 (pH 7.0). StageTips were washed with 50 ml of 1% formic acid to remove phosphate salts and eluted
with 80 ml of 50% MeCN/0.1% formic acid. Samples were dried down by vacuum centrifugation and reconstituted in 8 ml 3%
MeCN/0.1% formic acid.
NanoLC-MS/MS Analysis
All peptide samples were separated on an online nanoflow HPLC system (Agilent 1200) and analyzed on a LTQ Orbitrap Velos
(Thermo Fisher Scientific) mass spectrometer. Four microliters of peptide sample were autosampled onto a 14 cm reverse phase
fused-silica capillary column (New Objective, PicoFrit PF360-75-10-N-5 with 10 mm tip opening and 75 mm inner diameter) packed
in-house with 3 mm ReproSil-Pur C18-AQ media (Dr. Maisch GmbH). The HPLC setup was connected via a custom-made electro-
spray ion source to the mass spectrometer. After sample injection, peptides were separated at an analytical flowrate of 200 nl/min
with an 70 min linear gradient (!0.29%B/min) from 10% solvent A (0.1% formic acid in water) to 30% solvent B (0.1% formic
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acid/90% acetonitrile). The run time was 130 min for a single sample, including sample loading and column reconditioning. Data-
dependent acquisition was performed using the Xcalibur 2.1 software in positive ion mode. The instrument was recalibrated in
real-time by coinjection of an internal standard from ambient air (‘‘lock mass option’’) (Olsen et al., 2005). Survey spectra were
acquired in the orbitrap with a resolution of 60,000 and a mass range from 350 to 1750 m/z. In parallel, up to 16 of the most intense
ions per cycle were isolated, fragmented and analyzed in the LTQ part of the instrument. Ions selected for MS/MS were dynamically
excluded for 20 s after fragmentation. For the second biological replicate analysis peptides observed to be regulated in the first anal-
ysis were loaded into a global parent mass inclusion list and 4 MS/MS scans were reserved for precursors from the inclusion list
whereas 12 were performed on the most intense ions per duty cycle.
Identification and Quantification of Peptides and Proteins
Mass spectra were processed using the SpectrumMill software package (Agilent Technologies) v4.0 b that includes in-house devel-
oped features for SILAC-based quantitation and phoshosite localization and also with the MaxQuant software package (version
1.0.13.13) (Cox and Mann, 2008), which was used in combination with a Mascot search engine (version 2.2.0, Matrix Science).
For peptide identification in Spectrum Mill an International Protein Index protein sequence database (IPI version 3.60, mouse) was
used which was reversed on-the-fly at search time. In MaxQuant a concatenated forward and reversed IPI protein sequence data-
base (version 3.60, mouse) was queried. The mass tolerance for precursor ions and for fragment ions was set to 7 ppm and 0.5 Da,
respectively. Cysteine carbamidomethylation was searched as a fixed modification, whereas oxidation onmethionine, N-acetylation
(Protein) and phosphorylation on serine, threonine, or tyrosine residues were considered as variable modifications. The enzyme
specificity was set to trypsin and cleavage N-terminal of proline was allowed. The maximum of missed cleavages was set to 3.
For peptide identification the maximum peptide FDR was set to 1%. The minimum identification score was to 5 in Spectrum Mill
and to 10 in MaxQuant. SILAC ratios were obtained from the peptide export table in Spectrum Mill and the evidence table in Max-
Quant. Arginine to Proline conversion was determined to be 3.42% and 5.55% for both biological replicates, respectively. The
conversion was calculated by defining Arg-10 as a fixed modification and by quantifying the ratio between peptides containing
normal L-proline (Pro0) and 13C5-15N1-labeled proline (Pro6) with MaxQuant. Each peptide SILAC ratio was corrected for arginine
to proline conversion by the formula r[c] = r[o]/((1-p)^n), where r[c] is the corrected ratio, r[o] the observed ratio, p the conversion rate
and n the number of proline residues per peptide. The median ratios of all nonphosphorylated peptides were used to normalize the
M/L and H/L ratios of all phosphorylated peptides. To allow better peptide grouping, phosphosite localization information obtained
from SpectrumMill and MaxQuant were further simplified. Probability scores greater or equal 0.75 were called fully localized and
designated with (1.0), scores smaller 0.75 and greater or equal to 0.5 were called ambiguously localized and designated with
(0.5), whereas scores smaller than 0.5were called non-localized and the total number of phosphorylation sites per peptide was desig-
nated with an underscore after the peptide sequence. Median SILAC ratios of phosphopeptides for each experiment were calculated
over all versions of the same peptide including different charge states and methionine oxidation states. The highest scoring versions
of each distinct peptide were reported per experiment. Overlapping data between SpectrumMill and MaxQuant as well as between
different biological replicates was analyzed for discrepancies by calculating the mean and standard deviation over all residuals for
different ratios of the same phosphopeptide. Residuals were calculated by subtracting the two values for each phosphopeptide
derived by SpectrumMill or MaxQuant as well as by two different biological replicates. All peptides were filtered from the data set
that had residuals greater than 3 standard deviations distant from the mean as they were not reproducible between two biological
replicates or between SpectrumMill and MaxQuant. Data derived from both software packages was combined and MaxQuant
data was reported when the same phosphopeptide was identified and quantified by both programs. Log2 phosphopeptide ratios
of BI 2536 treated versus untreated dendritic cells followed a normal distribution that was fitted using least-squares regression.
Mean and standard deviation values derived from the Gaussian fit were used to calculate p values. An FDR-based measure was
used to assess significance of the findings (Storey and Tibshirani, 2003).
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Figure S1. A Systematic Approach to Dissect Signaling Pathways, Related to Figure 1
Shown is a schematic depicting the strategy consisting of four steps (from left to right): (1) extract both candidate signaling regulators and signature genes; (2)
perturb each candidate with shRNAs and measure the effect on the expression of signature genes; (3) compare perturbation profiles of signaling and tran-
scriptional regulators to start assembling pathways; (4) use small-molecule targeting of signaling nodes of interest to (a) evaluate the physiological relevance of
new signaling node and (b) identify underlying pathways by discovering downstream effector molecules.
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Figure S2. Perturbations of Signaling and Transcriptional Regulators Have Similar Effects on the TLR Signature Genes, Related to Figure 2
(A) Perturbation profiles of 6 canonical (purple) and 17 candidate (light blue) signaling regulators and 123 transcriptional regulators (TF) partitioned into regulators
of the inflammatory (orange) and antiviral (green) programs, and fine tuners (gray), as previously defined in Amit et al. (2009). Shown are the perturbed regulators
(columns) and their statistically significant effects (FDR < 2%) on each of the 118 TLR signature genes (rows). Red: significant activating relation (target gene
expression decreased following perturbation); blue: significant repressing relation (target gene expression increased following perturbation); white: no significant
effect. The column on the right indicates whether signature genes belong to the antiviral (light gray) or the inflammatory (dark gray) programs.
(B–D) Shown are the numbers of signature genes hits (y axis, ‘‘hits’’) significantly affected by knockdown of each regulator (x axis) for the regulator categories
shown in A: 123 transcriptional (B) and 6 previously known (C) and 17 candidate (D) signaling regulators.
(E) Candidate signaling regulators affect a similar number of ‘‘signature’’ genes compared to transcriptional regulators. Shown is the cumulative distribution of the
number of hits for the regulators shown in (B)–(D).
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Figure S3. Individual Perturbation of Plk Family Members Does Not Affect TLR Output Gene Expression in DCs, Related to Figure 4
(A) Plk2-deficient BMDCs respond to LPS similarly to wild-type cells. Shown are mRNA levels (qPCR; relative to t = 0) for Ifnb1 (left), Cxcl10 (middle), and Cxcl1
(right) in three replicates per time point. Error bars represent the SEM.
(B) Combinatorial knockdown levels of Plk2 and 4 in BMDCs. Shown are mRNA levels (qPCR), relative to nontargeting shRNAs (Control), of Plk2 and 4 in BMDCs
using two independent combinations of shRNAs (Plk2/4-1 and -2). Three replicates in each experiment; error bars represent the SEM.
(C) Perturbations of individual Plk family members do not affect TLR signature genes. Shown are the perturbed Plks (columns) and their statistically significant
effects (FDR < 2%) on each 118 TLR signature genes (rows). Red: significant activating relation (target gene expression decreased following perturbation); blue:
significant repressing relation (target gene expression increased following perturbation); white: no significant effect. The column on the right indicates whether
signature genes belong to the antiviral (light gray) or the inflammatory (dark gray) programs.
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Figure S4. BI 2536-Mediated Plk Inhibition Abrogates Antiviral Cytokine Production at the Protein and mRNA Levels, without Affecting the
Viability and Cell-Cycle Status of DCs, Related to Figure 4
(A) Gene enrichment analysis of BI 2536-dependent genes frommicroarray measurements. Overlaps between the 311 unique genes downregulated 3-fold by BI
2536 treatment upon LPS or poly(I:C) stimulation (Table S4), and Gene Ontology (GO) processes and canonical pathways (including the KEGG, REACTOME, and
BIOCARTE databases present in the Molecular Signatures Database [MSigDB]; see Experimental Procedures). Shown are p values (x axis) derived from the
overlaps (n/N; top of each bar) between the number of queried genes (n) and genes present in indicated genesets (N).
(B) BI 2536 strongly inhibits IFN-b secretion by BMDCs. Shown is IFN-b protein concentration (y axis; measured by ELISA) in the supernatant of BMDCs treated
with DMSO vehicle (!) or BI 2536 (1 mM; +), and stimulated with LPS (+) or left unstimulated (!) for 6 hr. Three replicates in each experiment; error bars are the
SEM.
(C) BI 2536 inhibits antiviral cytokine mRNA production in a dose-dependent manner. Shown are mRNA levels (y axis, qPCR; relative to vehicle control treatment)
for two antiviral cytokines (Ifnb1, Cxcl10) and one inflammatory cytokine (Cxcl1) following LPS stimulation in BMDCs pretreated with increasing amounts of BI
2536 (x axis). Three replicates in each experiment; error bars are the SEM.
(D) BMDC viability is unaffected by Plk inhibition with BI 2536. Shown are viable cell numbers (y axis, measured by Alamar blue; relative to a standard curve
generated using a range of cell densities) after treatment with BI 2536 (white bars) or DMSO vehicle (black bars) at different time points following addition of BI
2536 (x axis). Three replicates in each experiment; error bars are the SEM.
(E) The cell-cycle state of BMDCs remains unchanged upon Plk inhibition with BI 2536. Shown are DNA contents (flow cytometry) of BMDCs stained with
propidium iodide (PI) after treatment with BI 2536 or DMSO vehicle control for 0, 6, and 12 hr.
(F) Plk inhibitors structurally unrelated to BI 2536 also abrogate transcription of mRNAs for antiviral cytokines following stimulation with LPS. Shown are mRNA
levels (qPCR; relative to t = 0) for Ifnb1, Cxcl10, and Cxcl1 in BMDCs stimulated with LPS and treated with GW843682X (GW84; top) or Poloxipan (Plxp; bottom)
(black line), or with DMSO vehicle (gray line) for 1 hr prior to stimulation. Three replicates for each experiment; error bars are the SEM.
(G) Plks are directly downstream of TLR engagement. Shown are Ifnb1mRNA levels (y axis, qPCR; relative to t = 0) following LPS stimulation for indicated times (x
axis) in wild-type (top) and Ifnar1!/! (bottom) BMDCs treated with BI 2536 (1 mM; black) or vehicle control (DMSO; gray). Error bars represent the SEM.
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Figure S5. BI 2536-Mediated Plk Inhibition Blocks IRF3 Nuclear Translocation in LPS-Stimulated DCs, Related to Figure 5
(A) DCs plated on vertical silicon NW respond normally to TLR stimulation. Shown are cytokine mRNA levels (qPCR; relative to GapdhmRNA) in BMDCs plated on
NW or a flat silicon surface, and stimulated (LPS) or left untreated (control). Left to right: Cxcl1, Cxcl10, Ifnb1. Three replicates in each experiment; error bars are
the SEM.
(B) BI 2536 inhibits IRF3 nuclear translocation following LPS stimulation. Shown are confocal micrographs (left panel) of BMDCs plated on vertical silicon NW
precoated with vehicle control (DMSO), Plk inhibitor (BI 2536), or control Jnk inhibitor (SP 600125) and stimulated with LPS for 45 min (reflecting peak time of
nuclear translocation for IRF3 in the context of LPS stimulation) or left unstimulated. Cells were analyzed for DAPI and IRF3 staining. Scale bars, 5 mM. Nuclear
translocation (from confocal micrographs) of IRF3 was quantified (right panel) using DAPI staining as a nuclear mask (purple circles onmicrographs) to determine
the ratio of total versus nuclear fluorescence (y axis) in BMDCs cultured onNWcoatedwith BI 2536, SP 600125, or vehicle control (DMSO; x axis). Three replicates
in each experiment; error bars are the SEM.
(C) Decrease in IRF3 nuclear translocationmay bemore efficient with NW-mediated delivery of BI 2536 than with delivery in solution. Shown are quantifications of
confocal micrographs from BMDCs plated on vertical NW precoated with different amounts of BI 2536 (Nanowire; left panel) or left blank to allow in-solution
delivery of BI 2536 (In solution; right panel). Cells were stimulated with poly(I:C) for 2 hr prior to staining for DAPI and IRF3 as in (B). Error bars represent the SEM.
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Figure S6. Plks Are Critical in Antiviral Responses In Vitro and In Vivo, Related to Figure 6
(A) Plks are critical in RIG-I-mediated antiviral responses in vitro in DCs. Shown are mRNA levels (qPCR; relative to control, ‘‘medium’’) in conventional DCs (GM-
CSF-induced BMDCs) treated with BI 2536 (white bars) or DMSO vehicle (black bars) and infected at a multiplicity of infection (moi) 1 with Sendai virus (SeV; top)
or Newcastle disease virus (NDV; bottom). Three replicates in each experiments; error bars are the SEM.
(B) Plk inhibition does not affect DC response to Listeria monocytogenes, a natural TLR2 agonist. Shown are mRNA levels (qPCR; relative to t = 0) for Ifnb1,
Cxcl10, and Cxcl1 in BMDCs stimulated with heat-killed Listeria monocytogenes (HKLM; moi 5) and treated with BI 2536 (white bars) or with DMSO vehicle (black
bars) for 1 hr prior to stimulation. Three replicates for each experiment; error bars are the SEM.
(C) Plks are critical in type I interferon a2 (Ifna2) gene production by pDCs. Shown is the mRNA level (qPCR; relative to control, ‘‘medium’’) of Ifna2 in pDCs (Flt3L-
induced BMDCs) treated with BI 2536 (1 mM; white bars) or DMSO control (black bars) and stimulated with CpG-A or -B or infected with EMCV (moi 10). Three
replicates in each experiment; error bars are the SEM.
(D) Plk inhibition in vivo inhibits type I IFN a2 production in the lymph node. Shown is Ifna2mRNA level (qPCR; relative to uninfected animals) from popliteal lymph
nodes of mice injected with BI 2536 (white circles) or DMSO vehicle (black circles) prior to and during the course of infection with VSV intra-footpad. Nodes were
harvested 6 hr post-infection. Each circle represents one animal (n = 3). Data are representative of two or three independent experiments for each condition.
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Figure S7. Plk Inhibition Does Not Affect Known TLR Signaling Components but Affects Eleven Newly Identified Plk-Dependent Phos-
phoproteins, Related to Figure 7
(A and B) BI 2536-mediated Plk inhibition does not affect protein and/or phosphorylation levels of known TLR signaling nodes. (A) Shown are representativeMWA
(see Experimental Procedures) blots obtained from analyzing lysates from BMDCs pretreated with DMSO, BI 2536 (1 mM), or SP 600125 (5 mM) and stimulated
with LPS for 0, 20, 40, 80 min. Blots were analyzed using indicated antibodies (leftmost), and fold change in fluorescence signals was quantified relative to t =
0 (right; see Experimental Procedures). Error bars are the SEM of triplicate MWA blots. (B) Shown are the differential protein and phosphorylation levels (fold
change; y axis) of 6 proteins and 23 phosphosites in BMDCs treated with BI 2536 (red line), control JNK inhibitor (SP 600125; green line), or DMSO vehicle (blue
line), and stimulated with LPS (0, 20, 40, 80 min; x axis). Band intensities on MWA blots were quantified using Li-Cor Odyssey analysis software (Experimental
Procedures). For each antibody, data were normalized to b-actin levels; error bars are the SEM of triplicate MWA blots.
(C and D) Eleven Plk-dependent phosphoproteins are critical for TLR-mediated antiviral responses in DCs. Shown are mRNA levels (qPCR; relative to non-
targeting control shRNAs, Ctrl) for knockdown (KD) efficiency (left), Ifnb1 (middle), andCxcl10 (right) in BMDCs following LPS stimulation. Geneswith one and two
shRNAs are shown in (C) and (D), respectively. Three replicates in each experiment; error bars are the SEM.
(E) Comparison of phosphosites identified in our study and in two recent reports (Weintz et al., 2010 and Sharma et al.. 2010). Shown are proportional Venn
diagrams of the total unique phosphosites identified by the 3 studies (left), and the phosphosites harbored by kinases only (right). Total numbers of unique
phosphosites per study are indicated in parentheses. Error bars are the SEM.
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